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BCLC barcelona clinic liver cancer NTP nucleoside-5’-triphosphate 
bp base pair P phosphate/ p-value 
BSA bovine serum albumin PAA polyacrylamide 
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cDNA complementary DNA PBST phosphate buffered saline with tween 
CIP calf intestine phosphatase PCR polymerase chain reaction 
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2’-desoxynucleoside-5’- 
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qPCR quantitative PCR 
RFA radiofrequency ablation 
Dox doxycycline RNAi RNA interference 
EDTA ethylenediaminetetraacetic acid 
ROMA 
representation oligonucleotide 
microarray analysis e. g. exempli gratia (for example) 
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Fig figure sec second 
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GEMM 
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models 
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research 
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miR microRNA v/v volume/ volume 
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Summary 
 
Hepatocellular carcinoma (HCC), the third leading cause of cancer death worldwide, 
represents a highly chemoresistant tumor and only recently the multikinase inhibitor 
Sorafenib was approved as the first active systemic treatment against HCC. This illustrates 
that targeted therapies can be effective and therefore heralds a new era in HCC treatment. 
However, Sorafenib monotherapy increases survival of HCC patients by less than 3 months, 
thus emphasizing the strong need to understand the molecular mechanisms of Sorafenib 
sensitivity and resistance in order to inform new combination therapies with higher 
therapeutic efficacy. 
Activation of the Ras/MAPK signaling pathway was reported to play a major role in liver 
tumor development and progression. Taking advantage of genetically defined mosaic liver 
cancer mouse models, it was shown that Sorafenib treatment of NrasG12V; p19Arf-/- driven 
murine liver carcinomas results in moderate but distinct treatment responses resembling the 
response rates of Sorafenib treated human HCCs.  
To identify genes mediating resistance or sensitivity towards Sorafenib, we conducted an in 
vivo RNAi screen. Pools of shRNAs targeting genes found amplified in human hepatocellular 
carcinomas were applied and p19Arf-/- mice harboring NrasG12V expressing liver carcinomas 
with stable expression of shRNA library pools were either treated with Sorafenib or carrier 
(control). After 5 weeks of treatment, shRNA distribution was quantified in tumors from both 
cohorts using deep sequencing, whereas depleted shRNAs pinpoint potential resistance genes 
towards Sorafenib treatment.  
Functional validation experiments were performed with multiple independent single shRNAs 
against a possible “sensitizing” target (Mapk14 or p38α) and confirmed a significant survival 
benefit over Sorafenib treated tumors that express non-targeting control shRNAs.  
Cell proliferation and cell death assays pinpoint inhibition of proliferation as the main 
mechanism responsible for the synergism between Sorafenib and Mapk14 inhibition.  
Using mouse models and conditional RNAi technology, the sensitizing effect of Mapk14 
knockdown towards Sorafenib treatments could also be shown in advanced tumors in a 
preclinical treatment study. 
Importantly, Mapk14 represents a kinase and, taking advantage of readily available 
pharmacological inhibitors, it could be shown that combination therapy with Sorafenib results 
in a significant survival advantage of tumor bearing mice. Some of the used inhibitors 
(Skepinone-L and PH 797804) are believed to have a high potential to enter the clinic. 
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The identified new combination treatment was also expanded to murine HCC cell lines with 
additional genetic backgrounds. In these cell lines, therapeutic efficacy as a result of 
Sorafenib and p38 blockade was also found, but not every Mapk14 inhibitor worked 
efficiently in the tested cell lines. Additionally, it was shown that the newly identified 
combination therapy significantly decreased proliferation and induced cell death in a panel of 
well established human hepatoma cell lines (PLC/PRF/5, Huh7, Hep3B).  
To characterize how Mapk14 blockade sensitizes for towards Sorafenib treatment, microarray 
based mRNA expression analyses were performed and were analysed by Ingenuity pathway 
analysis. This analysis along with genetic validation experiments identified the Mapk14 
downstream target and transcription factor ATF2 as relevant for Mapk14 mediated resistance 
towards Sorafenib treatment.    
 
In summary, our study establishes a new Sorafenib-based combination therapy for the 
treatment of hepatocellular carcinoma.The study highlights the potential of in vivo RNAi 
screens to identify genes that modulate the treatment response of targeted therapies. 
Additionally, the screen was performed in a mosaic mouse model that resembles the natural, 
spontaneous cancer development and could be used to identify other treatment options in 
HCC.  
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1. Introduction 
 
1.1. Development of hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma is the sixth most common cancer and the third most common cause 
of cancer mortality worldwide. In 2008, around 700,000 new cases were identified and there 
were 696,000 deaths from HCC worldwide. Reasons accounting for the high lethality rate are 
HCC detection at advanced stages and also liver dysfunction due to liver cirrhosis [1;2]. The 
majority of HCCs arise in Eastern Asia and sub-Saharan Africa with the highest incidence 
rate (50 %) occurring in China. In contrast, the occurrence of HCCs is lower for North and 
South America, Northern Europe, Oceania and shows a more moderate rate for Southern 
Europe [3]. HCCs arise mainly from adult hepatocytes (80 %) and to a lesser extent from 
bipotential liver progenitor cells [4;5]. The highest risk of HCC development occurs in 
patients with chronic liver diseases which trigger rounds of cell death and proliferation that 
further give rise to nodules surrounded by collagen deposition and liver scarring, so-called 
cirrhosis. Cirrhotic nodules can further progress into hyperplastic and dysplastic nodules, and 
as a result into HCCs which can be categorized into well differentiated, moderately 
differentiated and poorly differentiated tumors (Fig. 1) [6].    
Major risk factors for liver cancer development are viral infection with hepatitis B and C, 
alcohol abuse, and infection with aflatoxin-B1 containing food [7]. Although normally higher 
risk for HCC is associated with cirrhosis, HBV infection can also elicit hepatocarcinogenesis 
in noncirrhotic liver disease. HBV is a DNA virus that can directly integrate into the host 
genome. HBV integration can cause chromosomal instability as a result of deletions, 
amplifications or translocations and can integrate into the genes coding for oncogenes or 
tumor suppressor genes, responsible for control of cell proliferation [8]. By contrast, HCV is 
an RNA virus that does not integrate into the genome but rather regulates cell cycle via direct 
interaction with proteins, like p53 or Rb tumor suppressor proteins. Aflatoxin B, a mycotoxin 
from Aspergillus flavus or Aspergillus parasiticus can exert its carcinogenic effects via 
generation of DNA mutations, for example in TP53 gene that may further decrease its tumor 
suppressive function [9]. Alcohol is also an important risk factor for development of HCC 
which may act synergistically with viral hepatitis to further increase risk of HCC. Hereditary 
hemochromatosis, an inherited liver disorder that increases the risk for HCC in individuals 
homozygous for HFE mutation.  
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Figure 1 Hepatocellular carcinoma development 
Different risk factors and liver diseases induce cycles of cell death and proliferation that may ultimately give rise 
to HCCs (adopted from [6]). 
 
There are other rare cases that may predispose for HCC development, such as Wilson’s 
disease (copper accumulation), α1-antitrypsin deficiency and type1 glycogen-storage disease 
[7]. Moreover, a nonalcoholic fatty liver disease with its most aggressive form known as 
nonalcoholic steatohepatitis (NASH) can also contribute to HCC carcinogenesis. Among the 
risk factors for NASH to develop are obesity, diabetes and iron deposition [10;11]. 
 
1.2. Molecular pathogenesis of hepatocellular carcinoma  
The exposure to different risk factors influences signaling pathways and consequently the 
gene expression profile. Some of the most important key signal transduction pathways that are 
implicated in hepatocarcinogenesis are Ras/MAPK signaling pathway, Akt/mTOR pathway, 
IGF and EGF signaling cascades, c-MET pathway and Wnt-βcatenin pathway [12].  
Signaling molecules like epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) can 
activate Ras/MAPK cascade by binding to receptor tyrosine kinases (RTK) [12]. Upon 
binding of those ligands, RTKs undergo activation as a result of phosphorylation of their 
tyrosine (Tyr) residues which further signal via SOS to Ras (Fig. 2a). Ras works as a 
molecular switch that relays the signals only when in its active, GTP-bound status.  
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Figure 2 Signal relay along the Ras/MAPK cascade 
Upon activation of tyrosine kinase receptors, Ras conveys the signal by firstly activating Raf-1 which in turn 
phosphorylates and activates Mek (MAP2K1 and MAP2K2) which subsequently activates Erk to influence cell 
cycle processes (a). Inactive, GDP-bound Ras is activated by GEF (guanine nucleotide exchange factor) which 
releases GDP and allowes GTP to bind to Ras, thereby forming its active GTP-bound state (b) (adopted from 
[13]). 
 
Guanine nucleotide exchange factors (GEFs) catalyse the replacement of GDP-bound, 
inactive state with GTP. Contrary, GTPase activating proteins (GAPs) catalyse the hydrolysis 
of bound GTP into inactive GDP-bound conformation via induction of GTPase activity of Ras 
itself (Fig. 2b) [14].    
Activated Ras binds and activates the kinase activity of Raf proteins (c-Raf1, B-Raf and A-
Raf). Further downstream, Raf phosphorylates and activates mitogen-activated protein kinase 
kinases 1 and 2 (MAP2K1 and MAP2K2 or also known as Mek1 and Mek2) which proceed in 
phoshorylation and consecutive activation of extracellular-signal regulated kinase (Erk1 and 
Erk2). Ras/MAPK pathway regulates many transcription factors which control the genes 
implicated in apoptosis, cell growth and differentiation [13]. 
Deregulation of the Ras/MAPK pathway may occur as a consequence of activating mutations 
in RAS which in case of HCC account for ~7 % in KRAS and ~4 % in NRAS [14]. These 
mutations normally influence the GTPase activity of Ras which by avoiding the hydrolysis of 
GTP  makes Ras to accumulate in its active, GTP-bound conformation [15]. Additionally, 
deletion of NF1 (neurofibromin), RASAL1 or DAB2IP, GTPase activating proteins with tumor 
suppressive role may promote Ras/MAPK upregulation and indeed are found depleted or 
downregulated in human HCCs [16]. Another frequently mutated gene in HCC (9.6 %) is 
RPS6KA3 encoding for the ribosomal S6 protein kinase 2 (RSK2) which exerts its inhibitory 
role on Ras/MAPK pathway by phosphorylating SOS [17].   
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Ras also regulates p38 MAPK pathway [18;19], also known as stress activated protein kinase 
pathway that is often found deregulated in cancers [20]. P38 MAPKs encompass 4 genes: 
MAPK14 (p38α), MAPK11 (p38β), MAPK12 (p38γ) and MAPK13 (p38δ). Although, p38α 
and p38β are much related in function and sequence, with p38α being mostly abundant and 
mostly characterized. The other two, p38γ and p38δ share more similarity and are more 
constrained in expression [20]. Interestingly, in cancer cell lines p38α can either have anti-
proliferative functions or can positively regulate cell proliferation [21;22]. For example, mice 
with liver specific deletion of Mapk14 showed stronger hepatocyte proliferation and enhanced 
chemically induced tumor development [23].  
The MAPK pathway can stimulate the growth of new vessels upon activation of vascular-
endothelial growth factor receptor (VEGFR). This process, termed angiogenesis, stimulates 
the tumor vascularization and therefore plays an important role in regulating tumor growth 
and metastatic potential. The major angiogenesis stimulant is VEGF that binds to two 
different receptors on endothelial cells, namely VEGFR-1 and VEGFR-2 that further 
transduce the signal along MAPK pathway proteins [24]. Aberrant VEGF expression occurs 
often in HCC and is associated with HCC tumour invasion and metastasis [25] and may also 
be involved in the development of the stroma in HCC [26].   
The PI3K (phospatidylinositol-3 kinase)/Akt pathway also plays a crucial role in 
hepatocarcinogenesis and importantly its catalytic subunit PIK3CA is found somatically 
mutated in 26 of 73 human hepatocellular carcinomas [27]. PI3Ks are capable of 
phosphorylating the inositol ring 3’-OH group in inositol phospholipids to induce the 
production of second messengers like PIP3, phosphatidylinositol-3,4,5-triphosphate. PIP-3 
activates the kinase PDK1 3-phosphoinositide-dependent protein kinase-1 which in turn 
phosphorylates and activates Akt kinase, also known as protein kinase-B. Akt modulates the 
activity of numerous downstream targets involved in the regulation of cell cycle progression, 
like NF-kappa B, mTOR (mammalian target of rapamycin) and GSK3β. A negative regulator 
of PI3K/Akt pathway is Pten (phosphatase and tensin homolog deleted on chromosome 10). 
Pten is a tumor suppressor gene and its loss of function constitutively activates its 
downstream elements such as Akt and mTOR [28;29]. Deregulation of PTEN in HCC occurs 
mainly via epigenetic silencing and it is localized in a region of frequent loss of 
heterozygosity (LOH) [30;31].  
A very important target of the Ras/MAPK- and PI3K/Akt pathways is the family of MYC 
protooncogenes (C-MYC, L-MYC and N-MYC). Myc is a pleiotropic transcription factor 
which coordinates many cellular processes like cell proliferation, angiogenesis or apoptosis. 
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Its overexpression in almost half of human cancers occurs as a result of epigenetic alterations. 
Interestingly, Ras can signal to Myc via two different cascades which influence Myc stability. 
If Ras conveys a signal through the classical MAPK pathway (along Raf and Erk) it becomes 
phosphorylated at Ser62 extending its half life. On contrary, Ras signals through 
phosphoinositide-3-kinase to block the activity of Gsk-3 (glycogen synthase-3) to further 
phosphorylate Myc at Thr58 that normally targets it for proteolytic degradation [32;33]. Myc 
activates the expression of high number of genes and has around 25,000 binding sites in the 
genome, called E-boxes with CANNTG sequence. Monomers of Myc have not been found, 
instead it forms dimers with its partner, Max. Concurrently, Max forms homodimers and 
heterodimers with other proteins, like Mad1, Mxi1, Mad3, Mad4 or Mnt. Interestingly, Myc-
Max dimers are typical for proliferating cells, whereas Mad-Max or Mnt-Max complexes are 
frequently found in resting or differentiated cells [34;35]. Myc regulates the pRb-E2F 
pathway, one of major cellular barriers to cancer development in which tumor suppressor 
retinoblastoma protein Rb controls the E2F transcription factor (Fig. 4) [36].  
In normal cells with wild type Rb, hypophosphorylated Rb binds and thereby sequesters 
E2F1, 2, and 3. However, phosphorylation of Rb by cyclin-dependent kinases (CDKs) 
together with their catalytic subunit cyclins causes release of E2F which can in turn induce 
the transcription of E2F responsive genes important for progression through G1/S transition. 
Complexes between Rb and E2F repress E2F responsive promoters by mainly recruiting 
histone deacetylases (HDACs) which silence genes upon deacetylation of nucleosomes 
[37;38]. The inhibition of CDKs by the INK4 proteins (p16INK4a, p15INK4b, p18INK4c and 
p19INK4d) prevents the phosphorylation of Rb [39].  
The gene locus of p16INK4a (CDKN2a) also encodes for the alternative reading frame protein 
p19Arf in mice (p14ARF in humans). Arf stands for an alternative reading frame since it shares 
two exons with p16INK4a but in another reading frame [40]. P19Arf is an important tumor 
suppressor that regulates p53, which is another potent tumor suppressor responsible for 
inducing cellular pathways of tumor suppression (apoptosis or growth arrests) upon oncogene 
activation, DNA damage or hypoxia (Fig. 3). P53 is negatively regulated by Mdm2 that 
targets it for proteosome-mediated degradation. In contrast, p53 is positively activated by 
p19Arf which binds to Mdm2 to antagonize its functions [41]. Rb and p53 are important 
mediators of cellular senescence, which act as a barrier to tumorigenesis and can be induced 
in response to oncogenic activation.  
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Figure 3 Scheme for the interaction between Rb and p53 pathways 
P19Arf is induced upon oncogenic activation and activates as well as stabilizes the tumor suppressor p53 via 
inhibition of p53 negative regulator Mdm2. P19Arf is also a target of E2F transcription factor that in turn is 
activated upon deactivation of tumor suppressor Rb by dephosphorylation. Rb protein is inhibited by Cdk4, the 
activity of which can be blocked by p16Ink4a, another important tumor suppressor gene (adopted from [41]). 
 
P16 and p21 are both cyclin-dependent kinase inhibitors (CDKIs) which keep Rb in its active, 
hypophosphorylated state which in turn curtails proliferation by not allowing for transcription 
of E2F target genes. Interestingly, p53 induces the expression of p21 and E2F constrains 
proliferation by inducing p19Arf transcription which implicates p53 [42]. The TP53 gene 
encoding for p53 is inactivated by genetic alteration in around half of human cancers [43]. It 
is also found mutated in 30 – 40 % cases of human HCCs [44;45]. Mutations of p14Arf are not 
common in HCC but rather found inactivated by promoter methylation in approximately 15 % 
of HCCs [46].  
Additionally, p16INK4A gene is also found inactivated usually by promoter methylation in 
around 65 % of HCCs, and sometimes by homozygous deletion [46]. Similarly, the 
expression of RB1 coding for Rb is reduced in 25 % of HCCs by promoter methylation [47].  
Another important pathway that is implicated in HCC is the Wnt signaling pathway. The Wnt 
signaling cascade is activated when Wnt ligands bind to their target Frizzled (Fz) receptors to 
interfere with the multi-protein destruction complex (including Axin, adenomatosis polyposis 
coli (APC) and GSK3β), resulting in the activation of transcription of β-catenin target genes. 
The presence of this complex is necessary for GSK3-mediated phoshorylation of β-catenin 
that targets it for proteasomal degradation. Upon pathway activation, the complex is 
disassembled and thus β-catenin cannot undergo phosphorylation and consequently can 
accumulate in the nucleus and activate TCF/LEF transcription factors which in turn activate 
specific oncogenes such as c-Myc and cyclin D [48]. Overexpression and mutations of β-
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catenin arise particularly in HCV-related HCCs [44;49]. Furthermore, β-catenin has also been 
implicated in HBV-related HCC due to stabilization of β-catenin by HBx protein [50]. 
According to some studies, β-catenin overexpression or mutations are associated with early-
stage HCCs [51] and according to others, with HCC progression [52]. In HCCs, activating 
mutations in the -catenin gene CTNNB1 occur in 17 % of all cases and inactivating 
mutations in the negative regulator of Wnt pathway, Axin gene AXIN1 arise in 7 % of HCCs 
[53]. Moreover, Wnt signaling cascade can also be activated by aberrant promoter 
hypermethylation of Apc [54].   
 
1.3. Treatment of hepatocellular carcinoma 
So far several staging systems for HCC have been defined, such as Barcelona Clinic Liver 
Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), TNM (tumor, node and 
metastasis), Okuda, and Japanese Integrated Staging Score (JIS). However, BCLC came up 
as a standard classification system for the management of HCC in the clinic in which tumor 
staging is associated with recommended treatment options [2]. BCLC distinguishes three 
main stages: early stage (0-A), intermediate-advanced stage (B-C) and end stage (D). The 
very early stage 0 is characterized by one single nodule ≤ 2 cm  and by lack of invasion into 
surrounding tissue. In stage A the tumor is defined as a single nodule 2-5 cm, or by 3 nodules 
each of which is ≤ 3 cm in size. Patients that are classified among 0-A stage have a well 
preserved liver function and are suitable for curative treatments such as: liver transplantation, 
surgical resection, or local ablation approaches, encompassing percutaneous ethanol injection 
(PEI) and radiofrequency ablation (RFA) [55]. The performance in terms of survival is 
usually good with 5-year survival rates between 50 - 70 % when using the aforementioned 
treatment options [56]. Patients with intermediate, stage B HCC are asymptomatic with 
multinodular tumors without an invasive pattern [57]. For those patients, transarterial 
embolization (TAE) or transarterial chemoembolization (TACE) are applicable [55]. 
Normally, a median survival of 16 months is typical for untreated patientsin this stage that 
can be further expanded up to 19 - 20 months upon application of chemoembolization [58]. 
On contrary, untreated patients with advanced stage C HCC exhibit symptomatic tumors with 
additional presence of vascular invasion or extrahepatic spread [57] and a median survival of 
6 months. Systemic treatments such as Sorafenib, systemic chemotherapy, immunotherapy or 
hormonal blockade can be applied to stage C patients. Here, however, only Sorafenib shows 
a significant increase in survival and there is no survival benefit for other therapy options. 
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Patients with stage D HCC do not benefit from antitumor therapies, show very severe tumor-
related symptoms and exhibit a median survival of 3 - 4 months [59].    
Surgical resection to remove the tumor while preserving enough liver tissue is mostly 
suitable for non-cirrhotic patients with one nodule. Tumor recurrence after resection arises in 
70 % of patients at 5 years. It occurs as a result of true recurrence (up to 2 years) or after 2 
years due to growth of de novo tumors. The risk of recurrence correlates with tumor size and 
the number of tumors, and vascular invasion increases with nodule size. Thus, surgical 
resection is not recommended for patients with vascular invasion or metastasis [60]. 
Interestingly, microscopic tumor invasion occurs in 20 % of nodules with 2 cm in size, 30 - 
60 % in 2 - 5 cm nodules and reach 60 - 90 % in nodules that exceed 5 cm in size [59]. 
Taking into account these criteria, only 10 - 15 % of patients are suitable for resection [1].  
Liver transplantation seems to be the best curative treatment since it fully replaces the 
diseased liver with a living donor graft. HCC patients eligible for liver transplantation are 
those with a solitary nodule smaller or not larger than 5 cm, or up to 3 nodules each of 3 cm 
or smaller, and additionally without vascular invasion or extrahepatic spread. These patients 
achieve a 4-year survival of 75 % with a recurrence rate below 15 %. The major 
disadvantage of this treatment is the shortage in donors and thus the number of candidates 
undergoing liver transplantation is small compared with the total number of patients with 
HCC [1;61]. 
Image-guided tumor ablation is based on direct application of chemical or thermal treatment 
to tumor(s). Ablation itself should significantly destroy the tumor as a consequence of 
induced necrosis either upon injection of chemicals (e.g. ethanol, acetic acid) or temperature 
change (e.g. cryoablation, or ablation by laser, or by radiofrequency). Most often used 
ablation procedures in HCC treatment are percutaneous ethanol injection (PEI) and 
radiofrequency ablation (RFA), both recommended for patients who are not good candidates 
for surgical resection or liver transplantation due to comorbidities or non-functional liver. 
PEI and RFA have an excellent outcome with complete necrosis in most HCCs with nodules 
< 2 cm in size and a survival benefit comparable with surgical resection or liver 
transplantation. Both procedures are not suitable for patients with nodules bigger than 5 cm 
[62]. The major drawback of PEI is high local recurrence rate that accounts for 33 % in 
nodules smaller than 3 cm, and 43 % in nodules greater than 3 cm [63]. RFA is regarded as 
having higher anticancer effect than PEI [64] and being more effective against nodules 
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bigger than 2 cm [62]. However, the occurrence of side effects is higher for RFA-treated 
patients (4.1 %) compared to 2.7 % for PEI-treated patients [65].     
Progression of HCC is accompanied by intense angiogenesis, and TACE (transarterial 
chemoembolization) is performed by injecting chemotherapeutic drugs (e.g. cisplatin, 
doxorubicin) mixed with an embolizing agent (e.g. gelfoam) into arterial vessels supplying 
the tumor. The same procedure but without the introduction of chemotherapy is called 
transarterial embolization (TAE). The aim of embolization is to cause tumor necrosis via 
arterial occlusion. It is mostly recommended for patients with multinodular disease, without 
vascular invasion or extrahepatic spread, and those being ineligible local for ablative 
procedures [62]. Another type of TAE for non-resectable liver tumors is selective internal 
radiation therapy (SIRT). SIRT is a means of delivery microspheres containing radioactive 
substance into hepatic artery which are selectively directed into liver tumors as a result of 
hepatic arterial supply to tumors [66;67]. 
HCC is a highly chemoresistant tumor and although many chemotherapeutic agents have 
been tested in HCC, no single or combination chemotherapy appeared to have a significant 
survival advantage. Doxorubicin is probably the most commonly used agent in HCC with a 
response rate ranging from 10 % to 15 %, but without survival benefit. Patients treated with 
this agent encounter grade 3 or 4 toxicities. Low response rates and no survival benefit were 
also observed for other chemotherapeutic drugs like cisplatin, epirubicin, 5-fluorouracil or 
etoposide, as well as their combinations. Newer chemotherapeutic agents like gemcitabine, 
paclitaxel, irinotecan, capecitabine, and pegylated liposomal doxorubicin did not yield better 
results. Given the disappointing results with single agents, different combination treatments 
were tested. Even if initially some of them showed interesting results in II phase trial, many 
of them did not succeed in phase III studies [68]. Combination chemotherapy with 
doxorubicin, cisplatin and 5-fluorouracil with or without interferon showed a moderate 
response rate of 13 % to 39 % without any influence on survival [69]. The combination of 
gemcitabine and oxaliplatin displayed a response rate of only 19 % in patients with advanced 
HCC [70].  
In fact, resistance to chemotherapy is linked to different drug resistance mechanisms 
occurring in HCCs. Doxorubicin targets DNA topoisomerase II and its frequent 
overexpression in HCC may be the reason for resistance to doxorubicin-based therapy [71]. 
Resistance to 5-fluorouracil is usually accounted for by high levels of dihydropyrimidine 
dehydrogenase present in HCC [72]. Moreover, overexpression of P-glycoprotein is 
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associated with poor response to paclitaxel [73]. Since p53 is important for induction of 
apoptosis, tumors with an impaired p53 pathway become refractory to chemotherapy. 
Cirrhosis plays also a role in responsiveness to chemotherapeutic agents. Cirrhotic tissue 
causes changes in liver architecture, and thus changes in blood flow and drug metabolizing 
enzymes [74].     
Other randomized trials employing anti-hormonal treatment with, tamoxifen, did not improve 
the overall survival of HCC patients [68].  
Similarly, immunotherapy with interferon appeared also to be ineffective. Studies conducted 
using a 3 times weekly scheme of interferon (dose of 3x106 IU) did not demonstrate any 
survival benefit [68].   
 
1.4. Molecular targeted therapies in HCC 
Although resection and liver transplantation are considered as the standard curative 
treatments for HCC, they are not suitable for patients with advanced stage HCC and poor 
liver function. Additionally, a problem is the waiting time due to a lack of liver donors that 
delays transplantation and also contributes to tumor progression during that time. Cancer 
development is regulated by a complex molecular network of signaling cascades comprising 
a multitude of proteins such as extracellular ligands, transmembrane receptors, intracellular 
proteins and transcription factors. Many standard anticancer agents affect rapidly growing 
cells (e.g. chemotherapy) in general, thus resulting in significant toxicities to rapidly dividing 
tissues such as bone marrow or intestine. In contrast, molecular targeted therapies are 
designed to specifically inhibit signaling pathways that are induced in cancer cells and hold 
the promise to allow for a more efficient and less toxic cancer therapy [75].    
Some hope for the patients with advanced HCC came with the development of Sorafenib 
(Nexavar). Many other molecular targeted therapies are under development for the treatment 
of HCC, but so far only Sorafenib showed a significant benefit that led to its approval for 
HCC treatment. Sorafenib is an oral multityrosine kinase inhibitor which was originally 
selected based on its high Raf (wild-type Raf1, and mutant and wild type B-Raf) inhibitory 
effect (Fig. 4). Additionally, it targets the vascular endothelial growth factor receptor 2 
(VEGFR-2) and VEGFR-3, platelet-derived growth factor receptor PDGFR-β, Fms-like 
tyrosine kinase 3 (Flt-3), Ret, and c-KIT [76]. Sorafenib exhibits antiproliferative effects in 
vitro in HCC cell lines (e.g. PLC/PRF/5 (also called Alexander), HepG2) and strong 
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antitumor effects in HCC xenograft models [77]. It demonstrates also a broad antitumor role 
in a panel of other human tumor xenograft models representing human colon, lung, breast, 
melanoma, ovarian, and pancreatic cancers [78;79]. Sorafenib showed improvement of overall 
survival in patients with advanced HCC in two phase III trials. One of them was carried out in 
121 centres for which 299 patients were randomly assigned into Sorafenib treatment (200 mg 
twice daily) and 303 patients to placebo group with no difference between the groups with 
respect to tumor stage, prognosis or demographic features. In this trial, patients who received 
Sorafenib had an almost 3-month median survival benefit over patients in the placebo group, 
with overall survival reaching 10.7 months for Sorafenib arm versus 7.9 months for placebo 
group (Fig. 5). Time to progression differed between the groups, with 5.5 months for 
Sorafenib treated patients and 2.8 months for placebo treated patients [80]. These results were 
also reproduced by another randomized trial in Asia in which the median overall survival was 
6.5 months in the Sorafenib group compared to 4.2 months in the placebo group [81]. 
The most common adverse effects associated with drug administration were diarrhea and 
hand-foot skin reaction [80]. These promising results led to approval of Sorafenib for the 
treatment of advanced hepatocellular carcinoma.  
Since Sorafenib shows only a moderate survival benefit, there is a strong need to further 
improve molecular targeted therapy against HCC. One other target for molecular inhibition 
within Raf/MAPK pathway is Mek (Fig. 4). 
 
 
Figure 4 Molecular therapies targeting the Ras/MAPK and PI3K/Akt pathway 
Within Ras/MAPK pathway targets for Sorafenib and AZD6244 are shown, furthermore targets for Everolimus 
and Bortezomib are depicted (adopted from [82]). 
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AZD6244 is an oral Mek inhibitor which was evaluated in HCC patients in a phase II study, 
however, as a single agent did not show any survival advantage. It was tested in 19 HCC 
patients  [83].  
As described before, also the PI3K/Akt pathway contributes to hepatocarcinogenesis. 
Therefore, several targeted therapies against this pathway have been developed (Fig. 4). The 
most common one is rapamycin (sirolimus), an mTOR inhibitor with antiproliferative and 
antiangiogenic functions. Rapamycin and its derivative, Everolimus, showed antitumor effects 
in preclinical studies and in xenograft HCC models [84;85]. A small study with 21 HCC 
patients who underwent treatment with Sirolimus showed a partial response for five patients 
and disease stabilization for at least 3 months in 24 % of patients. The median overall survival 
was 6.5 months, without severe side effects [86]. Bortezomib is a proteasome inhibitor that 
was approved for the treatment of multiple myeloma and a phase I and II in patients with 
HCC is under way [82].    
Other molecular therapies for HCC aimed to improve antiangiogenic efficacy underwent 
clinical evaluation (Fig. 6). One of them is Sunitinib. It is also an inhibitor of different kinases 
such as VEGFR-1, -2, PDGFR-α, -β, c-Kit, Flt-3 and RET [87]. 
Sunitinib showed antitumor efficacy in xenograft models of HCC by inducing apoptosis, 
decreasing microvessel density and inhibiting cell proliferation [88]. A phase III trial that 
aimed at comparing Sunitinib with Sorafenib in patients with advanced HCC was dismissed 
due to more frequent severe adverse effects in the sunitinib group than Sorafenib group [83].  
 
 
Figure 5 Overall survival of patients with advanced HCC assigned to Sorafenib or placebo treatment 
Randomized placebo controlled trial in patients with advanced hepatocellular carcinoma in which Sorafenib 
group shows an almost 3-month survival benefit over placebo group (adopted from [80]). 
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Figure 6 Molecular-targeting agents for VEGFR-, EGFR-, ErbB2-, and IGFR-induced signaling 
Shown are targeted therapies for pathways stimulated mainly by VEGF, EGF, and IGF (adopted from [82]). 
 
Bevacizumab (Avastin), a humanized monoclonal antibody that targets all VEGF isoforms 
showed antiangiogenic effects in orthotopic models based on the human HCC cell line Hep3B 
[89]. In a phase II study, 13 % of patients had a partial response and 65 % patients achieved 
stable disease  [90]. Similar results were obtained in a second phase II study in which partial 
response was observed in 12.5 % and stable disease in 29 % [83].  
A frequent deregulaton of signaling via EGFR in HCCs prompted the development of 
targeted therapies blocking its signaling (Fig. 6). One of them is Gefinitib (Iressa) that blocks 
EGFR. In a phase II study with  31 HCC patients , 3 % of patients showed a partial response 
and 22.6 % a stable disease. Later on, Gefinitib was considered as being inactive in patients 
with advanced HCC [83]. Erlotinib, another EGFR inhibitor was evaluated in two phase II 
studies in patients with advanced HCC. The first study with 38 patients demonstrated a partial 
response for 3 patients, and progression-free survival at 6 months for 12 patients, with a 
median overall survival of 13 months [91]. In another study with 40 patients, 17 patients 
experienced a progression-free survival at 16 weeks [92]. Cetuximab, a monoclonal antibody 
against EGFR underwent two phase II studies. In the first study with 30 HCC patients, a 
stable disease was observed for five patients, with a median overall survival of 9.6 months 
and with a progression-free survival of 1.4 months. In  another study with 32 patients, no 
responses were reported and the median time to progression was 8 weeks [82].  
Taken together, Sorafenib improves the survival of patients with advanced HCC in a 
significant but moderate way. Although Sorafenib is approved as a standard treatment for 
advanced HCC, there is a strong need for combining Sorafenib with other therapies to 
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enhance the response rate and the overall survival benefit for patients with advanced HCC. 
Preliminary results for combination of Sorafenib with doxorubicin were promising but 
doxorubicin causes severe toxicities, and hence trials with novel chemotherapeutic drugs are 
ongoing [1]. Inhibiton of Mek by AZD6244 enhanced the anticancer activity of Sorafenib in 
both orthotopic and ectopic HCC xenograft models [93]. Combination of Sorafenib with 
sunitinib failed due to toxicity; other combinatorial trials are underway [1].     
 
1.5. Mouse models for studying hepatocellular carcinoma 
The study of human cancers by characterizing cell lines, which were isolated from human 
tumors have made important contributions to the understanding of signaling and molecular 
mechanisms of tumorigenesis, however, cell lines they do not recapitulate the 
microenviroment and vascularization of tumors. Furthermore, these models do not reflect the 
complex interaction of tumors with the surrounding tissue and the immune system. 
Also the significance of tumors based on human cancer cells, which were inoculated 
subcutaneously or orthotopically in different organs of immunodeficient mice (xenograft 
models) is limited, because these tumors show a different vascularization and 
microenvironment. Furthermore, the implantation of human tumor cells necessitates the usage 
of immunodeficient mice, however, it has been shown that the immune system plays an 
important role in tumor development. Although almost each anticancer agent was subjected to 
testing in these xenograft models, treatment studies are limited because immunomodulatory 
agents cannot be tested and as a result the tested drugs may demonstrate a response in 
xenograft models but may be much less effective in the clinical evaluation [94-96]. 
Mice and humans share a high similarity in genetics and physiology [97] and 99 % of murine 
genes have a direct human counterpart [97]. Therefore, mouse models with an orthotopic and 
autochtonous tumor initiation are highly valuable to study the molecular mechanisms as well 
as potential treatment options of cancer [94]. 
To study hepatocellular carcinoma in mice, HCCs can be developed as a result of exposure to 
carcinogenic chemicals, like N-nitrosodiethylamine (DEN) to induce hepatocarcinogenesis 
[98;99]. However, arising tumors are not genetically defined, restricted in type and grade with 
variable latency [100].  
To establish genetically defined liver cancer mouse models, genetically engineered mouse 
models (GEMM) can be used which harbor hyperactive oncogenes and/or lack functional 
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tumor suppressor genes. To allow for oncogenic expression in specific organs, tissue specific 
promoters can be used (e. g. albumin promoter in the liver [101;102]) or hyperactive 
oncogenes can be activated by the Cre-lox system (using a lox-stop-lox sequence 5’ of gene 
of interest), whereas Cre is activated by a tissue specific promoter (Alb-Cre for the liver 
[103]). Additionally, tumor suppressor genes can be deleted by Cre activation, when the 
corresponding genes are flanked by lox sequences (lox-p) [104]. 
To avoid developmental compensation or embryonic lethality, conditional expression of 
transgenes as well as conditional loss of tumor suppressor genes is possible by using 
tetracycline responsive elements (TeT-Off or TeT-On systems), which induce Cre activation 
dependent on tetracycline or doxycycline administration [105].   
However, mouse models based on tissue specific expression of oncogenes pose a limitation 
due to the genetic field effect of expressing an oncogene in every cell of the tissue where the 
surrounding environment carries the same genetic event [106]. Importantly, this expression 
pattern does not reflect human carcinogenesis, where cancer development is based on the 
transformation of a single cell in the context of a normal microenvironment [100]. 
In order to induce oncogenic activation only in a subfraction of cells, which are sourrounded 
by non malignant cells (mosaic mouse model), Cre recombinase can be delivered manually 
into the corresponding organ of mice (e.g. using adenoviral gene transfer in the liver). 
Another mosaic liver cancer mouse model is based on a transplantation of liver progenitor 
cells (chimeric mouse model). Embryonic hepatoblasts can be isolated from p53-/- fetal livers 
and subjected to ex vivo viral gene transfer via MSCV-based retroviruses expressing different 
oncogenes. Such models were already efficiently used to identify new genes implicated in 
hepatocarcinogenesis via oncogenomic approaches [107;108]. Although this model closer 
resembles the physiological, spontaneous tumor developement, the requirement for ex vivo 
genetic manipulation may cause some unfavourable genetic alterations. Additionally, 80 % of 
HCCs are induced from hepatocytes, and this model relies on the usage of progenitor cells 
which account only for 20 % of HCCs [4;5]. 
Interestingly, DNA, proteins and viruses can be delivered to adult hepatocytes using a 
hydrodynamic tail vein injection [109;110]. Furthermore, the delivery of transposable 
elements in combination with a transposase (sleeping beauty) allows for efficient integration 
of target genes into the genome [111;112].  
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Figure 7 Hydrodynamic tail vein injection delivers DNA into the liver and efficiently induces tumor 
development 
Injection of transposable elements encoding oncogenes together with transposase (a). Stably transfected NrasG12V 
triggers HCC in p19Arf-/- mice (adopted from [113]).  
 
The delivery of oncogenes into hepatocytes with different genetic background allows for 
investigating the molecular mechanisms of liver cancer in adult hepatocytes [113-115]. 
Therefore, the delivery of oncogenic NrasG12V into p19Arf deficient mice elicits a high number 
of liver tumors within several weeks, which is an efficient genetic background to study 
hepatocarcinogenesis (Fig. 7) [113].  This mosaic mouse model is very attractive, as it allows 
for oncogenic transformation of a target cell that has never been taken out of its natural 
environment. 
 
1.6. RNAi screening for the discovery of novel modulators of cancer 
RNA interference (RNAi) emerged as a mechanism to silence gene expression and can be 
used to delineate gene function. RNAi can suppress gene expression at both transcriptional 
and posttranscriptional level [116;117] by different types of small non-coding RNAs, as small 
interfering RNA (siRNA), microRNA (miRNA) or Piwi-interacting RNA (piRNA).  
Availability of RNAi technology led to the development of high-throughput screens with 
RNAi-based libraries for elucidating signaling cascades and revealing cancer vulnerabilities. 
The libraries can contain either synthetic siRNAs or shRNAs that are expressed by DNA 
precursors. SiRNAs can be directly transfected into cells, whereas shRNA libraries are mainly 
available in the form of viral vectors (retrovirus, lentivirus). The application of siRNAs is 
most suitable for easily transfectable cells and a transient silencing of gene expression 
because siRNAs do not replicate simultaneously with DNA of the host cells and are therefore 
lost with time.  
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Figure 8 miR30-based shRNAs 
Schematic representation above depicts an example of secondary structure of miR30-based shRNA hybrid (a) 
(adopted from [118]), primary transcript of the miR30 miRNA (b), and shRNA embedded within the miR30 
context (c) (adopted from [119]). 
 
On the contrary, shRNAs are chosen if the cells are difficult to transfect and if a longer 
silencing of gene expression is needed. Since retroviruses expressing shRNAs are integrated 
into the genome of the host cell, they are copied along with the host cell DNA and 
consequently ensure stable gene silencing [120].  
Classical stem loop stem shRNAs are expressed from polymerase III (pol III) promoters such 
as U6 or H1. However, the discovery of microRNAs (miRNAs) has also stimulated the 
generation of shRNAs that resemble the endogenous miRNA transcripts. These shRNAs were 
embedded within the context of microRNAs (e. g. miR30) which allows for transcription 
from a polymerase II promoter (pol II) (Fig. 8). These microRNA-based shRNAs are shown 
as physiological and allow for efficient gene silencing even when present as single copy in the 
genome [119;121].  
RNAi screens can be divided into genome-wide screens, aimed at identifying all likely 
modulators of a cellular process or can be focused with respect to a specific pathway or a 
specific process. Both approaches have been widely used in cell culture and can be used either 
as arrayed format in multi-well plates or as high-complexity pools in bulk. 
In pooled shRNA screens, positive or negative selection screens are distinguished. In a 
positive screen, RNAi-mediated gene silencing gives rise to a phenotype that confers an 
advantage due to shRNA expression, whereas in a negative screen the expression of the 
shRNAs confers a disadvantage. 
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Taking advantage of the commonly available collections of siRNAs and shRNAs, a number 
of different RNAi screens have been performed to dissect cellular pathways, or identify new 
therapeutic targets, or modulators of drug resistance and sensitivity [120].   
As an example, RNAi screens can be performed to search for genes that are required only in 
the context of specific cancer-causing mutations, so called ‘synthetic lethal’ screens. Such a 
screen was performed to delineate genes necessary for the viability of cells with deregulated 
Myc. In this screen AMPK-related kinase 5 (Ark5) was found to be important for survival of 
Myc driven HCCs [122]. 
In another study, a genome-wide pooled lentiviral RNAi screen identified essential viability 
genes in 12 different human cancer cell lines. Among them were some known and probable 
oncogenes: Kras, Myc, Crkl or Cdk4. Those genes are involved in basic cellular processes 
like ribosomal function, mRNA processing, further underscoring the possibility for 
identifying the genes that are essential [123].  
RNAi screens in the presence of drugs could reveal new mechanisms of drug resistance and 
sensitivity, and as such identify targets for combination therapies. For instance, such a screen 
was performed in breast cancer cells with siRNAs in the presence of PARP inhibitor and 
identified new genes (e.g. CDK5, STK22c) whose inhibition sensitizes to the drug [124]. 
Other screens took advantage of siRNAs to identify sensitizing genes to paclitaxel or genes 
modulating the response to gemcitabine [125;126]. A retrovirally encoded miR30-based 
shRNA library containing 2,300 shRNAs was used to screen lymphoma cells for new genes 
mediating doxorubicin resistance [127].  
Although there have been many different in vitro RNAi screens in the arrayed, as well in the 
pooled format, so far there is only a limited number of conducted in vivo screens. One of them 
is a positive screen for shRNAs that promote tumorigenesis in a mouse model of 
hepatocellular carcinoma. This model was generated via ex vivo genetic manipulation of 
isolated liver progenitor cells which afterwards were transduced with miR30-based shRNAs 
and transplanted into mice. It revealed new genes with potential tumor suppressive functions 
involved in HCC development [108]. Another positive in vivo RNAi screen relies on the same 
model in which isolated fetal liver hematopoietic stem cells from Eµ-Myc transgenic mice 
were ex vivo infected with a complex shRNA library and transplanted into mice. In this 
lymphoma mouse model, analysis of enriched hairpins indicated new tumor suppressor genes 
like Numb, or Mek1, likely involved in lymphomagenesis [128]. In a negative selection in 
vivo RNAi screen, Eµ-Myc cells were ex vivo transduced with a pool of around 900 shRNAs, 
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transplanted and analyzed for depleted hairpins. This screen revealed new modulators of 
lymphoma cell motility such as Rac2 and Twf1. Suppression of those two candidate genes 
impaired lymphoma cell migration to the lymph nodes and other common organs of lymphoid 
metastasis [129].  
Taken together, RNAi screens have emerged as an efficient technology for identification of 
genes to identify molecular mechanisms of cancer development. Additionally, identified 
candidates can serve as potential therapeutic targets in cancer therapy. Genes which are 
identified as modulators of drug sensitivity or resistance may serve as therapeutic targets for 
combinatorial therapies.   
 
1.7. Aim of the study 
Considering the significant but moderate responses to Sorafenib treatment in the clinic, there 
is an urgent need to search for new treatment options that could improve the responsiveness 
towards Sorafenib. The aim of this study was to identify potential candidates for such a 
combinatorial therapeutic approach in a mosaic cancer mouse model. As a first step, it is 
necessary to determine an in vivo response to Sorafenib in a newly developed transposon-
based mosaic HCC model. Furthermore, an in vivo negative selection screen should be 
established to identify new modulators of response towards Sorafenib. A possibility of 
recapitulation the in vivo screen in the in vitro set-up under the same genetic conditions 
(NrasG12V; p19Arf-/-) should be further explored. Ultimately, the mechanism of synergism 
between Sorafenib and identified candidate should be delineated as well as the possibility of 
using this candidate as a target for combination therapy together with Sorafenib. 
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2. Materials 
 
2.1. Chemicals 
If not stated otherwise, all chemicals were purchased from the following companies: 
Amersham, Bioscience, BioRad, Boehringer Mannheim, Fermentas, GE Healthcare, 
Invitrogen, Life Technologies, Merck, Millpore, New England Biolabs, PAA, Promega, 
Qiagen, Roche, Roth, Sigma-Aldrich, Serva. 
 
2.2. Buffers 
The buffers which were used for this study are listed in Table 1. 
 
Table 1 Buffers 
name composition 
PBS (10x)  100 mM Na2HPO4x2H2O, 20 mM KH2PO4, 1.37 M NaCl, 27 mM KCl; pH 7.4 
TBS (10x)  500 mM Tris-HCl, 1.5 M NaCl; pH 7.4 
PBST 0.1 % Tween 20 in 1xPBS 
TBST 0.1 % Tween 20 in 1xTBS 
NP40 Lysis Buffer 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 % NP40, 1 tbl. Complete Mini (Roche) 
NP40 Phospho Lysis Buffer 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 % NP40, 1 tbl. Complete Mini 
(Roche), 1 tbl. PhosphoSTOP (Roche) 
gDNA Extraction Buffer 
20 mM Tris-HCl (pH 8.0), 100 mM EDTA, 100 mM NaCl, 1% SDS, 0.5 mg/ml 
Proteinase K 
SDS Running Buffer (10x) 250 mM Tris base, 1.92 M glycine, 1 % SDS 
Protein Loading Buffer (5x) 
150 mM Tris-HCl (pH 6.8), 6 % SDS, 15 mM DTT, 50 % glycerol, 0.25 % 
bromophenolblue 
Transfer Buffer  48 mM Tris-HCl (pH 8.3), 39 mM glycine, 20 % methanol, 0.037 % SDS 
Stripping Buffer 65.5 mM Tris-HCl (pH 6.7), 2 % SDS, 100 mM β-mercaptoethanol 
PFA  4 % paraformaldehyde in PBS; pH 7.4 
TAE (50x) 2 M Tris base, 1 M glacial acetic acid, 50 mM EDTA; pH 8.3 
DNA loading buffer (5x) 0.25 % orange G, 15 % Ficoll type 400 
Normal Goat Serum Blocking 
Solution 5 % NGS, 0.2 % Triton X-100, 0.1 % Tween 20 in PBS 
HBS (10x) 
7.5 mM Na2HPO4 (pH 7.0), 1.4 M NaCl, 250 mM HEPES, 60 mM dextrose, 50 mM 
KCl 
 
2.3. Cell culture reagents and placticware 
Cell culture media and additives were purchased from Gibco, Invitrogen, PAA or Sigma 
unless stated otherwise. Plasticware was obtained from Corning, Falcon, Nunc and PAA. 
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2.4. Enzymes and reagents for molecular biology 
All restriction endonucleases, alkaline calf intestinal (CIP), DNase I, DNA polymerase I, and 
T4 DNA ligase were used from New England Biolabs (NEB). Taq DNA polymerase and 
Platinum Pfx DNA polymerase were purchased from Applied Biosystems and Invitrogen, 
respectively.  
 
2.5. Plasmids 
Sleeping beauty (SB13) transposase was provided by Dres. David Largaespada and Mark 
Kay. Further expanded plasmids with transposable elements carrying NrasG12V were provided 
by Daniel Dauch (unpublished data). Murine stem cell virus (MSCV) plasmids containing 
IRES and GFP, MSCV plasmid with rtTA3 and MSCV plasmid with TREtight promoter were 
provided by Scott Lowe. 
 
2.6. Bacterial cultures 
The Escherichia coli bacteria DH5α and MegaX DH10B T1 Electrocomp from Invitrogen 
were used. 
 
2.7. Cell lines 
Cell lines applied to this study are listed in Table 2. All cell lines were abtained from the 
American Type Culture Collection. 
 
Table 2 Cell lines 
name species source 
Phoenix amphotropic Homo sapiens embryonic kidney (ATCC) 
Phoenix ecotropic Homo sapiens embryonic kidney (ATCC) 
PLC/PRF/5 (Alexander) Homo sapiens hepatocellular carcinoma (ATCC)  
Hep3B Homo sapiens hepatocellular carcinoma (ATCC)  
Huh7 Homo sapiens hepatocellular carcinoma (ATCC)  
 
2.8. Oligonucleotides 
Oligonucleotides used for this study are listed in Table 3. They were obtained from MWG. 
The sequences of hairpins from the used RomaAmplicon library are listed in Table 14. 
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Table 3 Oligonucleotides 
name sequence application 
5'miR30 XhoIF cagaaggctcgagaaggtatattgctgttgacagtgagcg PCR 
3'miR30 
EcoRIF ctaaagtagccccttgaattccgaggcagtaggca PCR 
Mir30fw tgtttgaatgaggcttcagtac Sequencing 
GFP_mid_seq1 acggcgtgcagtgct Sequencing 
p7+Loop caagcagaagacggcatacgatagtgaagccacaga Illumina seq 
p5+mir30 aatgatacggcgaccaccgactaaagtagccccttg Illumina seq 
ARF 1:  agtacagcagcgggagcatgg 
Arf 
genotyping 
ARF 2: tttgaggaggaccgtgaagccg 
Arf 
genotyping 
ARF 3: accacactgctcgacattggg 
Arf 
genotyping 
shMapk14.1095 
tgctgttgacagtgagcgaaagatgaacttcgcaaatgtatagtgaagccacagatgtatacatttgcgaagttcatcttctgcctact
gcctcgga 
Cloning of 
shRNAs  
shMapk14.2590 
tgctgttgacagtgagcgactcctttactatctttctcaatagtgaagccacagatgtattgagaaagatagtaaaggagctgcctact
gcctcgga 
Cloning of 
shRNAs 
shAtf2.1136 
tgctgttgacagtgagcgcaccaatggtgatactgtaaaatagtgaagccacagatgtattttacagtatcaccattggtatgcctact
gcctcgga 
Cloning of 
shRNAs 
shAtf2.1362 
tgctgttgacagtgagcgacagcttcaagatgccgacaaatagtgaagccacagatgtatttgtcggcatcttgaagctgctgccta
ctgcctcgga 
Cloning of 
shRNAs 
shcontrol 
tgctgttgacagtgagcgcaggaattataatgcttatctatagtgaagccacagatgtatagataagcattataattcctatgcctactg
cctcgga 
Cloning of  
shRNAs 
b-actin for ccaccgatccacacagagta qPCR 
b-actin rev ggctcctagcaccatgaaga qPCR 
ATF2 for aaactccggcttctccag qPCR 
ATF2 rev actgaacccacactttcct qPCR 
 
2.9. Antibodies 
Primary antibodies used in this study are listed in Table 4. Secondary antibodies are listed in 
Table 5. 
Table 4 Primary antibodies 
name species antigen application source 
2125 rabbit α-tubulin WB (1:3000) Cell Signaling 
2401 rabbit phospho-Hsp27 (Ser82) WB (1:1000) Cell Signaling 
sc-31 mouse N-Ras(F155) WB (1:1000) Santa Cruz Biotechnology 
4370 rabbit phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) WB (1:2000) Cell Signaling 
ab15580 rabbit Ki67 IF (1:200) Abcam 
ab7952 rabbit p38  WB (1:200) Abcam 
ab28848 rabbit p-ATF2 (T69 + T51) WB (1:1000) Abcam 
sc-596 rabbit Cyclin A WB (1:200) Santa Cruz Biotechnology 
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Table 5 Secondary antibodies 
name species  species antigen application conjugation source 
4Ac goat mouse WB (1:2000) peroxidase (PO) Dianova, Hamburg 
B4c goat rabbit WB (1:2000) peroxidase (PO) Dianova, Hamburg 
A-11037 goat rabbit IF (1:1000) Alexa 594 Invitrogen 
 
 
2.10. Kits 
All kits used in this study are listed in Table 6. 
Table 6 Kits 
name company 
QIAquick Gel Extraction Qiagen 
QIAprep Spin Miniprep Qiagen 
Qiagen Plasmid Maxi Qiagen 
Qiagen Plasmi Midi Qiagen 
Rapid DNA Ligation Roche 
Platinum Pfx DNA Polymerase Invitrogen 
Rneasy Mini Kit Qiagen 
TaqMan Reverse Transcription Reagents Applied Biosystems 
 
2.11. Culture media 
All cell lines were maintained and propagated in DMEM medium (Gibco) supplemented with 
10 % FCS, 1 mM sodium pyruvate, 0.1 mM Non-Essential Amino Acids Solution (in 
Minimum Essential Medium Eagle) (Gibco) and 1x PenStrep (Gibco). Cells were frozen in 
DMEM freezing medium containing 50 % FCS and 10 % dmso. 
Bacteria were cultured in LB Medium, containing 10 g/l bacto-tryptone 5 g/l bacto-yeast 
extract, 20 mM NaCl (pH 7.5) and ampicillin (50 µg/ml). Transformed bacteria were 
incubated in SOC medium (Invitrogen). Agar plates were made with LB medium containing 
15 g/L agar and ampicillin (50 µg/ml). 
 
 
2.12. Mouse strains 
Wild type C57 Bl/6 mice were purchased from Harlan or Janvier. P19Arf-/- mice have been 
generated by Charles Sherr [130] and were obtained in a C57 BL/6 background from Scott 
Lowe.
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3. Methods 
 
3.1. Molecular biology techniques 
 
3.1.1. PCR cloning of shRNAs 
DNA fragments were amplified and restriction sites were added to their ends by standard 
cloning PCRs with the Platinum Pfx DNA Polymerase Kit from Invitrogen. For the reaction 
10-300 ng template DNA was used and incubated in the supplemented buffer with: 0.02 - 0.1 
Unit/µL polymerase, 0.3 mM dNTP mixture (Peqlab), 0.3 µM of forward and reverse cloning 
primers, and 1 mM MgCl2 (Invitrogen). The following PCR protocol was used (Tab. 7): 
 
Table 7  PCR protocol with Pfx Polymerase 
94 °C 2 min     
94 °C 15 sec 
 
 
X °C 30 sec 25-35 cycles 
68 °C 1 min per kb 
 
68 °C 5 min 
  
4 °C ∞     
 
 
3.1.2. Digestion of DNA with endonucleases 
For analytical digests approximately 0.2 to 1 ug DNA was used. Preparative digests were 
performed with 10-15 µg DNA. Digestions with restriction endonucleases (NEB) were carried 
out with 0.1 - 1 Units/µl in 37 °C for 2 to 4 hours in corresponding reaction buffers (NEB). 
 
3.1.3. Dephosphorylation of digested DNA  
To avoid religation of digested plasmids, 10 - 15 µg DNA was dephosphorylated with 0.1 - 1 
Units/µl of Calf Intestinal Alkaline Phosphatase in the corresponding buffer (NEB) for 1 to 3 
hours at 37 °C. 
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3.1.4. Agarose gel electrophoresis 
The separation of DNA fragments was done via agarose gel electrophoresis. The 
corresponding agarose gels were prepared with 1 - 2 % agarose, dissolved in 1x TAE buffer 
and supplemented with 0.01 % ethidium bromide. The DNA was separated together with the 
peqGOLD low range DNA ladder or the 1kb DNA ladder (Peqlab) under 50 - 120 V in 1x 
TAE and visualized under UV light. In some cases DNA was extracted from the gels by using 
the QIAEX II Agarose Gel Extraction Kit (Qiagen). 
 
3.1.5. Ligation 
For standard ligations the T4 DNA Ligase (NEB) was used. 100 - 1000 ng DNA was ligated 
usually in a 5:1 molar ratio of insert to backbone DNA. The reaction was performed with 20 
U/µL T4 DNA ligase in T4 DNA ligase reaction buffer for 1 - 3 hours at 16 °C. 
For cloning of high complexity shRNA libraries the Rapid Ligation Kit from Roche was used. 
300 - 500 ng of DNA was used in a 5:1 molar ratio of insert to backbone DNA. Ligation was 
run overnight starting at 4 °C with warming up to room temperature. All ligation reactions 
were also performed without insert as a negative control. 
 
3.1.6. Transformation of recombinant DNA 
For cloning of single constructs DH5α Competent Cells (Invitrogen) were used for 
transformation. 1 - 10 ng of DNA were incubated with bacteria on ice for 30 minutes and 
subjected to a 20 second heat shock at 42 °C. 
For transformation of bacteria with DNA containing shRNA libraries, MegaX DH10B T1 
electrocompetent bacteria (Invitrogen) were used. The transformation with 1-10 ng DNA was 
performed by electroporation with 2 kV, 200 Ώ and 25 µF. Transformed bacteria were 
incubated with 950 µL SOC medium (Invitrogen) at 37°C for 1 hour shaking at 225 rpm and 
afterwards plated on LB-agar plates with ampicillin (50 µg/µL). The plates were then 
incubated for 12-16 hours at 37 °C. 
 
3.1.7. Sequencing 
Standard DNA capillary sequencing was processed in the HZI array and genome analysis 
facility (Head: Robert Geffers) with corresponding sequencing primers (10 µM) which are 
listed in Table 4. 
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3.1.8. DNA purification 
DNA was purified via the QIAquick Gel Extraction Kit from Qiagen using the DNA 
purification protocol. Additionally, in some cases (e. g. cloning of shRNA libraries) DNA was 
purified via Phenol-Chloroform extraction and ethanol precipitation. Phenol-chloroform 
extractions were performed either with a mixture of phenol, chloroform and isoamylalcohol 
(25/24/1) or, for small DNA fragments, with phenol (both from Roth). These solutions were 
mixed with DNA in the same volume and centrifugated (17.000 x g, 10 minutes) to separate a 
DNA containing phase. Subsequently ethanol precipitation was done with 3 M sodium acetate 
(1/10 volume of DNA solution), ethanol (three times volume of DNA solution) as well as 1 
µL pellet paint (Novagen). The solution was incubated at -20 °C (1- 4 hours) and centrifuged 
(17.000 x g; 30 minutes). The pellet was washed twice with 70 % ethanol, dried and dissolved 
in water.         
 
3.1.9. Plasmid DNA preparation 
DNA plasmids were amplified by overnight bacteria cultures, shaking at 37 °C in LB medium 
with 50 µg/ml ampicillin.  The bacteria were centrifuged with 3.500 – 6.000 x g for 10 min 
and the DNA was extracted using either the Qiagen Plasmid Maxi Kit (for high amounts of 
DNA) or the Qiagen Miniprep Kit (for small amounts of DNA). For hydrodynamic tail vein  
injection or cell transfection the EndoFree Qiagen Plasmid Maxi Kit from Qiagen was used 
for DNA preparation. 
 
3.1.10. Isolation of DNA from cells and mouse tissues 
Genomic DNA was isolated from cells, smashed mouse livers or tails. The samples were 
incubated overnight with a corresponding volume of gDNA extraction buffer (7,5 ml for 
whole liver extraction, 750 µL for tails and cells). Subsequently, proteinase K was inactivated 
at 90 °C for 10 minutes.  1/3 volume of 5 M NaCl solution was added to the solution, which 
was incubated for 5 minutes at 55 °C and centrifuged with 17000 x g for 10 minutes. 
Afterwards, 2/3 volume of isopropanol was added to the supernatant incubated at -20 °C and 
centrifuged with 17000 x g for 30 minutes. The pellet was washed with 70 % ethanol and 
after a drying step dissolved in water. In some cases (e.g. Solexa PCR) the DNA was 
additionally purified by phenol-chloroform extraction and ethanol precipitation (see DNA 
purification).    
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3.1.11. RNA isolation and RNA purification 
RNA was isolated from cells by using TRIZOL RNA isolation protocol (Invitrogen). 
Contaminating DNA was digested via DNase I (NEB) (0.05 U/µL) in a 30 minutes reaction at 
room temperature in the corresponding reaction buffer (NEB). Afterwards the reaction was 
purified by the RNeasy Mini Kit (Qiagen) using the RNA cleanup protocol. 
 
3.1.12. cDNA synthesis 
cDNA synthesis from mRNA templates was performed with  the TaqMan Kit (Applied 
Biosystems) using the corresponding protocol. 2 µg of RNA and random hexamer primers 
were used. The reaction was performed at 25 °C for 10 minutes, at 48 °C for 30 minutes and 
at 95 °C for 5 minutes. 
 
3.1.13. Nucleic acid concentration measurement 
DNA and RNA concentrations were determined with the NanoDrop 1000 from peqlab. 
 
3.1.14. Quantitative polymerase chain reaction (qPCR) 
The primers for qPCR were designed by means of Pearl Primer software. As a template, 2 µL 
cDNA was used with 0.3 µM of both forward and reverse primers. Primers were used either 
for the gene of interest or for beta-actin [108] that served as a control (Tab. 4). qPCR was 
performed with the 7500 real-time PCR system cycler (Applied Biosystems) using SYBR 
green detection (passive reference rox dye) and the SYBR green PCR Master Mix (Applied 
Biosystems). The used PCR protocol is shown in Table 8. 
 
Table 8 qPCR protocol 
95 °C 10 min     
95 °C 15 sec 
 
 56 °C 1 min 45 cycles 
60 °C 1 min 
 95 °C 15 sec 
  60 °C 1 min 
  95 °C 15 sec 
  60 °C 15 sec   
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To analyze the size of PCR fragments a dissociation curve was performed subsequent to the 
PCR reaction. The calculation of mRNA concentrations was done via manual cT values 
(hhreshold 0.2 in cycles 3-15). The fold expression was calculated with dilution rows. 
 
3.2. Cell culture methods 
 
3.2.1. Cell culture 
Cells were cultured in DMEM medium containing 10 % FCS at 37 °C, 90 % humidity and     
7 % CO2. Cells were splitted using Trypsin/EDTA solution (Gibco). Cells were frozen in 
DMEM freezing medium and stored in liquid nitrogen. 
 
3.2.2. Isolation of cells from tumor nodules 
Cell lines were generated from murine tumor tissues. Mice were euthanized and sterilized 
with 70 % ethanol for 10 minutes and tumor nodules were cut out from adhering tissue under 
sterile conditions, smashed and incubated with Dispase (1000 U/ml) and Collagenase (0.1 
U/ml) (Roche) in DMEM medium, containing 1xHBS buffer for 30 minutes at 37 °C with 
gentle shaking. The cells were filtrated with nylon mesh filter (100 µm), centrifuged at 80 x g 
for 10 min and washed twice with medium. The cells were placed on a 0.1 % gelatin solution 
and maintained in culture as long as remaining contaminating fibroblasts were removed. 
 
3.2.3. Calcium-phosphate-mediated transfection 
Eucaryotic cells were transfected using calcium phosphate transfection. 20 - 30 µg DNA was 
used for 70 - 80 % confluent cells in 10 cm plates. The cells were incubated for 15 minutes 
with DMEM medium, containing 25 µM chloroquine. 500 µL of DNA solution, containing 2 
M CaCl2 was dropwise added by bubbling to 500 µL 2x HBS buffer. The received precipitate 
was added dropwise to the cells and incubated with the chloroquin containing medium for 14-
16 hours.     
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3.2.4. Retroviral gene transfer for generation of stable cell lines 
Retroviral gene or shRNA transfer was accomplished using phoenix packing cells which 
produce viral particles with retroviral vector DNA. The phoenix cells were transfected with 
retroviral DNA via calcium phosphate-mediated transfection. The viral supernatant was 
collected every 6 hours during 24-72 hours after transfection [131]. The viral supernatant was 
filtered through a syringe filter (0.45 µM) and 100 – 1000 µL of viral supernatant was applied 
directly to the medium of 30 % confluent target cells. To improve the infection efficiency of 
differently infectable target cells, the infection was accompanied by addition of polybrene (1-
10 µg/ml). Target cells were selected by addition of corresponding antibiotics, either 
puromycin (1 - 10 µg/ml) or hygromycin (300 - 1000 µg/ml).  
 
3.2.5. In vitro drug treatment 
Sorafenib was dissolved in dmso (stock concentration: 4.3 mM) and added to different final 
concentrations into the medium of the corresponding cells.  
BIRB 796 (stock concentration: 15.76 mM), SB 202190 (stock concentration: 25.15 mM) 
Skepinone-L (stock concentration: 10mM) and PH 797804 (stock concentration: 10.4mM) 
were also dissolved in dmso and added to different final concentrations into the medium of 
the corresponding cells. 
 
3.2.6. Crystal violet staining 
Cells were washed with PBS and fixed with 10 % formaldehyde solution for 30 - 60 minutes. 
After fixation, the cells were washed with water and dried and stained with a 0.07 % crystal 
violet solution for 30 – 60 minutes. The cells were washed again and dried.  
 
3.2.7. Cell doubling assay 
The quantification of cell proliferation rates was evaluated by cell doubling assay. For this, 
the cell number (cells / µL) was counted using Guava flow cytometer and Guava EasyCyte 
Plus software. For counting, trypsinized cells were resuspended in medium and measured in a 
corresponding dilution with PBS. The doubling time was calculated as fold-changes in 
comparision to an intial point measurement. 
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3.2.8. Trypan blue staining 
To estimate the percentage of dead cells, tryphan blue staining of cells was performed. For 
staining, the medium containg floating cells, PBS after cell washing as well as the trypsinized 
cells were collected and centrifuged at 80 x g for 10 – 15 minutes. The pellet was resuspended 
in 1-2 mL medium and mixed with tryphan blue solution (0.4 %) (Sigma) in a 1:1 ratio. The 
total number of cells and tryphan blue positive cells were counted by means of Neubauer 
hemocytometer. 
 
3.3. Biochemical methods 
 
3.3.1. Preparation of protein extracts from cultured cells 
NP40 lysis buffer or NP40 phospho lysis buffer were used to extract proteins from cultured 
cells and mouse tissue. Culture cells were washed twice with PBS and the NP40 lysis buffer 
was added directly to the cells, which were removed from the dish using a cell scraper.  
Tissues were also washed with PBS and homogenized in the NP40 buffer. Cells and 
homogenized tissue were incubated with shaking for 10 min at 4 °C, and centrifuged for 10 
min at 11000 x g at 4 °C. The supernatant with the proteins was separated from the pellet.  
 
3.3.2. Measurement of protein concentration 
Protein concentration was determined using the Precision Red Advance protein assay 
(Cytoskeleton) according to the manufacturer’s manual.   
 
3.3.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
essentially according to Laemmli (Laemmli, 1970). SDS-PAGE gels were run in BIO-RAD 
apparatures with 1mm spacers. 20 - 80 µg of proteins were incubated with protein loading 
buffer at 95 °C for 5 minutes and seperated with the prestained protein marker broad range 
(NEB) on SDS stacking gels with 30 mM and on separation gels with 35 mA. (Tab 9, 10).  
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Table 9  10 % seperating gel  
 
Table 10  5 % stacking gel 
10 % Acrylamid 
 
5 % Acrylamid 
0.27 % Bisacrylamid  
 
0.13 % Bisacrylamid 
375 mM TrisHCl (pH 8.8)  
 
125 mM TrisHCl (pH 6.8) 
0.1 % APS 
 
0.1 % APS 
0.01 % TEMED  
 
0.01 % TEMED 
 
3.3.4. Western blotting 
Proteins from SDS-PAGE gels were transferred onto nitrocellulose membrane (Amersham 
Hybond ECL Nitrocellulose Membrane) usind a semidry blotting system and a transfer buffer 
for 30 min at 15 V. Membranes were blocked for 30 min at room temperature or at 4 °C 
overnight with 5 % BSA (Roth) in TBS-Tween. Afterwards, membranes were incubated for 1 
hour at room temperature or overnight at 4 °C in TBS-Tween buffer containing primary 
antibodies. Membranes were washed 3 times in TBS-Tween buffer 15 min and then incubated 
for 1h at room temperature in TBS-Tween buffer containing the corresponding secondary 
antibodies (1:1000) (Tab. 7). Membranes were again washed 3 times with TBS-Tween buffer 
and incubated for up to 4 min with Lumi-Light Western Blotting Substrate (Roche) and 
exposed to Hyperfilm ECL (Amersham Biosciences). 
  
3.4. Mouse experimental methods 
 
3.4.1. Mouse husbandry 
All animal experiments have been approved by the German legal authorities. All mice were 
housed and maintained under pathogen free conditions in accordance with the institutional 
guidelines of the Helmholtz Centre for Infection Research. 
 
3.4.2. Genotyping 
The genotype of p19Arf mice was analysed via PCR of genomic tail DNA. The PCR was 
performed with Taq polymerase (Applied Biosystems) (0.04 - U/µL) in the corresponding 
buffer and 0.16 mM dNTPs, 4 % dmso, and three primers, Arf-1 (0.4 µM), Arf-2 (0.96 µM) 
and Arf-3 (0.96 µM). The following PCR programs were used (Tab. 11). 
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Table 11 p19Arf genotyping PCR 
95 °C 5 min 
  
95 °C 1 min 
 
 
65 °C 1 min      37 cycles 
72 °C 1 min 
 
72 °C 5 min 
  
4 °C 
∞ 
    
 
 
Genotyping PCRs were analyzed on agarose gels which identified the wildtype allele with a 
415 bp and a mutant allele with 250 bp PCR product. 
 
3.4.3. Hydrodynamic tail vein injection 
DNA for hydrodynamic tail vein injection was prepared, using the Qiagen EndoFreeMaxi Kit 
and disolved in 0.9 % NaCl solution to a final volume of 10 % of body weight. Animals were 
injected within ten seconds with 25 µg transposon plasmids and 5 µg transposase.  
 
3.4.4. Orthotopic transplantation of tumor cells 
Mice were anasthesized with rompun/ketamin solution (450µl ketamine + 50µl rompun + 
4500µl NaCl) and dosed intraperitoneally as 10µl/g body weight and subjected to laparotomy. 
1,000,000 murine hepatoma cells were injected into the left murine liver lobe. To avoid the 
extravasation of tumor cells the abdominal cavitiy was washed with prewarmed deoinized 
water.     
 
3.4.5. Doxycycline administration 
Doxycycline hyclate (Sigma) was added to the drinking water of mice to a final concentration 
of 2 mg/ml. Additionally, saccharose (Roth) was added to a final concentration of 1 g/100 ml 
water. Doxycycline containing water was prepared fresh and changed once per week. 
 
3.4.6. Drug treatment of mice 
The treatment of mice with Sorafenib, BIRB 796 or the corresponding vehicles was 
performed by oral gavage every second day.  
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The mice were treated with 100 mg/kg body weight Sorafenib (Nexavar), which was freshly 
dissolved in a Cremophor EL / 95 % ethanol / water solution (12.5:12.5:75). BIRB 796 was 
dissolved in 25 % ethanol and delivered to mice in a dose of 50 mg/kg body weight. 
 
3.4.7. Dissections of murine livers 
Mice were harvested either due to a critical tumor burden (survival plots) or at defined time 
points. Livers were photographed, sampled and processed for further analysis. 
 
3.4.8. In situ GFP detection 
In vivo GFP Imaging of mice and tumor bearing livers was done using the Hamamatsu 
Imaging system.  
 
3.5. Histological methods 
 
3.5.1. Sections of paraffin embedded tissues 
The corresponding samples were fixed overnight with 4 % PFA in PBS. They were embedded 
in paraffin and cut by Nina Struever (Hannover Medical School) or Anna Rinkel (HZI 
histopathology core facility). 
 
3.5.2. Haematoxylin and eosin staining 
Hämatoxylin and eosin (H&E) stainings were performed by the HZI histopathology core 
facility. 
 
 
3.5.3. Preparation of frozen sections frozen tissue samples. 
Sections were made with the HM 560 cryostat (Microtom) at -20 °C. Snap frozen tissue 
embedded in Tissue-Tec OCXT compound (Sakura) were used. 
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3.5.4. Ki67 staining 
Ki67 stainings were performed with 8 µm sections of snap frozen tissues. The slides were 
fixed with 4 % paraformaldehyde (in PBS) for 10 minutes at RT and then washed three times 
for 5 min with PBS. The slides were blocked with normal goat serum (NGS) blocking 
solution for 1 hour at RT. After rinsing the sections shortly in PBST, the primary Ki67 
antibody was applied (1:200) in 1 % NGS in PBST and the samples were incubated overnight 
at 4 °C. After washing tree times with PBST the slides were incubated with the rabbit 
secondary antibody (1:1000) and 1 µg/ml DAPI in PBST with 1 % NGS for 1 hour at room 
temperature in the dark. Finally, the sections were washed three times in PBST in the dark 
and mounted with Vectashield H-1000. The sections were stored at 4°C. 
 
3.5.5. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
Apoptotic cells were detected by using of the Terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) Kit from Roche. The staining was performed on 8 µm sections of 
snap frozen tissues. Additionally, DNA was stained by 1 µg/ml DAPI for 1 hour at 37°C. 
 
3.5.6. Microscopy 
All stainings were photographed with the Zeiss Photomicroscop Axiophot2. Pictures were 
taken with the ORCA-ER camera from Hamamatsu and the Simple PCI software. 
 
 
3.6. Microarray and deep sequencing analysis 
 
3.6.1. PCR-based amplification of shRNA cassettes 
Genomic DNA was isolated from corresponding mouse livers. The hairpin sequences of 
genomic tumor  DNA and plasmid pools were amplified with primers harboring the Illumina 
adapter sequence and a sample identifier (3 bp barcode). The PCR was done with Taq 
polymerase (Applied Biosystems). Up to 64 samples were pooled and subjected to Illumina 
deep sequencing. (Nature protocols)   
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3.6.2. Determination of shRNA abundance by deep sequencing analysis 
Deep sequencing was carried out in HZI array and genome analysis facility (Head: Robert 
Geffers). Illumina GA IIx with a 46 bp single end run was applied to deep sequencing 
analysis. Base calling and export of the sequencing results were performed with FASTA files 
via Illumina Pipeline Vers.1.8. The data analysis was accomplished by Michael Jarek (HZI 
array and genome analysis facility) using a Perl-Script. The data were separated using the 
corresponding barcodes and the unique reads of the separated samples were determined. The 
sequences were further aligned to the shRNA library data (Tab. 14) (only 100 % matches) and 
summarized. 
 
3.6.3. Expression array 
mRNA gene expression microarray analyses were performed by Robert Geffers and the HZI 
array and genome analysis facility by using Affymetrix GeneChip MOE430 2.0. The image 
analysis was done using the GCS3000 Scanner and the GCOS1.2 Software Suite 
(Affymetrix). Analysis of microarray data was performed using GeneSpring 11.5.1 (Agilent 
Technologies). Upstream factors were analysed by Ingenuity pathway analysis software 
(Ingeuity Systems, Inc) 
 
3.7. Statistics and bioinformatical methods 
 
3.7.1. De novo design and synthesis of shRNAs 
DSIR and Biopred algorithms/webtools were used to design hairpin sequences as 21 
nucleotide RNAs [132]. These sequences were combined with common hairpin sequences to 
obtain 97mer oligonucleotides with a stem loop stem sequence (Tab. 3).  
 
3.7.2. Statistical analysis 
Two-tailed student’s t-test or log-rank test were applied to statistical analyzes.  
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4. Results 
4.1. Sorafenib treatment results in moderate but distinct treatment responses of       
           aggressive murine hepatocellular carcinomas (HCCs) 
To study the therapeutic efficacy of Sorafenib in vivo, we treated murine HCCs that were 
generated in a new mosaic liver cancer mouse model. In this model, a transposon-mediated 
delivery of oncogenes and marker genes was applied into adult hepatocytes. Transposons 
were delivered together with the sleeping beauty transposase (SB13) in a 5:1 ratio into 
hepatocytes via hydrodynamic tail vein injection (HDI). In a recent study, it had been shown 
that two transgenes can be integrated via single transposon where both genes are expressed 
bicistronic, separated by an internal ribosome entry site (IRES).  
We took advantage of a transposon construct, wherein oncogenic NrasG12V and GFP were 
expressed by the Caggs promoter (pCaggs-NrasG12V-IRES-GFP) (Dauch and Zender, 
unpublished data) (Fig. 9a). As described before transposon-mediated delivery of pCaggs-
NrasG12V into p19Arf deficient hepatocytes induces aggressive hepatocarcinogenesis [113]. 
Additionally, the tumors can be imaged by GFP expression in the liver (Dauch and Zender, 
unpublished data).  
To study the effect of Sorafenib on these tumors, a cohort of mice was injected with NrasG12V-
IRES-GFP and treated with Sorafenib or carrier, respectively (Fig. 9a). The mice were 
subjected to a dose of 100 mg/kg body weight every second day, starting 7 days after 
injection. The Sorafenib treated, as well as the carrier treated groups developed a high amount 
of liver tumors which were identified as hepatocellular carcinomas by experienced 
pathologists (Thomas Longerich and Peter Schirmacher, University of Heidelberg) (Fig. 
9b,c). The mice treated with the carrier manifested a comparable tumor development to non 
treated mice and died after median survival of 33 days. Interestingly, the number of tumors in 
Sorafenib treated mice was not lower than in carrier treated mice but these mice exhibited in 
general tumors with smaller size (Fig. 9b). These mice died after a median survival of 41 days 
upon injection and showed therefore a moderate but significant survival benefit to carrier 
treated mice (p = 0.0239) (Fig. 9d).  
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Figure 9 A mosaic cancer mouse model allows for studying the in vivo response to Sorafenib in HCC 
Shematic outline of a transposable element carrying oncogenic NrasG12V and GFP which was delivered together 
with the sleeping beauty transposase into p19Arf deficient mice, which were subsequently treated with Sorafenib 
or carrier, respectively (a). Intrahepatic tumor burden with GFP imaging of p19Arf deficient livers of carrier and 
Sorafenib treated mice, 33 days upon NrasG12V injection (b). H&E staining for Sorafenib and carrier treated mice 
(c). Survival curves of Sorafenib and carrier treated mice upon NrasG12V-IRES-GFP injection (d). Weight 
development for Sorafenib and carrier treated mice over a period of 3 weeks (e).  
 
To uncover potential side effects of Sorafenib, a weight analysis was recorded over a 3-week 
period. This analysis identified a stable but slightly lower weight of Sorafenib treated mice in 
contrast to carrier treated mice (Fig. 9e). 
Tumorigenic cells in cancer mouse models can be used as a source to establish cell lines 
which then allow for investigating cancer related mechanisms in vitro. HCCs derived from 
transposon-based delivery of NrasG12V into p19Arf deficient hepatocytes were used to isolate 
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cell lines in a defined genetic background (Fig. 10a,b). Importantly, these cells could be 
retransplanted into the livers of immuncompetent wild type mice where they again formed 
HCCs (Fig. 10c). 
These cells were also subjected to Sorafenib treatment in order to determine the Sorafenib 
response in an in vitro model, carrying the same genetic leasions as the in vivo model.  
As described before, Sorafenib targets specifically Raf/Mek/Erk pathway (MAPK pathway) 
by inhibiting Raf kinases (C-Raf, also known as Raf1 and B-Raf) which is reflected by a 
downregulation of downstream target Erk.  
 
Figure 10 Treatment of NrasG12V driven p19Arf deficient HCC cells in vitro 
Schematic outline of a transposable element carrying oncogenic NrasG12V that was injected with the sleeping 
beauty transposase into p19Arf deficient mice to generate tumors for isolation of cells (a,b). In situ injection of  
NrasG12V; p19Arf-/- cells (1 million) into the liver of wild type mice allows for in situ tumor development (c). 
Western blot against phosphorylation status of the Raf downstream target Erk upon Sorafenib or dmso treatment 
(d). Visualization of crystal violet staining of  Sorafenib (8 µM) or dmso treated NrasG12V; p19Arf-/- cells (e).  
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Indeed, western blot analysis identified a lower amount of phosphorylated Erk upon a 3-day 
treatment with Sorafenib compared to a dmso (carrier) treatment (Fig. 10d). Furthermore, a 
visualization of cells by crystal violet staining shows a lower amount of cells after a 3-day 
treatment by Sorafenib compared to dmso treatment, implying a visual but also moderate 
effect of Sorafenib on those cells (Fig. 10e). 
Taken together, an established in vivo mouse model as well as an in vitro HCC model 
carrying the same genetic background allow for studying the response towards Sorafenib. 
  
4.2. In vivo and in vitro RNAi screens identify putative genes involved in resistance  
towards Sorafenib 
To improve treatment of human HCCs towards Sorafenib it is of high importance to identify 
new candidate genes involved in mediating resistance to this therapy. Such candidate genes 
could be potential targets for a combination therapy with Sorafenib which may improve the 
survival of patients compared to Sorafenib monotherapy. As desribed before, a mosaic liver 
cancer mouse model was established that reveals a significant but moderate response to 
Sorafenib treatment. This model was used to apply high throughput functional genetics by an 
in vivo RNAi screen. Expanded transposable elements were used, wherein transgenic 
expression of oncogenes and marker genes were combined with miR30-based shRNA 
technology. In these constructs transgenes and shRNAs were transcribed on a single transcript 
(expressed by Caggs promoter) which allows for an efficient intrahepatic gene knockdown in 
a physiological manner (Fig. 11a), (Dauch and Zender, unpublished data).  
To conduct the screen, we took advantage of an shRNA library targeting genes found 
amplified in human HCCs (Powers, McJunkin, Zender and Lowe, unpublished data). Genetic 
amplifications in 200 human HCCs were identified by representative oligonucleotide 
microarray analysis (ROMA). Hairpins were designed against 70 target genes (~250 shRNAs) 
using the BIOPREDsi algorithm [133], pooled and cloned into TRMPV vector [134] (Tab. 
14). To allow expression of genes and shRNAs on one transcript we took advantage of 
hairpins, which were embedded into the sequence of microRNA 30 [118]. To transfer the 
Roma Amplicon library into the NrasG12V-IRES-GFP transposon plasmid, the shRNAs from 
TRMPV were first shuttled via the restriction enzymes XhoI and EcoRI into MSCV plasmid, 
which contain the miR30 sequence [108;118]. Next, the shRNAs were shuttled together with 
the 3`miR30 sequence via the restriction enzymes XhoI and MluI/AscI into the NrasG12V-
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IRES-GFP vector containg the 5` miR30 precusor sequence. To ensure the transfer of all 
shRNAs, both cloning steps were performed with a 1000 fold overrepresentation of colonies. 
The transposable elements, carrying NrasG12V, GFP and the ROMA Amplicon library were 
delivered by HDI into p19Arf deficient hepatocytes (Fig. 11a). 7 days upon injection, mice 
were subjected to Sorafenib or carrier treatment (n = 8-10) every second day. After 5 weeks, 
the mice were sacrificed and genomic DNA was extracted from tumor bearing livers (Fig. 
11b). To determine the abundance of each individual hairpin in these livers of treated and 
non-treated mice, deep sequencing analysis was performed. The integrated hairpin sequences 
were amplified via PCR, which also added a 3-base barcode sequence that allows for 
analyzing multiple samples in a high-throughput manner.  
To make a thorough analysis, the abundance of consecutive hairpins was compared between 
the average of Sorafenib treated mice and the average of carrier treated mice (Tab. 1).  
The differences of invidual hairpins between both groups were determined by the quotient of 
average hairpin abundance of Sorafenib treated mice over the average hairpin abundance of 
carrier treated mice.  
 
 
 
Figure 11 Schematic outline of an in vivo RNAi screen to identify genes mediating resistance to Sorafenib 
Transposable elements, carrying oncogenes, marker genes and miR30-based shRNAs (a). Schematic outline of 
an in vivo RNAi screen in tumors growing in p19Arf deficient mice, which were injected with NrasG12V-IRES-
GFP  in combination with a shRNA library. Mice were treated either with Sorafenib or carrier (n = 8-10) and the 
hairpin distribution in the liver tumors was evaluated via deep sequencing of extracted gDNA (b).  
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This overview identifies the abundance of the majority of shRNAs not influenced by 
Sorafenib treatment    (63.2 % of all shRNAs have a fold-change compared to carrier group < 
5). However, some hairpins were shown to be enriched or depleted after Sorafenib treatment 
(Tab. 15). In total, 19 hairpins were found depleted more than 10 fold and 3 hairpins are 
depleted more than 100 fold compared to the carrier group (Tab. 12).   
Interestingly, among the group of hairpins with a more than 100 fold depletion rank two 
hairpins targeting the Mitogen Activated Pathway Kinase 14 (Mapk14 or p38alpha) with the 
hairpins Mapk14.1095 (depletion 138.28 fold) and Mapk14.2590 (depletion 324.16 fold).  
 
Table 12 Most depleted shRNAs under Sorafenib treatement (in vivo RNAi screen) 
hairpin average carrier std. dev. carrier average Sorafenib 
std. dev. 
Sorafenib depletion 
Stk32c.2014 0,014 0,038 0,003 0,004 -5,599 
268893_Gstp1 0,695 1,951 0,122 0,150 -5,671 
Bcl2l1.101 0,004 0,013 0,001 0,001 -5,912 
Fkbp5.2813 1,327 1,902 0,218 0,295 -6,088 
Pim2.1464 0,019 0,040 0,003 0,005 -6,508 
Neu1.452 0,037 0,066 0,006 0,011 -6,710 
Rxra.2278 0,132 0,351 0,019 0,056 -6,874 
Mmp8.2236 0,031 0,090 0,004 0,005 -7,385 
Stk32c.2134 0,174 0,492 0,023 0,053 -7,611 
CYP27B1.1252 0,174 0,340 0,018 0,034 -9,698 
Mmp3.1478 0,459 1,316 0,047 0,071 -9,836 
Mmp7.256 0,008 0,023 0,001 0,001 -10,405 
Ccnd1.3415 0,661 1,532 0,062 0,091 -10,711 
Sparc.1758 0,009 0,021 0,001 0,001 -10,861 
Pld1.2050 0,267 0,564 0,022 0,061 -12,052 
RNASE4.499 0,210 0,409 0,017 0,024 -12,578 
Tmprss2.1667 0,354 0,699 0,026 0,046 -13,777 
Oat.136 2,553 4,642 0,169 0,172 -15,116 
Rxra.2109 0,056 0,086 0,004 0,004 -15,450 
Neu1.1710 0,151 0,432 0,007 0,010 -20,524 
Acy3.902 0,999 2,524 0,048 0,081 -20,606 
Mapk13.417 0,018 0,051 0,001 0,001 -23,589 
Mettl1.259 0,107 0,259 0,003 0,004 -37,513 
Met.3642 0,236 0,392 0,005 0,011 -44,385 
Hck.420 0,845 2,323 0,012 0,018 -69,178 
Mmp8.708 0,983 2,909 0,013 0,016 -76,167 
BAK1.1809 0,361 1,081 0,005 0,010 -79,266 
Mapk14.1095 2,014 5,832 0,015 0,029 -138,285 
PMPCA.1841 1,910 5,655 0,012 0,019 -163,065 
Mapk14.2590 0,616 1,823 0,002 0,003 -324,163 
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As described before, Mapk14 is a member of the MAP kinase pathway, and involved in 
several cell regulatory mechanisms and is described to have pro and anti proliferative 
functions. A possible role of Mapk14 in resistance to Sorafenib treatment may be interesting 
due to the fact that it is a good target for pharmacological inhibition and inhibitors are already 
available [135;136].  
To address whether this candidate could only be depleted in an in vivo RNAi screen and 
therefore to address the general significance of in vivo RNAi screens, the screen was repeated 
under in vitro conditions. For this screen, the already described NrasG12V; p19Arf-/- cells were 
used. These cells were stably transduced with retroviral particles of Murine Stem Cell Virus 
(MSCV) which carries the pool of 250 shRNAs of the ROMA Amplicon library that was also 
used for the in vivo screen. Secreted viral particles were applied on target cells to allow for a 
viral-based gene transfer (Fig. 12a) [131]. The infection rate was kept low (< 25 % of GFP 
positive cells) to assure a population of cells with single copy integration of viral vectors. 
Targeted cells were selected with puromycin to achieve a pure population (> 99 % of GFP 
positive cells).  
Several independently infected populations (n = 4) were expanded after selection and divided 
into different flasks, for Sorafenib and dmso treatment, respectively. 
 
Figure 12 Layout of in vitro RNAi screen in NrasG12V; p19Arf-/- liver cancer cells 
MSCV construct used for viral gene transfer into NrasG12V; p19Arf-/- cells (a). Draft of screening procedure, where 
NrasG12V; p19Arf-/- cells were infected with viral particles, harboring the corresponding hairpin pool (ROMA 
Amplicon). Infected cells were selected to pure populations and subjeted to Sorafenib (8 µM) or dmso treatment. 
The hairpin distribution of both sets was determined by deep sequencing analysis (b).  
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After a 3-day treatment, genomic DNA was extracted to analyze hairpin distribution by deep 
sequencing analysis (Fig. 12b).  
Similar to the in vivo screen analysis the presence of hairpins was compared between the 
average value of Sorafenib treated cells and the average value of dmso treated cells (Tab. 15). 
A pattern with a majority of shRNAs being non-affected hairpins (81,6 % have a fold-change 
compared to dmso group < 5) was comparable to the in vivo screen (Tab. 15). However, 
although depleted hairpins were found in the in vitro setup, the hairpins in general did not 
deplete that pronounced as in the in vivo system (Fig. 13a,b). Therefore, only 14 hairpins are 
found depleted more than 10 fold, and only one hairpin depletes more than 100 fold compared 
to dmso group (Tab. 13).  
 
Table 13 Most depleted shRNAs under Sorafenib treatement (in vitro RNAi screen) 
hairpin average dmso std. dev. dmso average Sorafenib std. dev. Sorafenib depletion 
Bcl2l1.974 0,090 0,110 0,016 0,025 -5,729 
Itfg1.1897 0,049 0,069 0,008 0,011 -5,825 
Ndufv1.221 1,623 2,876 0,265 0,436 -6,117 
NUDT3.1284 0,079 0,165 0,012 0,025 -6,360 
FGF12.1241 0,292 0,591 0,045 0,079 -6,457 
Stk32c.724 0,322 0,377 0,046 0,061 -6,932 
Rpo1-1.311 0,217 0,451 0,031 0,064 -6,995 
CLIC1.1126 0,171 0,219 0,024 0,023 -7,069 
Mmp7.256 0,072 0,161 0,010 0,012 -7,097 
Mmp8.2236 0,035 0,067 0,004 0,006 -8,070 
Ehhadh.1876 0,031 0,032 0,004 0,005 -8,702 
NDUFS8.807 0,673 1,296 0,077 0,072 -8,772 
FGF12.1933 0,410 0,459 0,046 0,072 -8,870 
BRMS1.1002 0,228 0,409 0,025 0,040 -9,205 
Pim1.602 0,350 0,819 0,037 0,063 -9,501 
Mmp7.170 0,044 0,088 0,004 0,003 -10,762 
Brd3.1245 0,353 0,480 0,030 0,061 -11,871 
Sparc.1196 0,413 0,433 0,035 0,048 -11,937 
Cdkn1a.639 0,250 0,253 0,020 0,019 -12,339 
Sparc.1898 0,740 1,347 0,060 0,047 -12,347 
Ehhadh.2855 0,205 0,323 0,015 0,015 -14,082 
LIPH.291 0,025 0,046 0,002 0,002 -15,123 
CYP27B1.1244 0,580 1,361 0,028 0,036 -20,959 
Grhpr.361 0,048 0,097 0,002 0,003 -22,233 
Pim1.685 0,311 0,640 0,013 0,025 -24,115 
Mapk14.1095 0,530 1,288 0,011 0,020 -49,379 
Ccnd1.1856 0,039 0,091 0,001 0,001 -50,624 
Parp2.574 0,517 0,856 0,009 0,009 -58,230 
Bcl2l1.2091 0,060 0,146 0,001 0,001 -81,355 
Mmp8.708 0,462 1,098 0,005 0,005 -101,143 
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The most depleted hairpin was Mmp8.708 (101.143 depletion), targeting Matrix 
Metallopeptidase 8 (Tab. 13). Although the depletion was lower, the top-scored candidate 
from the in vivo screen (Mapk14) was also found clearly depleted in vitro (Mapk14.1095) for 
which depletion accounted for 49.379 fold.  
 
 
 
Figure 13 Identification of a potentially therapeutic target for Sorafenib treated HCCs by different RNAi 
screens 
Enrichment and depletion of shRNAs in the in vivo RNAi screen after Sorafenib treatment compared to carrier 
treated mice. Plotted are quotients of average values for Sorafenib treated and carrier treated mice (n = 8-10) (a). 
Enrichment and depletion of shRNAs in the in vitro RNAi screen after Sorafenib treatment of NrasG12V; p19Arf-/- 
cells in comparison to dmso treated cells, plotted are also quotients of average values for Sorafenib treated and 
carrier treated dishes of cells (n = 4) (b) (Mapk14 hairpins = red, remaining hairpins = blue). 
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However, if candidate selection had been based on in vitro screening alone, four other 
candidates would have been prioritized for functional testing before MAPK14 and it is 
unclear whether these other candidate would have shown robust effects in vivo. Nevertheless, 
comparing the screening results from both systems, Mapk14 was found depleted in both 
screens (Fig. 13a,b). This target could be a potential candidate gene for mediating resistance 
to Sorafenib. However, this candidate would not have been selected from an in vitro shRNAi 
screen alone, indicating the significance of screens perfomed in an in vivo model.   
 
 
4.3. Knockdown of Mapk14 sensitizes towards Sorafenib treatment in HCC 
The in vivo and in vitro RNAi screens implied Mapk14 as a potential mediator of resistance 
towards Sorafenib. To validate this candidate, the effect of single hairpin introduction under 
Sorafenib treatment was determined by in vivo and in vitro follow-up experiments. Therefore, 
the two Mapk14 hairpins (Mapk14.1095 and Mapk14.2590) that were found depleted were 
cloned as single constructs into MSCV and transposon plasmids.  
For this purpose, the hairpin sequences were ordered as 97mer oligonucleotides to which the 
restriction sites XhoI and EcoRI were added via PCR amlification. The amplified DNA was 
then cloned with XhoI and EcoRI into MSCV plasmid and next shuttled via XhoI and 
MluI/AscI restriction sites into transposon plasmid.  
Next, the knockdown efficiency of the Mapk14 hairpins was determined, which is important 
to identify whether the hairpins hit their target and to exclude off-target effects. For this 
knockdown test NrasG12V; p19Arf-/- cells were used. The Mapk14 hairpins as well as non-
targeting control hairpin were introduced into those cells by MSCV-based viral gene transfer. 
After puromycin selection, proteins and mRNA were extracted to determine Mapk14 
expression level.  
 
Figure 14 Knockdown efficiency of different Mapk14 hairpins 
Western blot analysis of knockdown efficiency of Mapk14.2590 and 1095 shRNAs and a control shRNA after 
stable transdution of NrasG12V; p19Arf-/- cells, measured by whole cell extracts of proteins. 
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Western blot analysis identified lower protein level of Mapk14 in the presence of respective 
hairpins and therefore both hairpins exerted a significant knockdown in contrast to a control 
hairpin (Fig. 14).  
For in vivo validation of this candidate, several cohorts of p19Arf-/- mice were injected with 
transposable elements carrying NrasG12V-IRES-GFP and either Mapk14 hairpins 
(Mapk14.1095 and Mapk14.2590) or non-targeting control hairpin. 7 days after injection the 
treatment with Sorafenib or carrier was commenced with standard treatment protocol. 
One cohort of mice was harvested simultaneously 5 weeks after injection to compare the liver 
cancer development between consecutive groups (n = 4) (Fig. 15a). The other cohort was 
sacrificed due to critical tumor burden to determine the differences in survival for individual 
groups (Fig. 15b).  
 
 
 
 
Figure 15 Knockdown of Mapk14 gives rise to smaller tumor burden and a survival benefit for mice 
under Sorafenib treatment  
Intrahepatic tumor burden of p19Arf-/- deficient mice, 5 weeks after injection of transposons containing NrasG12V-
IRES-GFP and two different hairpins against Mapk14 or control after treatment with Sorafenib or carrier (n = 4) 
(a). Survival curve of p19Arf deficient mice after injection of NrasG12V-IRES-GFP in combination with 2 different 
Mapk14 or control hairpins for Sorafenib and carrier group, respectively (b). 
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Carrier treated mice carrying a control hairpin showed massive tumor burden after 5 weeks 
and had to be sacrificed due to liver failure with a median survival of 33 days. Administration 
of Sorafenib reduced tumor growth in a moderate way and prolonged median survival up to 
41 days. These data were in accordance with prior observations of the initial treatment study.  
Carrier treated mice harboring Mapk14 hairpins showed a similar pattern of tumor burden and 
survival as carrier treated mice with control hairpin (with median survival of 35 days for both 
shMapk14.2590 and shMapk14.1095), indicating no general impact of Mapk14 knockdown 
on tumor development.  
Interestingly, knockdown of Mapk14 in combination with Sorafenib showed smaller tumor 
burden after 5 weeks and also significantly extended survival compared to Sorafenib treated 
mice (with control hairpin) with a median survival of 53 days for shMapk14.2590 and median 
survival of 51 days for Mapk14.1095 (p = 0.0466 between shcontrol and shMapk14.2590; p = 
0.0125 between shcontrol and Mapk14.1095, under Sorafenib treatment). These data indicate 
that knockdown of Mapk14 induces survival benefit under Sorafenib treatment.   
To allow for in vitro experiments, which may be relevant to get mechanistic input, cells 
harboring transposons carrying NrasG12V-IRES-GFP and either Mapk14 hairpin 
(shMapk14.1095) or control hairpin were isolated by collagenase/dispase digestion of tumors 
from p19Arf deficient mice. To estimate whether cells carrying Mapk14 hairpin are more 
sensitive to Sorafenib treatment than cells with a control hairpin, a colony formation assay 
was performed.  For this, 5000 cells were plated onto 10-cm dish plates, allowed to seed and 
subjected to Sorafenib or dmso treatment on next day. After 8 days, the size and number of 
colonies were visualized by crystal violet staining of cells (Fig. 16). 
 
 
Figure 16 Knockdown of Mapk14 reduced proliferation of NrasG12V; p19Arf-/- cells under Sorafenib 
treatment 
Colony formation assay of NrasG12V; p19Arf-/- cells, carrying Mapk14 or control hairpin (5000 cells were plated 
for each condition). Shown is visualization of cells stained with crystal violet 9 days later, after an 8-day 
Sorafenib (8 µM) or dmso treatment. 
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Due to the fact that dmso treated cells with shMapk14 showed slightly smaller colonies than 
dmso treated cells with shcontrol, a small difference between both cell lines was observed.  
However, Sorafenib treatment diminished colony formation in cells with Mapk14 hairpin 
much stronger than in cells with control hairpin, supporting the important role for Mapk14 
under Sorafenib treatment and implies Mapk14 as a potential target for combinatorial therapy. 
 
4.4. Sorafenib treatment and Mapk14 knockdown act synergistically by inhibition of  
 proliferation 
As described above, Mapk14 knockdown improves the response of HCC to Sorafenib 
treatment. Next, it was determined whether the slower tumor growth under Mapk14 
knockdown is caused by a decreased proliferation rate or a higher amount of cell death. 
Therefore, NrasG12V; p19Arf-/- murine HCCs were analysed by Ki67 staining to evaluate the 
proliferation rate and by Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling 
(TUNEL) to count the rate of apoptotis. These stainings were conducted 5 weeks after 
injection, with Sorafenib or carrier treatment and with Mapk14 or control hairpins, 
respectively.  
The percentage of Ki67 positive cells was comparable between all carrier treated mouse 
livers, with 22.6 ± 4.9 % for shcontrol mice, 23.3 ± 5.8 % for shMapk14.1095 mice and 23.4 
± 7.0 % for shMapk14.2590 mice. In contrast, the number of Ki67 positive cells was in 
general lower for Sorafenib treated mice. Interestingly, mice with Mapk14 hairpins showed 
lower percentages of Ki67 positive cells with 13.9 ± 1.9 % for shMapk14.1095 mice and 10.6 
± 3.6 % for shMapk14.2590, compared to the control hairpin with 18.4 ± 4.2 % of positive 
cells (p < 0.05) (Fig. 17a).  
The number of apoptotic, TUNEL positive cells was in general not higher than 5 % for both 
Sorafenib and carrier treated mice. In the Sorafenib group, the average percentage of dead 
cells was 5.1 ± 2.5 % for the control hairpin, and 4.4 ± 0.7 % or 4.2 ± 2.9 % for 
shMapk14.1095 and shMapk14.2590, respectively. The percentages were similar for carrier 
treated groups, with 3.8 ± 3.8 % for the control hairpin, and 4.9 ± 2.9 % or 4.9 ± 1.6 % for 
shMapk14.1095 and shMapk14.2590, respectively (Fig. 17b).     
These data suggest that smaller tumor burden under Mapk14 knockdown in Sorafenib treated 
mice is due to a decreased proliferation rate of murine HCCs. 
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Figure 17 Reduced level of Mapk14 in murine NrasG12V driven p19Arf-/- tumors results in a decreased 
proliferation rate but has no significant effect on apoptosis upon Sorafenib treatment 
Quantification of cell proliferation rates by staining tumor samples against proliferation marker Ki67. Shown is 
the number of Ki67 positive cells in tumors treated with Sorafenib or carrier , 5 weeks after injection of NrasG12V 
and shMapk14 or shcontrol into p19Arf deficient mice with representative pictures of stained liver tumors (400 x) 
(a). Evaluation of cell death by TUNEL staining of tumor samples 5 weeks after injection of NrasG12V and 
shMapk14 or shcontrol into p19Arf deficient mice, and treatment with Sorafenib or carrier. Shown are also 
representative pictures of stained liver tumors (400 x) (b). 
 
Apart from the effect of the combinatorial treatments on murine HCCs, it was shown that 
Mapk14 knockdown also reduced the size of Sorafenib treated colonies of NrasG12V; p19Arf-/- 
cells in an in vitro assay. To determine whether this result is also based on a decreased 
proliferation rate under Mapk14 knockdown and not due to induced cell death, a cell doubling 
assay was carried out in combination with trypan blue staining under Sorafenib or dmso 
treatment. 
120,000 of NrasG12V; p19Arf-/- cells carrying shMapk14.1095 or control hairpin were seeded 
per plate and subjected to either Sorafenib or dmso treatments after 24 hours. The number of 
attached cells was subsequently measured everyday for a 4-day time period and compared to 
the initial point (day 0) to calculate a fold-change. 
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Figure 18 Knockdown of Mapk14 in combination with Sorafenib treatment decreases proliferation rate in 
NrasG12V; p19Arf-/- cells 
Cell proliferation rates of p19Arf-/- cells carrying shMapk14.1095 or control hairpin upon treatment with 8 µM 
Sorafenib. Plotted are averages of fold-changes in comparison to the initial point (day 0). 120,000 cells were 
plated, subjected to treatment a day later and the number of cells was determined by Guava FACS measurements 
(a). Quantification of cell death evaluated by trypan blue staining after 4 days of treatment with 8 µM Sorafenib. 
Depicted are percentages of trypan blue positive cells, counted by the Neubauer hemocytometer upon mixing 
cell suspension with trypan blue solution in a 1:1 ratio (b). 
 
The proliferation profile identified dmso treated cells growing in general faster than Sorafenib 
treated cells. Shcontrol cells reached after 4 days a fold-change in cell number of 32 ± 0.5, 
slightly more than shMapk14 cells with a fold-change in cell number of 24.9 ± 0.8. The 
proliferation rate of cells expressing a control hairpin was diminished by Sorafenib treatment 
to a fold-change in cell number of 11.0 ± 0.5 after 4 days. However, Sorafenib treated 
shMapk.1095 cells showed a significantly lower amount of cells with only a fold-change in 
cell number of 3.3 ± 0.2 after 4 days (p < 0.0001 shMapk14 vs. shcontrol, both Sorafenib 
treated) (Fig. 18a). At this timepoint the number of dead (trypan blue positive) cells reached 
16 ± 4.8 % for dmso treated shcontrol and 8.5 ± 3.2 % for dmso treated shMapk14 cells. 
Sorafenib treated cells showed a slightly higher amount of dead cells with 19.1 ± 3.4 % for 
shcontrol and 16.7 ± 1.8 % for shMapk14 cells (Fig. 18b). 
Taken together, these in vivo and in vitro observations indicate that a decreased proliferation 
rate is responsible for the observed tumor inhibitory effect of combinatorial treatment.  
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4.5. Combination of Mapk14 knockdown together with Sorafenib treatment can be 
applied to treat advanced HCCs 
Due to the fact that our transposon-based shRNA-mediated gene knockdown is constitutively 
active, the knockdown is directly induced upon transposon-based gene delivery. Although this 
setup allows for tracking genes involved in reducing tumor development, it does not allow to 
distinguish whether this inhibition influences advanced HCC tumors in an intervention 
setting. 
However, recent systems allow for a regulatable induction of gene knockdown, based on 
tetracycline responsive elements (TRE) [137]. In this system, a tetracycline/doxycycline 
binding protein (rtTA3) is constitutively expressed, which regulates expression from a TRE 
promoter and as a result, of a gene or a shRNA of interest. Therefore, the expression of a 
gene/shRNA of interest occurs upon addition of tetracycline (Tet) or doxycycline (Dox) (Tet-
on system).  
To determine whether a tumor inhibiting effect by knockdown of Mapk14 in combination 
with Sorafenib can be seen in an intervention setting, this tet-on system was used where GFP 
and miR30-based shRNAs against Mapk14 were expressed by a TREtight promoter (a 
modified version of TRE promoter resulting in further reduced basal expression of 
gene/shRNA of interest [138]). Therefore, NrasG12V; p19Arf-/- HCC cells were double 
transduced with an MSCV vector expressing rtTA3 and a second MSCV vector expressing 
TREtight–GFP carrying either shMapk14.1095 or shcontrol.  
Each vector contains its own selection marker, which allows for generating homogenous cell 
populations containing both vectors as single copy integrants. These cells (1 million) were 
transplanted into the livers of wild type mice followed by doxycycline administration 7 days 
after injection in combination with Sorafenib administration (Fig. 19a). 
Mice with activated Mapk14 or control hairpin (+ Dox) as well as mice with non-activated 
Mapk14 hairpin (- Dox) were followed up for intrahepatic tumor development under 
Sorafenib therapy. Mice harboring an activated control or non-activated Mapk14 hairpin died 
with a comparable median survival of 20 days (shcontrol) or 22 days (shMapk14). 
Interestingly, mice carrying an activated shMapk14 lived significantly longer with a median 
survival of 49 days (p = 0.033 shcontrol vs. shMapk14.1095, +Dox) (Fig. 19b). Phenotypic 
analyses revealed intrahepatic tumor burden to be the cause of lethality (Fig. 19c).  
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Figure 19 Knockdown of Mapk14 sensitizes towards Sorafenib treatment also in a therapeutic 
intervention setting 
Schematic representation of inducible gene/shRNA expression in the tet-on system upon in situ transplantation 
(a). Survival curves for wild type mice after in situ transplantation of double transduced NrasG12V; p19Arf-/- cells 
with an MSCV vector expressing rtTA3 and a second MSCV vector expressing TRETight-GFP carrying either 
shMapk14.1095 or shcontrol. Injection of 1 million cells was followed by doxycycline administration for the 
corresponding groups, together with Sorafenib treatment 7 days later (b). Representative pictures of developed 
tumors after transplantation of NrasG12V; p19Arf-/- cells (1 million) also followed by doxycycline administration 
for the corresponding groups, together with Sorafenib treatment 7 days later (c). 
 
In general, GFP imaging of livers showed that tumors with activated hairpins are GFP 
positive, whereas tumors with non-activated hairpins did not show GFP signal. However, in 
HCCs with activated Mapk14 hairpin the intensity of GFP signal was frequently weaker than 
in tumors with activated shcontrol (Fig. 19c). These findings imply a selection against 
activated Mapk14 hairpin under Sorafenib treatment.      
Taken together, these data show that knockdown of Mapk14 improves the response of murine 
NrasG12V; p19Arf-/- HCCs towards Sorafenib even when Mapk14 hairpin is activated to a later 
time point in already advanced tumor cells. Due to the fact that there was a selection against 
cells with active Mapk14 hairpins under Sorafenib treatment, the resultant data are likely to 
underestimate the response to advanced HCCs. 
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4.6. A pharmacological inhibition of Mapk14 phenocopies the shRNA-mediated 
knockdown of Mapk14 
Based on the finding that knockdown of Mapk14 improves Sorafenib treatment of HCC also 
in an intervention setting, the question arises whether a pharmacological inhibition of Mapk14 
(p38α) could recapitulate the effect of shRNA-mediated knockdown and therefore improve 
the efficacy of Sorafenib therapy.  
The kinase activity of Mapk14 can be inhibited by different pharmacological inhibitors. Some 
of them were developed as agents against cancer and inflammation diseases. Several Mapk14 
inhibitors are in clinical trials, however, none of them are at the moment approved for patient 
treatment [20].  
For pharmacological inhibition of Mapk14, two different inhibitors were applied, BIRB 796 
and SB 202190 (Fig. 20a,b). Since BIRB 796 was already investigated in clinical trials, it 
shows a putative potential for Mapk14 inhibition in in vivo systems [139;140]. However, 
although SB 202190 was often exploited in in vitro assays, it was never applied for clinical 
studies [140]. 
To determine the inhibitory efficiency of these compounds in mice, a short-term in vivo 
treatment study was performed. P19Arf deficient mice were injected with NrasG12V transposons 
and daily treated for 3 days with the inhibitors. The inhibition was tested by analyzing the 
efficiency of the Mapk14 kinase to phosphorylate its downstream target Hsp27. Western blot 
analysis identified a lower level of phosphorylated Hsp27 upon administration of BIRB 796 
and SB 202190, confirming a target specific inhibition by these compounds (Fig. 20c).  
 
 
 
 
Figure 20 The p38 inhibitors BIRB 796 and SB 202190 efficiently inhibit Mapk14 activity in mouse livers 
Schematic structure of BIRB 796 (a) and SB 202190 (b). Western blot analysis of phosphorylation level of 
Mapk14 downstream target, Hsp27 upon 3-day treatment with BIRB 796 and SB 202190 in murine livers of 
p19Arf-/- mice directly upon injection of NrasG12V (c). 
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The described in vitro system of NrasG12V; p19Arf-/- cells was used to determine the effect of 
pharmacological inhibition of Mapk14 for Sorafenib treatment. Therefore, NrasG12V; p19Arf-/- 
cells were treated with Sorafenib, BIRB 796/SB 202190 alone, or the combination thereof. 
Dmso treated cells were run in parallel for each condition. The effect of these treatments to 
the cells was determined by cell doubling assays and crystal violet staining to identify cell 
proliferation and by trypan blue staining to detect cell death.  
As described before, the cell doubling assay was carried out to evaluate the proliferation rate 
of the cells by daily measurements of the cell number over a 4-day period time. This assay, 
using SB 202190 as a Mapk14 inhibitor revealed dmso treated cells with comparable growth 
activities (fold-change in cell number was between 30.6 and 34.6). The administration of 
Sorafenib reduced the cell growth to fold-change in cell number of 8.6 ± 3.6. Interestingly, in 
contrast to shRNA-mediated knockdown, the chemical inhibition of Mapk14 by SB 202190 
caused also a reduced proliferation rate (fold-change in cell number 9.2 ± 1.1). However, a 
combination treatment with Sorafenib and SB 202190 together induced a much stronger 
decline in proliferation rate than either treatment alone (fold-change in cell number 2.7 ± 0.3, 
p < 0.0001 combinatorial treatment vs. Sorafenib) (Fig. 21a). These results were confirmed by 
cell doubling assay in which BIRB 796 was used as a Mapk14 inhibitor. Within a 4-day time 
period, dmso treated cells grew to fold-changes in cell number between 14.9 and 18.8. In 
contrast, under Sorafenib treatment a fold-change in cell number of 3.5 ± 0.2 was determined. 
Under BIRB 796 treatment, however, the cell proliferation rate was higher and reached a fold-
change in cell number of 9.6 ± 0.6. Also,  a combinatorial treatment further attenuated the 
proliferation rate compared to single treatements (fold-change in cell number 2.0 ± 0.2, p < 
0.0016 combinatorial treatment vs. Sorafenib) (Fig. 21b). These results were also 
recapitulated by crystal violet staining after 4 days of treatment. It showed a reduced number 
of cells by treatments with Sorafenib or Mapk14 inhibitors, however, this phenotype was 
additionally enhanced by simultaneous incubation of Sorafenib with Mapk14 inhibitors (Fig. 
21c,d).  
The trypan blue staining using SB 202190 as a Mapk14 inhibitor did not reveal by treatment 
with dmso high percentages of dead cells (8.9 - 16.7 %). Under Sorafenib treatment the 
number of dead cells increased slightly to 18.0 ± 1.0 %. Interestingly, upon treatment with SB 
202190 the number of dead cells increased to 45.3 ± 2.7 % and therefore was higher as under 
Sorafenib treatment alone.  
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Figure 21 Combinatorial treatment with Sorafenib and chemical inhibitors of Mapk14 decreases cell 
proliferation and increases cell death of NrasG12V; p19Arf-/- cells 
Proliferation rates of NrasG12V; p19Arf-/- cells upon treatment with 8 µM Sorafenib and 50 µM of the Mapk14 
inhibiors SB 202190 or BIRB 796 as well as the combination thereof. Plotted are averages of fold-changes in 
comparison to the initial point (day 0). The number of cells was determined by Guava FACS measurements 
(a,b). Visualization of cells by crystal violet staining after 4 days of treatment with 8 µM of Sorafenib and 50 
µM of SB 202190 or BIRB 796 or combination thereof. 120,000 cells were plated one day before treatment 
onset (c,d). Cell death assay with trypan blue staining after 4 days of treatment with above mentioned conditions. 
Shown are percentages of trypan blue positive cells, counted by the Neubauer hemocytometer. The trypan blue 
solution was mixed with the cell suspension in a 1:1 ratio (e,f). 
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Combination treatment further elevated the number of dead cells up to 74.5 ± 6.9 % (p < 
0.0001 combinatorial treatment vs. Sorafenib alone, p = 0.0024 combinatorial treatment vs. 
SB 202190 alone) (Fig. 21e). In case of treatment with BIRB 796 the results were 
comparable.  
Whereas the percentages of dead, dmso treated cells were comparable (2.6 - 2.9 %), Sorafenib 
treated cells showed a percentage of 12.9 ± 3.7 % dead cells and BIRB 796 treated cells a 
percentage of 28.3 ± 6.7 % dead cells. Also in this case the combinatorial treatments 
increased the percentage of dead cells to 48.1 ± 10.1 % (p = 0.0048 combinatorial treatment 
vs. Sorafenib alone, p = 0.0476 combinatorial treatment vs. BIRB 796 alone) (Fig. 21f).  
These in vitro data showed that the pharmacological inhibition of Mapk14 by SB 202190 or 
BIRB 796 improves Sorafenib treatment similarly to the shRNA-mediated knockdown. 
However, the chemical inhibition alone shows already an effect to NrasG12V; p19Arf-/- cells by 
reduced proliferation. Additionally, the pharmacological inhibition of Mapk14 increased cell 
death, which was enhanced by a combinatorial treatment of Mapk14 inhibitors with 
Sorafenib. These data indicate that the sensitization towards Sorafenib treatment by Mapk14 
inhibition, which is in gerenal linked to a decreased proliferation rate after double treatment is 
to a minor role also induced by induction of cell death, but only when Mapk14 inhibition is 
applied by pharmacological inhibitors and not by shRNA-mediated knockdown. 
To identify the effect of chemical inhibition of Mapk14 in concert with Sorafenib to tumor 
development, an in vivo double treatment study was conducted using BIRB 796, a 
pharmacological inhibitor which was already applied in in vivo studies. Therefore, p19Arf 
deficient mice were injected with NrasG12V and subjected to treatment 7 days after injection. 
The mice were treated either with Sorafenib or BIRB 796 alone (50 mg/kg) or with 
combination thereof. 
To exclude unspecific effects, the carrier for Sorafenib was added to BIRB 796 monotherapy 
and also Sorafenib treatment alone was supplemented with the carrier for BIRB 796. 
Additionally, carriers of both compounds were combined for a control group. One cohort of 
mice was harvested 4 weeks after injection to analyze the intrahepatic tumor burden (Fig. 22a) 
(n = 4), and a second cohort of mice was dissected due to critical tumor development to assess 
the survival of different groups in a Kaplan-Meier curve (Fig. 22b). 
Tumor development for carrier treated mice was comparable to the described study of in vivo 
response to Sorafenib treatment and showed a median survival of 28 days. Treatment with 
Sorafenib or BIRB 796 alone showed a moderate survival advantage to mice with a median 
survival of 34 days for both Sorafenib and for BIRB 796 treated cohorts of mice.  
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Figure 22 Inhibition of Mapk14 by BIRB 796 causes a survival benefit for mice under Sorafenib treatment 
Intrahepatic tumor burden of p19Arf deficient mice at a 4-week timepoint after injection of NrasG12V and 
treatment onset 7 days upon injection. The mice were treated either with Sorafenib (100 mg/kg) and carrier for 
BIRB 796, with BIRB 796 (50 mg/kg) and carrier for Sorafenib, with Sorafenib and BIRB 796 combination or 
treated with both carriers (n = 4) (a). Survival plot of p19Arf deficient mice after single or combinatorial 
treatments of Sorafenib and BIRB 796 or with the carriers upon injection of NrasG12V (b). 
 
Interestingly, the combinatorial treatment significantly slowed down tumor development and 
extended the survival period with a median survival of 43 days (p = 0.0283 between Sorafenib 
and combinatorial treatment). 
These data imply that disadvantageous effect of shRNA-mediated knockdown of Mapk14 in 
concert with Sorafenib treatment to tumor development is reflected by pharmacological 
inhibition of Mapk14 together with Sorafenib, suggesting a potential for this combinatorial 
targeted therapy to be used in HCC patients.  
Taken together, these data show that therapy resistance of HCC can be overcome by a 
combination treatment with pharmacological p38 inhibitors and Sorafenib. 
 
4.7. The outcome of combination therapy in different genetic backgrounds 
The in vivo RNAi screen which identified Mapk14 as a potential target in combination with 
Sorafenib treatment was conducted in a genetically defined background with expression of 
oncogenic NrasG12V in p19Arf-/- mice. The expression of NrasG12V activates the MAPK 
pathway, a frequently upregulated signaling cascade in human HCC. Nevertheless, profiling 
of human HCCs identified dysregulation in many pathways as potential driver for HCC 
development [27;34;53;107;141]. The genetic complexity of human HCCs impedes the 
success of targeted therapies because treatment strategies which are dependent on a genetic 
background might be only applicable for a small subgroup of human HCC patients.  
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Figure 23 HCCs cell lines with different oncogenic combinations show also an effect to combinatorial 
therapy 
Visualization of cells by crystal violet staining after 4 days of treatment with 8 µM of Sorafenib and 50 µM of 
SB 202190 or BIRB 796 or combination thereof. Shown are NrasG12V/Akt-1; p19Arf-/- cells treated with SB 
202190 (a), NrasG12V/Akt-1; p19Arf-/-  cells treated with BIRB 796 (b), NrasG12V/c-myc; p19Arf-/-  cells treated with 
SB 202190 (c), NrasG12V/c-myc; p19Arf-/-  cells treated with BIRB 796 (d) Akt-1/c-my; p19Arf-/-  cells treated with 
SB 202190 (e) and Akt-1/c-myc; p19Arf-/-  cells treated with BIRB 796 (f). 
 
To investigate whether the outcome of combination therapy is limited to the genetic profile of 
the RNAi screen or works also in other oncogenic backgrounds, we applied murine HCC 
cells, which were isolated from tumors driven by different oncogenic combinations in p19Arf 
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deficient backgrounds using standard collagenase/dispase digestion. These tumors were also 
induced by transposon based gene transfer of the corresponding oncogenes upon 
hydrodynamic tail vein injection into p19Arf deficient mice (Dauch, Hohmeyer, Zender, 
unpublished data). The first tested cell line was driven by oncogenic NrasG12V in combination 
with activated Akt1 (a constitutively active form of Akt, by attachment of a N-terminally 
myristoylation signal) [142], another cell line combined the expression of NrasG12V with the 
oncogene c-myc and a third used cell line was driven by a combination of c-myc and Akt1 
and therefore without expression of oncogenic NrasG12V.  
These cells were now used to test the efficiency of combinatorial effect of Sorafenib and the 
Mapk14 inhibitors BIRB 796 and SB 202190 in in vitro assays. 120,000 cells were plated and 
after one day the cells were treated either with Sorafenib or Mapk14 inhibitor alone, the 
combination thereof, or corresponding amounts of carrier (dmso). The same concentrations of 
Sorafenib and Mapk14 inhibtors were used as in earlier experiments for NrasG12V; p19Arf-/- 
cells. On 4th day of treatment, the attached cells were washed and stained with crystal violet to 
visualize the abundance of cells under different conditions.  
As observed for NrasG12V; p19Arf-/- cells, Sorafenib monotherapy reduced the number of 
NrasG12V/Akt-1; p19Arf-/- cells to a low amount. The admistritation of SB202190 and BIRB 
796 alone showed only marginal effects. Importantly, due to combinatorial treatment of the 
Mapk14 inhibitors together with Sorafenib a strong reduction was seen regardless of which 
Mapk14 inhibitor was used. However, by using SB 202190 the reduction in cell growth was 
much stronger than using BIRB 796 (Fig. 23a,b).  
By testing NrasG12V/c-myc; p19Arf-/- cells, it was seen that Sorafenib monotherapy showed a 
much lower effect than in NrasG12V; p19Arf-/- or NrasG12V/Akt-1; p19Arf-/- cells. Also 
administration of the Mapk14 inhibitors alone showed lower effect than in previously tested 
cells. The combination of Sorafenib and SB 202190 reduced the amount of cells significantly 
more than individual monotherapies. However, by using BIRB 796 together with Sorafenib 
no additional effect was seen (Fig. 23c,d).         
The administration of Sorafenib monotherapy to Akt-1/c-myc; p19Arf-/- cells showed also 
lower responses than NrasG12V or NrasG12V/Akt-1 driven cells and therefore similarities to 
NrasG12V/c-myc; p19Arf-/- cells. Also the administration of the Mapk14 inhibitors alone did not 
show strong effects, which was also comparable to NrasG12V/c-myc; p19Arf-/- cells. However, 
the combination of Sorafenib and the Mapk14 inhibitors in these cells showed much stronger 
effects than in NrasG12V/c-myc; p19Arf-/- cells. Especially a strong effect was seen in the 
presence of SB 202190. 
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Taken together, these data indicate that HCC cell lines triggered by the oncogenic 
combinations NrasG12V/Akt-1, NrasG12V/c-myc and Akt-1/c-myc in p19Arf deficient 
backgrounds show also responses towards the combinatorial treatment. However, NrasG12V/c-
myc; p19Arf-/- cells showed a much lower effect than the other tested cell lines and no effect 
was seen when using BIRB 796 as a Mapk14 inhibitor. In general, SB 202190 showed 
stronger inhibitory effects than BIRB 796 in combinatorial therapy. 
 
4.8. A combination treatment of Sorafenib with Mapk14 inhibitors decreases  
proliferation of different human hepatoma cell lines 
It could be shown, that the effect of the combinatorial therapy is in general not limited to the 
genetic background of the RNAi screen, in which Mapk14 was identified as a potential target 
for combinatorial therapy with Sorafenib, but also showed responses in murine HCC cell lines 
which were driven by different oncogenic combinations. However, these results indicate 
differences in the outcome indicating that the genetic background might influence the efficacy 
of the combinatorial therapy. To see the response of cells to the combinatorial treatment, we 
applied a panel of human hepatoma cell lines as PLC/PRF/5 (Alexander), Huh7 and Hep3B 
cells. 
These cells were also treated either with Sorafenib monotherapy, the Mapk14 inhibitors SB 
202190 and BIRB 796 alone and the combination thereof. Also controls with corresponding 
dmso concentrations were applied. The different treatment effects on cell proliferation rates 
were determined by cell doubling assays which were performed, as described before, by daily 
quantification of the number of attached cells. One day after plating the cells, the number of 
cells was quantified (initial point) and consecutive cell quantifications over a 4-day period 
were compared to initial point (fold-changes) to determine cell proliferation rates. 
Additionally, cell staining using crystal violet were performed upon 4 days of treatment which 
was also started one day after plating the cells, to visualize the effect of the different 
conditions.  
Furthermore, trypan blue stainings were performed to quantify the number of dead cells 
(trypan blue positive). As described before, all collected cell fractions were mixed with a 
trypan blue solution in a 1:1 ratio and cells were counted with Neubauer hemocytometer. To 
determine the amount of dead cells, the percentage of trypan blue positive cells was calculated 
with respect to the total number of cells.   
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Figure 24 Treatment of PLC/PRF/5 cells with Sorafenib and Mapk14 inhibitors greatly decreases cell 
proliferation 
Proliferation rates of PLC/PRF/5 cells upon treatment with 4 µM Sorafenib and 20 µM of the Mapk14 inhibiors 
SB 202190 or BIRB 796 as well as the combination thereof. Plotted are averages of fold-changes in comparison 
to the initial point (day 0). The number of cells was determined by Guava FACS measurements (a,b). 
Visualization of cells by crystal violet staining after 4 days of treatment with 4 µM of Sorafenib and 20 µM of 
SB 202190 or BIRB 796 or combination thereof. 80,000 cells were plated one day before treatment onset (c,d). 
Cell death assay with trypan blue staining after 5 days of treatment with above mentioned conditions. Shown are 
percentages of trypan blue positive cells, counted by the Neubauer hemocytometer. The trypan blue solution was 
mixed with the cell suspension in a 1:1 ratio (e,f). 
                                                                                                                                           Results 
 
72 
 
To determine the effect of combinatorial therapy on the proliferation of PLC/PRF/5 cells, first 
a cell doubling assay was performed using SB 202190 as a Mapk14 inhibitor. The cells were 
treated either with Sorafenib or SB 202190 alone, with the combination of both medicaments 
or the corresponding dmso (carrier) concentrations. All three populations of dmso treated 
cells showed a comparable proliferation rate with a fold-change of cell number between 4.4 
and 5.2. The Sorafenib monotherapy reduced the proliferation rate to a fold-change of 1.7 ± 
0.1. Also with SB 202190 administration a lower proliferation of cells (fold-change of cell 
number: 1.4 ± 0.1) was determined. 
Interestingly, the combination treatment reduced the number of cells compared to the initial 
point and a fold-change of 0.2 ± 0.01 was determined. This proliferation rate is significant 
different to the monotherapies (p < 0.0001 Sorafenib vs. Sorafenib/SB 202190) (Fig. 24a).  
A similar pattern in cell proliferation rates was recapitulated by cell doubling assay with 
BIRB 796, as a Mapk14 inhibitor. Also here monotherapies of Sorafenib and BIRB 796 were 
compared to a combination therapy, where again dmso treated cells served as controls. 
Similarly, in this assay the different groups of dmso treated cells showed comparable 
proliferation rates with fold-changes in cell numbers after 4-days between 3.2 and 3.9. The 
Sorafenib monotherapy reduced the proliferation rate to a fold-change in cell number of 2.6 ± 
0.1 whereas treatment with BIRB 796 resulted in a fold-change in cell number                       
of 2.5 ± 0.1. A combinatorial therapy abrogate cell proliferation and a fold-change in the cell 
number of  0.7 ± 0.02 was measured after 4 days which is significantly different to 
monotherapies (p < 0.0001) (Fig. 24b). 
The already described visualization of cells with crystal violet after 4 days of treatment 
reproduced the results from the cell doubling assays. The Sorafenib monotherapy as well as 
incubation with the Mapk14 inhibitors reduced the number of cells compared to the DMSO 
treated cells. However, the combination of Sorafenib and Mapk14 inhibitor induced a much 
stronger effect in cell reduction than the single treatments (Fig. 24c,d).  
To identify the percentage of dead cells, trypan blue stainings were conducted upon 
combinatorial treatment compared to single treatments and corresponding dmso 
concentrations (see above). In this assay, using SB 202190 as a Mapk14 inhibitor, the number 
of DMSO treated cells was in general low, between 11.4 and 18.0 % of dead cells. The 
application of Sorafenib increased the number of dead cells to 25.5 ± 3 % and the application 
of SB 202190 to 37.2 ± 0.5 %. Nevertheless, a combinatorial therapy induced a much stronger 
amount of dead cells (73.2 ± 2.0 %) which was significantly different in comparison to both 
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monotherapies (p < 0.0001) (Fig. 19e). A quantification of trypan blue positive cells using 
BIRB 796 as a Mapk14 inhibitor, showed similar results. The number of DMSO treated cells 
was again low between 13.2 and 16.5 % of dead cells. The Mapk14 inhibition by BIRB 796 
resulted in 20.2 ± 2.5 % of dead cells and therefore lower than upon SB 202190 treatment. 
However, a combinatorial treatment with Sorafenib and BIRB 796 increased cell death to 
51.5 ± 5.0 %, again significantly higher than monotherapies (p = 0.0006 Sorafenib vs. 
Sorafenib/BIRB 796) (Fig. 4f). 
These data illustrate that pharmacological inhibition of Mapk14 can efficiently sensitize also 
human HCC cells towards treatment with Sorafenib. To investigate whether this effect could 
be shown in a broader spectrum of human hepatocarcinoma cells, the same assays were 
performed with the same conditions for Huh7 cells. 
Also for these cells the cell doubling assay was performed with SB 202190 as a Mapk14 
inhibitor. Due to the fact that these cells grow faster than PLC/PRF/5 cells, dmso treated cells 
showed higher proliferation rates but they were also very comparable between the different 
dmso treated groups (fold-changes of cell number after 4 days: ~ 22). Also in Huh7 cells the 
treatment with Sorafenib dimished cell proliferation and a fold-change in the cell number of 
4.5 ± 0.3 was determined. The treatment with SB 202190 resulted also in a reduced 
proliferation rate displayed by a fold-change in cell number of 8.2 ± 0.8. However, the 
combinatorial treatment increased further the proliferation rate and amounted to a fold-change 
in cell number of 1.9 ± 0.1, which is significantly different to Sorafenib monotherapy  (p = 
0.0002) (Fig. 25a).  
These results were also confirmed by taking BIRB 796, as a second Mapk14 inhibitor. Here 
dmso treated cells showed after 4 days fold-changes in the number of cells between 16.0 and 
18.0.  Sorafenib treatment declined the proliferation rate of cells considerably to a fold-change 
in the cell number of 6.2 ± 0.4. By administration of BIRB 796 a fold-change in the cell 
number of 4.9 ± 0.5 was calculated. A double incubation of cells with Sorafenib and BIRB 
796 aggravated a reduction in the proliferation rate, determined by a fold-change in cell 
number of 1.5 ± 0.1 (p = 0.0003 Sorafenib vs. Sorafenib/BIRB 796) (Fig. 25b).  
Visualization of Huh7 cells by crystal violet recapitulates the results of cell doubling assays. 
Whereas dmso treated cells showed no impact on proliferation, monotherapies with Sorafenib 
or the Mapk14 inhibitors SB 202190 or BIRB 796 reduced the number of cells to a small 
extent. Nevertheless, a combination treatment with Sorafenib and Mapk14 inhibitors reduced 
the number of cells much stronger than the corresponding monotherapies (Fig. 25c,d). 
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Figure 25 Mapk14 inhibition in Huh7 cells sensitizes cells towards Sorafenib treatment 
Cell proliferation rates of Huh7 cells upon treatment with 4 µM Sorafenib and 20 µM of the Mapk14 inhibiors 
SB 202190 or BIRB 796 as well as the combination thereof. Plotted are averages of fold-changes in comparison 
to the initial point (day 0). The number of cells was determined by Guava FACS measurements (a,b). 80,000 
cells were plated 1 day before treatment onset and above is shown the visualization of cells stained with crystal 
violet after 4 days of treatment with 4 µM of Sorafenib and 20 µM of SB 202190 or BIRB 796 or combination 
thereof (c,d). Presented are percentages of trypan blue positive cells, indicative of cell death, counted with 
Neubauer hemocytometer after 5 days of treatment with above mentioned conditions. The trypan blue solution 
was mixed with the cell suspension in a 1:1 ratio (e,f). 
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Quantification of cell death by counting trypan blue positive Huh7 cells indicated a similar 
response to the different treatment options as it was shown for PLC/PRF/5 cells. Using SB 
202190 as a Mapk14 inhibitor the number of dead cells under dmso treatment was in general 
low between 6.0 and 10.2 %. 
Application of Sorafenib increased the number of dead cells to 13.2 ± 2.4 %. Treatment with 
SB 202190 resulted in 9.2 ± 0.9 % of dead cells and therefore a little bit lower amount than 
under Sorafenib treatment. However, a combination of Sorafenib and SB 202190 increased 
the number of dead cells to 47 ± 2.4 %, a significant difference to monotherapies (p < 0.0001) 
(Fig. 25e). These striking differences were also yielded by using BIRB 796 as a Mapk14 
inhibitor. Whereas dmso treated cells showed again low amounts of dead cells with 5.0 – 
14.5 %, inhibition of Mapk14 increased the number of dead cells to 15.6 ± 2.8 % and 
therefore comparable to Sorafenib. A combinatorial therapy using Sorafenib and BIRB 796 
resulted in 54.0 ± 1.6 % of dead cell, a value which was again significantly different to 
monotherapies (p < 0.0001) (Fig. 25f). 
Finally, as a last example of a human HCC cell line Hep3B cells were used for 
aforementioned experiments. Also for those cells, cell doubling assays were carried out in 
order to determine the proliferation rate under different conditions.  
Using SB 202190 as a Mapk14 inhibitor, the highest proliferation rates were reached by dmso 
treated cells (fold-changes in cell number after 4 days: ~ 30.0). Treatment with Sorafenib 
reduced the proliferation rate of the cells to a fold-change in the cell number of 16.0 ± 0.07. 
The administration of SB 202190 to Hep3B cells changed the proliferation rate of cells only 
in a marginal way compared to dmso treated cells (fold-change in cell number after 4 days: 
24.0 ± 2.0). However, similarly as PLC/PRF/5 and Huh7 cells, Hep3B cells showed also an 
impact from the combinatorial treatment. Under Sorafenib/SB 202190 treatment, the 
proliferation rate of cells was lower and a fold-change in the number of cell of 6.5 ± 0.5 was 
determined (p < 0.0001 Sorafenib vs. Sorafenib/SB 202190) (Fig. 26a).  
Importantly, a similar pattern in the proliferation rates was shown for BIRB 796. In this assay, 
all groups of dmso treated cells proliferated in a comparable way. The fold-changes in cell 
number after 4 days ranged between 21.0 and 26.0. Single treatment with Sorafenib displayed 
a fold-change in cell number of 14.9 ± 0.3. This proliferation rate was comparable to BIRB 
796 treated cells with a fold-change in cell number of 13.5 ± 0.2.  
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Figure 26 BIRB 796 and SB 202190 enhance response towards Sorafenib in Hep3B cells 
Cell proliferation rates for Hep3B cells treated with 2 µM Sorafenib and 12 µM of the Mapk14 inhibitors SB 
202190 or BIRB 796 as well as the combinatorial treatment. The number of cells was evaluated by Guava FACS 
measurements and plotted are averages of fold-changes in comparison to the initial point (day 0) (a,b). 
Visualization of cells stained with crystal violet after 4 days of treatment with 2 µM of Sorafenib and 12 µM of 
SB 202190 or BIRB 796 or combination thereof. 80,000 cells were plated one day before treatment onset (c,d). 
Determination of cell death by counting trypan blue positive cells upon mixing cell supsenstion with trypan blue 
solution in a 1:1 ratio. Shown are percentages of trypan blue positive cells, counted by the Neubauer 
hemocytometer after 5 days of treatment with above mentioned conditions (e,f). 
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A combination treatment with Sorafenib and BIRB 796 further reduced the proliferation rate 
and a fold-cange in cell number of 3.5 ± 0.1 was determined, which was significantly 
different compared to monotherapies (p < 0.0001) (Fig. 26b). 
A visual depiction of crystal violet assay upon 4 days of different treatments also 
recapitulated a disadvantegous effect of combinatorial treatment. As shown, a significantly 
reduced number of cells for combinatorial treatment was stained with crystal violet compared 
to single treatments with Sorafenib or with Mapk14 inhibitors (Fig. 26c,d).   
Comparable to Huh7 and PLC/PRF/5 cells, this combinatorial therapy also induced higher 
percentage of dead cells than for single treatments and for dmso treated (control) groups. 
Using SB 202190 as a Mapk14 inhibitor the values for trypan blue positive cells of dmso 
treated groups ranged from 6.5 % to 14.4 %. Sorafenib treated cells reached a value of 17.1 ± 
3.7 % of dead cells which was comparable to SB 202190 treated cells with a value of 15.0 ± 
3.6 % of dead cells. The number of dead cells in Hep3B cells was further increased by 
combination treatment of Sorafenib and SB 202190 and reached a value of 40.6 ± 4.8 % of 
dead cells. These values were significantly different to monotherapies with a p value of 
0.0027 compared to Sorafenib and a p value of 0.0018 compared to SB 202190 treatment 
(Fig. 26e). 
These results were also confirmed by the usage of BIRB 796 as a Mapk14 inhibitor.  After 
trypan blue staining, dmso treated cells showed between 13.3 % and 16.3 % of dead cells. 
Sorafenib treatment induced 18.4 ± 2.4 % of dead cells and which was comparable to a value 
of  20.2 ± 4.2 % of dead cells for BIRB 796 monotherapy. The combination of Sorafenib and 
BIRB 796 further increased the number of dead cells to 63.2 ± 4.5 % and showed a statistical 
significance in comparison to single treated cell populations (monotherapies) (p = 0.0001 to 
Sorafenib and p = 0.0003 to BIRB 796) (Fig. 26f).  
Taken together, quantification of cell proliferation rates using a cell doubling assay and 
crystal violet staning as well as determination of cell death by quantification of trypan blue 
positive cells in a panel of human HCC cell lines shows a promising, disadvantegous effect on 
human HCC cell lines by a combinatorial treatment of Sorafenib and different Mapk14 
inhibitors. This sensitization effect of the combinatorial therapy is achieved by significantly 
lower cell proliferation rates and higher amounts of dead cells compared to individual 
monotherapies. Interestingly, these results in human HCC cells showed an even more potent 
effect of the combinatorial therapy than the murine NrasG12V; p19Arf-/- cells. These data 
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indicate that this combination therapy constitutes a strong potential in the treatment of human 
hepatocellular carcinoma. 
 
4.9.  ATF2 plays a role as a downstream target in Mapk14 mediated resistance   
            towards Sorafenib treatment  
Our treatment studies of several different rodent and human HCC cell lines indicate the 
combination of Sorafenib and Mapk14 inhibitor as a potent treatment strategy for human 
HCC patients. Nevertheless, so far it is not clear how Mapk14 induces resistance towards 
Sorafenib treatment. In chapter 4.4 (Figure 17 and 18) it could already be shown that 
knockdown of Mapk14 did not influence the amount of dead cells but reduced the 
proliferation rate of Sorafenib treated tumors and HCC cells. Although this is different upon 
pharmacological inhibition of Mapk14 (possible off target effects of compounds), it indicates 
that Mapk14 is necessary for a signaling cascade which induces proliferation in the absence of 
Sorafenib targets Raf1, c-Raf, VEGFR-2 and VEGFR-3. To see whether this signaling 
cascade is upregulated upon Sorafenib treatment, western blot assays of activated Mapk14 (P-
Thr-180/Tyr-182) was performed 6 hours, 24 hours and 3 days upon Sorafenib treatment or 
dmso in murine NrasG12V; p19Arf-/- und human Hep3B cells. Interestingly, the amount of 
phosphorylated Mapk14 in NrasG12V; p19Arf-/- cells did not increase upon Sorafenib treatment 
but was even slightly reduced 3 days after treatment (Fig. 27a) which shows that the Mapk14 
pathway is not upregulated upon short-term Sorafenib treatment. Likewise, no difference was 
seen for phosphorylated Mapk14 at different timepoints after Sorafenib treatment for Hep3B 
cells (Fig. 27b). Nevertheless, independently of whether Mapk14 is upregulated or not upon 
Sorafenib administration, previous data showed that this pathway is necessary for 
proliferation upon Sorafenib treatment.  
To identify how the Mapk14 pathway induces resistance towards Sorafenib treatment in more 
detail, mRNA gene expression analyses were carried out in NrasG12V; p19Arf-/- cells harboring 
Mapk14 or control shRNA upon 3 days of treatment with Sorafenib or dmso, respectively. 
The analysis was performed with whole cell mRNA extracts using Affymetrix gene chip (in 
cooperation with Robert Geffers, Helholtz Centre for Infection Research).  
The expression data from shcontrol cells treated with Sorafenib, shMapk14 cells treated with 
dmso and shMapk14 cells treated with Sorafenib were normalized towards the expression 
data of shcontrol cells treated with dmso and compared (log2 ratio). Interestingly, the 
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expression of several genes related to cell proliferation and cell growth were highly reduced 
in cells carrying the hairpin against Mapk14 and which were treated with Sorafenib, 
compared to dmso treated shcontrol cells. These data are in line with previous data which 
showed a lower proliferation rate of Sorafenib treated tumors or cancer cells carrying a 
Mapk14 hairpin compared to Sorafenib treated tumors/cells with a control hairpin or carrier 
treated tumors/cells (Figure 17 and 18). To evaluate the underlying signal cascades of this 
expression pattern, a bioinformatical analysis of the expression data was conducted by using 
Ingenuity pathway analysis software (Ingenuity Systems, Inc). This software applies a 
literature based analysis of upstream factors, which activation or deactivation might be 
causative for the observed gene expression phenotype (illustrated by a positive or negative z-
score). This analysis was done for shcontrol cells treated with Sorafenib and shMapk14 cells 
treated with Sorafenib or dmso, which where previously normalized to dmso treated shcontrol 
cells. All three groups were compared between each other upon bioinformatical analysis.  
Interestingly, several upstream regulators were identified as significantly deactivated in HCC 
cells upon Sorafenib treatment in combination with knockdown of Mapk14 compared to 
Sorafenib monotherapy and Mapk14 knockdown alone. In Figure 27c the 50 most depleted 
upstream factors upon combinatorial therapy are listed (No value = no significant regulation 
found).  
As a proof of principle the activity of the Sorafenib targets Raf and VEGF was analyzed. 
Importantly, in cells treated with Sorafenib monotherapy (sh-control cells) a deactivation of 
the major Sorafenib target Raf1 (c-raf) [76] was identified (z-score = -3.05). In line with these 
data, also deactivation of VEGF (-3.24) and PDGF (-3.16) (together with the PDGF subunit 
PDGFBB [143] (-4.51)) were seen, which are ligands for Sorafenib targets VEGFR-2, 
VEGFR-3 or PDGFR, respectively [76]. Moreover, the deactivation of Raf1 and VEGF was 
even stronger under combinatorial therapy with Mapk14 knockdown, illustrated by z-scores 
of -6.22 (RAF-1), -5,80 (VEGF). Similar results were observed by analyzing the downstream 
targets of Raf1, ERK and MAP2K1 (MEK-1). Also here a strong reduction upon Sorafenib 
monotherapy was seen (z-score of ERK = -2.41/-2,97 and of MAP2K1 = -1,64), however, 
there was also reduction upon Mapk14 knockdown and a stronger reduction upon 
combinatorial therapy with z-scores of -4.80/-4.00 (ERK) and -3.64 (Mapk2K1). 
Apart from VEGF and PDGF, also the growth factors EGF (-4,85), IGF1 (-3,88 ) (in 
combination with Insulin (-4,13)), TGFA (-4,38) and HGF (-4,40) were identified as 
deactivated upon combinatorial therapy. 
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Figure 27 Mapk14 is not activated upon Sorafenib treatment but influences several cell regulatory factors 
involved in cell proliferation 
Western blot assay against activated Mapk14 (p-p38) in NrasG12V; p19Arf-/- cells (a). Western blot assay against 
activated Mapk14 (p-p38) in human Hep3B cells (b). Bioinformatical analysis of upstream factors (Ingenuity 
pathway analysis) based on gene expression data which were collected from NrasG12V; p19Arf-/- cells carrying a 
control shRNA or a shRNA against Mapk14 and which were treated with Sorafenib or carrier for a 3day period. 
The data from Sorafenib treated cells and dmso treated Mapk14 cells were normalized towards dmso treated 
shcontrol cells.  
 
Also several cytokines as IL1 (-4.19/-4.32), IL2 (-4.22), IL17A (-3,70), IL18 (3,70), 
interferon gamma (IFNG -4.42) and TNFSF11 (-4.34) were found deactivated upon 
combinatorial therapy. 
As another proof of principle also activity of Mapk14/p38 was determined and a strong 
deactivation was seen upon Mapk14 knockdown, independenly of whether the cells were 
treated with Sorafenib or with carrier (z-score = -3.38 in dmso treated, -3.98 in Sorafenib 
treated cells). Interestingly, also the activity of Mapk14 downstream target ATF2 (Activating 
transcription factor 2) was found strongly diminished upon Mapk14 knockdown (-3.67 in 
dmso treated, -3.69 in Sorafenib treated cells), indicating a putative role of ATF2 in Mapk14 
mediated resistance towards Sorafenib treatment.  
ATF2 is a transcription factor which binds to a DNA sequence called cAMP-responsive 
element (CRE). It builds a complex, which is called Ap-1 (activator protein 1) with several 
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other transcription factors, as members of the Jun, Fos, Maf and ATF/Creb gene families 
[144]. Interestingly the Ap-1 complex was also found strongly deactivated upon 
combinatorial therapy (-4.24), but in this case not upon knockdown of Mapk14 alone. Also 
CREB1, one member of the ATF/Creb gene family which is also a downstream target of 
Mapk14 [145] and a binding partner of ATF2 [146] was found dimished upon combinatorial 
therapy (-4.41).  
To validate the results from this bioinformatical analyses, western blot analysis were 
performed for activated ATF2 (phosphorlyated at Thr69 and Thr51) upon combinatorial 
therapy (using two different Mapk14 shRNAs), as well as upon Sorafenib treatment and 
Mapk14 knockdown alone. These data showed diminished activation of ATF2 upon 
combinatorial therapy (Fig. 28a).  
To determine whether ATF2 is necessary for Mapk14 mediated resistance towards Sorafenib 
therapy, genetic validation experiments were performed using two independent shRNAs 
targeting ATF2 (ATF2.1136 and ATF2.1362). As described before, these hairpins were also 
ordered as 97base oligos and cloned by PCR cloning using XhoI and EcoRI into MSCV 
plasmids. NrasG12V; p19Arf-/- cells were stably transduced with these hairpins and upon 
quantitative PCR analysis, using whole cell extracts a clear reduction of ATF2 mRNA 
(>40%) was seen compared to a control shRNA, indicating a good knockdown efficiency of 
the ATF2 shRNAs (Fig. 28b). 
To allow for conditional expression of these shRNAs, the hairpins were shuttled using XhoI 
and EcoRI cloning into MSCV plasmids carrying a tetracycline resposive element. NrasG12V; 
p19Arf-/- cells carrying constitutively expressed tetracycline/doxycycline binding protein 
(rtTA3) were stably transduced with viral particles carrying these constructs, and upon 
puromycin selection the shRNAs were activated due to doxycycline (5µg/ml medium) 
administration.  
Next, the cells were either treated with Sorafenib or with dmso and subjected to quantification 
of proliferation rates and colony formation assay, which was visualized by crystal violet 
staining. For cell doubling assay, 120,000 cells were seeded per plate, subjected to 
doxycycline and 24 hours later the treatment with Sorafenib or dmso was started. Similar to 
previous cell doubling assays, the number of attached cells (GFP positive) was subsequently 
measured everyday for a 4-day time period and again compared to the initial point (day 0) to 
calculate a fold-change (Fig. 28c). 
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Figure 28 ATF2 is downregulated upon combinatorial treatment and is an important Mapk14 
downstream target mediating resistance towards Sorafenib therapy 
Western blot assay against activated ATF2 in NrasG12V; p19Arf-/- cells carrying a control shRNA or two different 
shRNAs targeting Mapk14 (a). Quantitative PCR analysis of knockdown efficiency of ATF2.1136 and 
ATF2.1362 shRNAs compared to a control shRNA after stable transdution of NrasG12V; p19Arf-/- cells, measured 
by mRNA level of whole cell extracts (b). Cell proliferation rates of NrasG12V; p19Arf-/- cells carrying a control 
shRNA or two different shRNAs targeting ATF2 either treated with 8 µM Sorafenib or dmso respectively. The 
number of cells was evaluated by Guava FACS measurements and plotted as averages of fold-changes in 
comparison to the initial point (day 0) (c). Cell doubling assay of NrasG12V; p19Arf-/- cells carrying a control 
shRNA or shRNAs targeting ATF2 either treated with 8 µM Sorafenib or dmso. Cells were visualized by crystal 
violet staining (d). mRNA expression analysis of Cyclin A2 and Cyclin D1 in NrasG12V; p19Arf-/- cells carrying a 
control or a shRNA targeting Mapk14 and which were treated either with Sorafenib or carrier. Microarray data 
using affymetrix gene chip upon whole cell mRNA extraction. Values were normalized towards the expression 
data from dmso treated shcontrol cells (e). Western blot analysis of Cyclin A2 in NrasG12V; p19Arf-/- cells also 
carrying a control shRNA or a shRNA targeting Mapk14 upon treatment either with Sorafenib or carrier (f).     
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Dmso treated shcontrol cells reached after 4 days a fold-change of 13.59 ± 1.1. Due to 
knockdown of ATF the NrasG12V; p19Arf-/- cells grew slower and reached after 4 days fold-
changes of 9.90 ± 0.2 (shATF2.1362) and 7.93 ± 0.4 (shATF2.1136), implying that 
knockdown of ATF2 influences already cell growth of non treated cancer cells. However, 
Sorafenib treated shcontrol cells reached only a fold-change of 4.48 ± 0.4, indicating that 
Sorafenib monotherapy dimished cell growth stronger than ATF2 knockdown. Interestingly, 
cells carrying ATF2 hairpins which were treated with Sorafenib showed a much stronger 
reduction in cell growth (fold change 2.57 ± 0.5 with ATF2.1136 and 2.77 ± 0.3 with 
ATF2.1362) than Sorafenib treated shcontrol cells (p=0.016).  
The results from the cell doubling assay could be reproduced by colony formation assay, 
which was also performed as previously described. 5000 cells, carrying a non targeting 
control shRNA or the previously described shRNAs against ATF2 were plated onto 10-cm 
dish plates, treated either with Sorafenib or with dmso and subsequently visualized using 
crystal violet staining. The combination of ATF2 knockdown and Sorafenib treatment 
reduced the amount of cells much stronger than Sorafenib treated shcontrol cells and dmso 
treated cells (Fig. 28d).   
Taken together, these data illustrate that knockdown of ATF2 can phenocopy the knockdown 
of Mapk14 implying that ATF2 might play a major role as a downstream target of Mapk14 
towards Sorafenib treatment. 
Some of the most relevant targets of ATF2 mediated transcriptional activation are the Cyclins 
A and D [146]. Interestingly, in the mRNA based gene expression microarray analysis, which 
was used for the Ingenuity based identification of upstream factors, we identified Cyclin A2 
(the somatic isoform of Cyclin A [147]) strongly downregulated in Sorafenib treated 
shMapk14 cells compared to dmso treated control cells (log2 fold = -2.17 ± 0.2). Moreover, 
no downregulation was seen in Sorafenib treated shcontrol cells and shMapk14 cells treated 
with dmso (p = 0.0033 shMapk14 vs. shcontrol, both Sorafenib treated) (Fig. 28e). The 
expression data of Cyclin D1 were different to Cyclin A2 and upon combinatorial therapy no 
downregulation was seen compared to dmso treated control cells (log2 fold = -0.05 ± 0.06) 
(Fig. 28e). These data indicate a special role of Cyclin A2 as a transriptional target of ATF2 
upon Sorafenib treatment. To validate the data from the expression array, western blot 
analysis of Cyclin A2 was performed in shcontrol and shMapk14 cells, which were again 
either treated with Sorafenib or with dmso. These data also showed lower amount of Cyclin 
A2 protein upon combinatorial therapy (Fig. 28f).   
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Taken together, these data indicate that ATF2 and its transcriptional target Cyclin A2 play a 
role in Mapk14 mediated resistance towards Sorafenib treatment in hepatocellular carcinoma.  
             
4.10. New Mapk14 inhibitors (Skepinone-L, PH 797804) which are promising 
          candidates for clinical development are effective in combinatorial treatment  
In this study there could be shown an effect of combinatorial therapy for Sorafenib and 
different Mapk14 inhibitors in reducing the growth of murine hepatocellular carcinoma and 
various murine/human HCC cell lines. This indicates that this combinatorial therapy could be 
useful in the clinic to treat HCC patients, however, the Mapk14 inhibitors which were tested 
so far (SB 202190 and BIRB 796) were not approved in clinical studies. SB 202190 was not 
at all tested in clinical studies and BIRB 796 has been dismissed after phase I of clinical trials 
due to occurring toxic side effects. Nevertheless, currently different newly designed Mapk14 
inhibitors are currently under development or clinical testing, which might have a higher 
potential for treating patients. Among them is Skepinone-L, which was so far not tested in 
clinical studies and PH-797804 which completed phase II clinical studies. Both inhibitors 
showed only marginal side effects and in contrast to BIRB 796 and SB 202190 seem to be 
more specific for Mapk14 (the α-form of p38) [148;149]. Therefore, the effect of these 
Inhibitiors should be also tested in combination with Sorafenib treatment (in cooperation with 
Stefan Laufer, Universitiy of Tübingen). 
To determine the efficacy also for those Mapk14 inhibitors in the previously shown in vitro 
setting, murine NrasG12V; p19Arf-/- and human Hep3B HCC cells were applied. 120,000 cells 
were seeded per plate and after 24 hours the cells were treated with Sorafenib, with the 
corresponding Mapk14 inhibitor alone or in combination thereof. Also controls with 
corresponding dmso concentrations were performed. Similar to previous assays, the amount 
of cells upon treatment was visualized by crystal violet staining. 
As shown before, the treatment of NrasG12V; p19Arf-/- cells with Sorafenib induces only 
marginal reduction in cell growth. By using Skepinone-L as a Mapk14 inhibitor also a 
reduction in cell growth was seen, which was even slightly stronger than upon Sorafenib 
treatment. Importantly, the combination of Sorafenib and Skepinone-L reduced cell growth 
much stronger than monotherapies (Fig. 29a). By using PH 797804 as a Mapk14 inhibitor 
nearly no reduction was seen upon PH 797804 monotherapy. In combination with Sorafenib 
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PH 797804 also reduced cell growth stronger than monotherapies. However, the difference 
was not as pronounced as for Skepinone-L (Fig. 29b).         
By treating the human HCC cell line Hep3B, the effect of Sorafenib monotherapy was again 
moderate and therefore comparable to previous studies. As shown in NrasG12V; p19Arf-/- cells, 
the application of Skepinone-L monotherapy showed a slightly higher effect in diminishing 
cell growth than Sorafenib treatment. However, the combination of Sorafenib and Skepinone-
L reduced cell growth of Hep3B cells also significantly stronger than monotherapies (Fig. 
29c). The treatment of Hep3B cells with PH 797804 alone showed an effect, which was 
comparable to Sorafenib treatment. However, the combination of Sorafenib and PH 797804 
was not as pronounced as for the combination of Sorafenib and Skepinone-L in Hep3B cells 
or for the combination of Sorafenib and PH 797804 in murine NrasG12V; p19Arf-/- cells (Fig. 
29d).  
 
 
Figure 29 Highly specific Mapk14 inhibitors show enhanced response towards Sorafenib in NrasG12V; 
p19Arf-/- and Hep3B cells 
Visualization of NrasG12V; p19Arf-/- cells stained with crystal violet after 4 days of treatment with 8 µM of 
Sorafenib and 20 µM of Skepinone-L or 20 µM PH 797804 or combination thereof (a,b). The respective 
visualization for Hep3B cells was performed for treatment with 2 µM Sorafenib and 15 µM Skepinone-L or 20 
µM PH 797804 or combination thereof (c, d). 120,000 cells were plated one day before treatment onset. 
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Taken together, both newly developed Mapk14 inhibitors showed a significant effect in 
combinatorial treatment with Sorafenib in diminishing HCC cell growth. Skepinone-L 
showed in general stronger effects with Sorafenib than PH-797804, however, small effects 
were already seen upon Skepinone-L monotherapy. Nevertheless, these Mapk14 inhibitors 
might be promising compounds to organize clinical studies, which might approve this 
combinatorial therapy to HCC.  
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5. Discussion and outlook 
 
Hepatocellular carcinoma represents the sixth most frequent type of cancer and the third 
leading cause of cancer related death worldwide [1]. This high lethality rate (5 year survival 
rate of only 8.9 %) is mainly be due to a lack of efficient treatment options. Surgical resection 
of tumors is only applicable to a small subgroup of patients and chemotherapeutic drugs are 
often shown to be not effective [56].  
As for melecular targeted therapies, only the small kinase inhibitor Sorafenib is approved, 
however Sorafenib prolongs survival of HCC patients only by 2.8 months. Nevertheless, the 
tumor inhibitory effect of Sorafenib shows that a targeted therapy in general can be effective 
to treat HCC [80]. Sorafenib is a multikinase inhibitor with several targets. The main targets 
are members of the Raf family (C-Raf also known as Raf1, mutant and wild type B-Raf) and 
the vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3) [76]. Currently it 
is under scientific discussion which target plays the major role in tumor inhibition. However, 
it may be possible that the combinatorial inhibition of both, proliferative and angiogenic 
targets explains the effectiveness of Sorafenib in HCC treatment as it is known that 
combinatorial targeting may improve targeted therapies in general. These facts provide the 
rationale that HCC treatment with Sorafenib may be more effective with addition of other 
targeted agents [150]. Recently, several combinatorial therapies with Sorafenib are under 
investigation as for example the combination of Sorafenib with the EGFR inhibitor Erlotinib 
or the VEGF receptor Bevacizumab (Avastin) [151]. 
To identify new promising targets for a combinatorial therapy with Sorafenib, either a 
hypothesis driven approach could be applied, based on the molecular background of HCC 
development and Sorafenib treatment or an unbiased approach could be chosen. In this study, 
a combinatorial treatment is described that improves Sorafenib treatment significantly in 
different experimental setups. This combinatorial treatment is based on the inhibition of the 
Mitogen activated kinase 14 (Mapk14 or p38α). This candidate was identified by an unbiased 
approach using an in vivo RNAi screen in a mosaic cancer mouse model.  
As decribed before, RNAi screens in the presence of drugs were already performed and 
identified potential new targets for combinatoral therapies. For example, in the presence of 
PARP inhibitor, a screen in breast cancer cells using siRNAs was performed which identified 
CDK5 and STK22c as potential drug sensitizing targets [124]. Also in the presence of 
paclitaxel or gemcitabine, siRNA screens were conducted [125;126]. Genes mediating 
doxorubicin resistance were identified with a miR30-based shRNA library in lymphoma cells 
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[127]. These screens showed the utility of drug sensitizing screens; however, these screens are 
based entirely on cell culture systems.  
Although candidates for human treatment were identified by cell culture or xenograft models, 
it became evident that new treatment strategies that were identified using in vitro systems are 
of limited value for the treatment of human cancer patients due to differences in cell growth 
and cell environment [96]. A human tumor is influenced by several cell extrinsic factors, as 
growth factors, angiogenesis and the role of the immune system. These factors are not 
reflected accurately in an in vitro model. Also in transplanted cells in a xenograft model, 
arising tumors differ strongly to tumors occurring directly in the corresponding organ [96].  
To identify possible treatment options for a therapy in humans, a model is requested that 
mimics human cancer induction and development. In our mosaic cancer mouse model, 
malignancy is induced in cells which are surrounded by normal tissue cells of the 
corresponding organ. This resembles carcinogenesis in a better way than a simultaneous, 
tissue specific expression of transgenes in all cells of the organ. Furthermore, the genomic 
lesions are induced in adult cells, thus avoiding developmental compensation as seen in 
germline transgenic mice.  
The mosaic cancer mouse model described in this study induces tumor development by 
transposon-based gene transfer. Therefore, transposable elements carrying oncogenes and 
marker genes were integrated into adult hepatocytes by hydrodynamic tail vein injection. This 
is entirely assured of in vivo manipulation of hepatocytes, the major target cells for HCC 
transformation [5]. Ex vivo cell manipulation steps which are necessary for previously used 
mosaic cancer mouse models [107;108] and which can already influence cell behavior are 
therefore no longer necessary. The described model was already used to characterize liver 
cancer development and to identify new cell extrinsic or intrinsic tumor suppressive 
mechanisms in liver cancer ([113;115] and Dauch and Zender, unpublished data). In these 
studies these model was characterized as highly physiological. 
In some of the studies it was shown that transposon-based gene transfer of oncogenic 
NrasG12V can trigger HCC development in p19Arf deficient mice. Delivery of oncogenic 
NrasG12V activates the MAPK pathway, a signaling cascade which is frequently upregulated in 
several human cancers and also in human HCC [14;152]. Mutation in genes of the Ras family 
occurs in 11 percent of human HCCs (4 % NRAS, 7 % KRAS) [14]. Additionally, genes which 
induce Ras activation as the transforming growth factor α or insulin-like growth factor II are 
found activated or overexpressed in human HCCs [44]. Furthermore, negative regulatory 
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factors of Ras as NF1, RPS6KA3 or the Ras GAP genes RASAL1, DAB2IP are found 
downregulated or depleted in several human HCCs [16], which induce a higher activity of 
Ras.  
The deficiency of p19Arf in this mouse model is necessary to abrogate tumor suppressive 
pathways, which are found to be activated due to oncogenic activation [153]. It is an 
important tumor suppressor protein in different types of cancer, as also in HCC. Although the 
human counterpart p14Arf is not often mutated in liver cancer it is often found inactivated by 
promoter methylation in around 15 % of HCC cases [46]. 
Consequently, this relevant setup was used to identify the response of HCC development to 
Sorafenib by treatment of mice after NrasG12V injection. Interestingly, only a small survival 
benefit could be reported upon Sorafenib treatment. This is remarkable, since signaling to Raf 
is one of the major targets of Sorafenib and this is important for the Ras/MAPK signaling 
cascade. Nevertheless, this small but significant response mimics closely the Sorafenib 
response of human HCCs [80] in contrast to experiments in vitro or xenograft models, were in 
general a strong response to Sorafenib treatment was determined [77]. Interestingly, a cell line 
established from the NrasG12V; p19Arf-/- tumor shows a higher response to Sorafenib than the in 
vivo tumors, although the genetic background was identical. This strong effect of Sorafenib in 
the in vitro setup shows further that Sorafenib influences cell intrinsic targets (as Raf). 
In contrast to pure transgenic mouse models, an advantage of mosaic cancer mouse models is 
the ability to perform in vivo RNAi screens. For this screen expanded transposable elements 
were used, where miR30-based shRNAs were combined with expression of oncogenes and 
marker genes on one construct. The use of shRNAs, wich were embedded into a miR30 
context was shown to induce a physiological knockdown of genes [118]. In a recent study it 
was shown that these expanded transposon constructs induce a good knockdown and are 
suitable to perform a positive selection screen to identify new tumor suppressor genes in HCC 
(Dauch and Zender, unpublished data). Additionally, comparable constructs have already 
been used for a positive non cancer related RNAi screens in the liver [154]. However, to 
identify putative targets for the treatment options, oncogenic candidates have to be identified 
and a negative selection screen has to be performed. Due to technical limitations based on the 
complexity of shRNA screens, negative selection screens are until now restricted to in vitro 
screens and in mouse models only positive selection screens are feasible.  
However, because the stable delivery of oncogenic NrasG12V gives rise to hundreds of 
macroscopically visible tumors and even more microscopic tumors, this setup should allow 
for negative screens. Since each neutral shRNA is expressed in many tumors a shRNA which 
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inhibits tumor development can be found depleted, in comparison to the performance of 
neutral hairpins.     
The screen was performed using an shRNA library (designated as ROMA Amplicon Library), 
targeting genes which were found amplified in human HCCs and therefore may play roles as 
driver genes in tumor progression. These amplifications were identified via Representational 
Oligonucleotide Microarray Analysis (ROMA). This method was already used to identify 
depleted genes in human HCCs and the collected data were applied to conduct a shRNA 
library which was used for a positive RNAi selection screen to identify possible tumor 
suppressor genes [108]. This screen showed already that the integration of human data into an 
in vivo screen in mice can identify candidates which can give an insight into human cancer 
development. 
The ROMA Amplicon library consists of 250 shRNAs. In order to define the maximal pool 
size for the screen, dilution experiments were performed where two individual hairpins were 
mixed in different ratios and injected with oncogenic NrasG12V into p19Arf deficient mice. The 
experiments identified that also haipins, which were diluted 1:250 with another hairpin can be 
found in the arising tumors in the same ratio (Pesic and Zender, unpublished data). These data 
illustrated that screening with a high complexity pool of 250 shRNAs is possible. 
 
The comparison of the hairpins distribution between Sorafenib and carrier treated mice allows 
to identify shRNAs whose knockdown of target genes, may improve Sorafenib treatment. Due 
to the fact that the variability between different mice in one group was relatively high, bigger 
groups with 8-10 mice per condition were used. This screen identified different hairpins 
targeting the Mapk14 (p38α) gene depleted under Sorafenib treatment compared to the carrier 
treated group.  
The fact that two different hairpins against one target were identified ensured that this target 
is relevant in the screening context. Therefore, off-target effects, which are in general possible 
by shRNA-mediated knockdown, can be excluded, a fact which was further confirmed by a 
knockdown test where both depleted hairpins show a good knockdown efficiency against 
Mapk14.  
In follow-up validation experiments knockdown of Mapk14 using different single shRNAs 
improved significantly the treatment effectiveness of Sorafenib. This was shown in the in vivo 
model where knockdown of Mapk14 induces a lower tumor burden and a longer survival of 
Sorafenib treated mice compared to a control hairpin, as well as in an in vitro model where 
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the number of Sorafenib treated NrasG12V; p19Arf-/- cells was significantly reduced under 
Mapk14 knockdown.  
Interestingly, the knockdown of Mapk14 without Sorafenib treatments has no or only a 
marginal effect to tumor development and tumor cell reduction. This indicated that this 
candidate gene plays a special role under Sorafenib treatment. 
  
One hairpin against Mapk14 was also found depleted, in an in vitro RNAi screen, which was 
performed with cells from an NrasG12V; p19Arf-/- driven tumor and therefore in the same 
genetic background as in the in vivo screen. However, the depletion was in general low and 
hairpins against Mapk14 are not found as strong depleted as in the in vivo model. Therefore, 
the most depleted Mapk14 hairpin ranked only on position 5 of the most depleted hairpins and 
hence questionable is whether Mapk14 would be chosen as a possible candidate without the 
information from the in vivo screen.  
This is an intesting observation, due to the fact that Mapk14 could be validated as a candidate 
also in the in vitro setting. A possible explanation could be that the in vivo RNAi screen is in 
general more selective than the in vitro screen, which is also indicated by the in general lower 
changes in shRNA distribution upon Sorafenib treatment. A higher selectivity in the in vivo 
screens could be explained by the fact, that Sorafenib shows in general a lower effect in the in 
vivo setting. Also the strong amplification of not affected shRNAs in single cell derived 
tumors might induce a strong selectivity. Taken together these data highlight the need for in 
vivo RNAi screens in relevant models even for investigating cell-intrinsic mechanisms of 
tumor development. 
 
Mapk14 is a member of the p38 gene family, consisting of p38α (Mapk14), p38β (Mapk11), 
p38γ (Mapk12) and p38δ (Mapk13) [20]. Although this gene family has similarities, 
especially in activation, they have different functions due to different downstream targets. 
Interestingly, Mapk13 which is also included into the ROMA Amplicon library, was not 
found as much depleted as Mapk14 due to Sorafenib treatment. The Mapk14 kinase activity 
can phosphorylate many downstream targets and can therefore regulate many different 
processes in the cell. Intriguingly, it has proliferative as well as anti-proliferate functions and 
can induce survival and growth of cells as well as apoptosis or cell cycle arrests and 
senescence. Important downstream targets are p53, ATF2 and Creb1 [155]. 
Mapk14 is involved in the signaling cascades of the MAPK pathway and can be activated by 
MKK3, MKK4, MKK6 and MKK7. It can be stimulated by inflammatory cytokines, 
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environmental stress and growth factors. Interestingly, Mapk14 is also linked to Ras signaling 
either while it is activated by MKK4 and MKK7 [156] or when it is activated via Rac-
MKK3/6 [18;157].  
By quantification of cell proliferation rates it was shown that knockdown of Mapk14 reduces 
the proliferation of Sorafenib treated cells or tumors, which results in a better response 
towards Sorafenib. Induction of cell death was not identified as beeing relevant for the effect 
of combinatoral treatment.  
To get more mechanistic insight how Mapk14 induces resistance towards Sorafenib treatment 
bioinformatical analyses of expression profiling data were performed. These analyses 
identified ATF2 as an important factor in Mapk14 induced resistance towards Sorafenib 
treatment in hepatocellular carcinoma. ATF2, a known downstream target of Mapk14 
influences as a transcription factor the expression of several genes involved in proliferation 
and cell growth [145;146]. It forms a complex with several other transcription factors as c-
Fos, Maf and other members of the ATF gene family which is called AP-1 [144]. The analysis 
of the expression data indicates that knockdown or inhibition of Mapk14 in HCC cells inhibits 
also the activation of ATF2 and upon Sorafenib treatment also the AP-1 complex. This could 
be explained by the fact that beside Mapk14, ATF2 can be also activated by the 
Raf/Mek/ERK pathway, which is inactivated upon Sorafenib treatment.  These results were 
validated via western blot by analysing the expression of ATF2 phosphorlyated at Thr-69 
which is together with Thr-71 the main phosphorylation side for ATF2 activation [146]. 
ATF2 is known to play also a role in cancer development [144;146].  Therefore, it is not 
suprising that shRNA-mediated knockdown of ATF2 reduce the proliferation rate of HCC cell 
lines in general. However, by cell doubling and colony formation assays, it could be shown, 
that ATF2 knockdown cooperates with Sorafenib in inhibiting HCC cell growth extensively.  
Among several genes which are transcriptionally regulated by ATF2, there are also the 
Cyclins A2 and D1 [146]. Cyclins cooperate with Cyclin dependent kinases (Cdks) to regulate 
the progression of the cell cycle. Cyclin A2 interacts with cyclin dependent kinase 2 (Cdk2) 
and its expression induces cell cycle progression in S phase and G2/M phase [147]. Cyclin D1 
is important for the transition from G1 into S phase  [158]. To the fact, that Mapk14 
knockdown did not influence Cyclin D1 expression, other signal cascades might influence its 
transcription in hepatocellular carcinoma. 
 
Apart from the Mapk14-ATF2 pathway, also several other upstream factors were found 
deactivated upon combinatorial therapy. Among them are several growth factors as VEGF, 
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PDGF, EGF IGF1, TGF and HGF. These growth factors might play also a role in Mapk14 
mediated resistance, however so far it is not clear which growth factor is relevant for this 
mechanism. Also several cytokines were found downregulated upon combinatorial therapy. 
Therefore, it might be interesting to illuminate the role of growth factors and cytokines during 
Sorafenib therapy in follow-up studies.   
An interesting observation was made by looking deeper into the activity of the Sorafenib 
targets VEGFR and Raf-1 and their downstream targets ERK and MAP2K1. These genes 
were identified as deactivated upon Sorafenib treatment; however a combination of Sorafenib 
and Mapk14 knockdown induces a stronger inhibition than Sorafenib monotherapy. So far it 
is not known, whether this is a direct consequence due to Mapk14 knockdown, or an indirect 
effect, based on general reduction of growth factors and mitogens. Nevertheless, this effect 
could be also an interesting topic for ongoing studies.    
 
For the application of Mapk14 as a potential target for a combinatorial therapy with 
Sorafenib, there is a strong need to clarify, whether the effect of Mapk14 knockdown also 
affects advanced tumors in an intervention setting. Using regulatable expression of shRNAs, 
based on a tetracycline/doxycycline responsive system (tet-on), it was shown that indeed 
knockdown of Mapk14 enhances Sorafenib treatment even when it is induced in already 
established tumors. Interestingly, in Sorafenib treated mice it was possible to see a tumor-
intrinsic selection against cells harboring an active Mapk14 hairpin. These intriguing results 
imply again the disadvantage of Mapk14 knockdown in Sorafenib treated tumor cells and 
indicate that the findings from this intervention mouse model might be underestimated. 
Due to the fact that this regulatable system needs shRNAs and marker genes expressed by a 
regulatable promoter (TREtight), in combination with a constitutive active rtTA gene, it is 
currently difficult to apply this for transposon-based gene transfer. Therefore, NrasG12V; 
p19Arf-/- cells were transduced with the corresponding plasmids and injected into the livers of 
wildtype mice. Although the effect in the intervention system could be nicely identified with 
this model, a transposon-based regulatory model would be also desirable due to the fact that it 
would enable intervention-based in vivo RNAi screens to indentify new potential treatment 
targets.  
 
The observed effect of Mapk14 knockdown under Sorafenib treatment in advanced tumors 
enables the possibility of using Mapk14 as a therapeutic target. Since RNAi-based therapy is 
still in its infancy with many physiological obstacles to be solved [159], it was investigated 
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whether the combinatorial effect of Mapk14 knockdown and Sorafenib treatment can be 
phenocopied by pharmacological inhibition of Mapk14. Importantly, a handful of p38 
inhibitors are known and described but so far none is available for clinical use. Some of these 
inhibitors are only used for experimental investigations, but some inhibitors have being 
already investigated in clinical trials [160]. Many of them exert high specificity towards p38α 
(Mapk14) but target, albeit with a lower affinity, also other members of the p38 gene family 
(e.g. p38β) [161]. Although, some have yielded promising results in preclinical studies for 
treating mainly inflammatory diseases, only few have progressed beyond Phase I clinical 
studies (e.g. BIRB 796 or PH 797804). An important consideration, given the suspension 
from futher development due to side effects (liver damage), is that side effects could result 
from off-target effects of the drug [139;162]. Importantly, liver cancer is associated with 
chronic inflammation which is an important cancer promoting factor [163]. In this process are 
involved different pro-inflammatory mediators with cancer survival properties (e.g. 
cytokines) which are regulated by Mapk14. However, Mapk14 inhibition can also activate 
anti-inflammatory cytokines, and therefore its inhibition can suppress or activate 
inflammatory reactions. Thus, Mapk14 inhibition can either predispose to cancer or its 
inhibition can be important for treating inflammation-asscociated cancer, like for example 
HCC, given its role in the production of pro-inflammatory cytokines [20]. 
The inhibitors SB 202190 and BIRB 796 that were firstly chosen for here presented studies 
are relatively specific for Mapk14 and showed a high inhibitory efficiency, although some 
activity to inhibit p38β cannot be excluded [161]. Both inhibitors were used to investigate the 
response in combination with Sorafenib in the experimental setups. By targeting NrasG12V; 
p19Arf-/- cells, it was possible to achieve with both inhibitors a significant reduction in cell 
proliferation under Sorafenib treatment. Using SB 202190 which showed a higher inhibitory 
efficiency while used alone, showed also a higher effect in the combinatorial treatment with 
Sorafenib. Although, it was possible to phenocopy the results of shRNA-mediated 
knockdown, two striking differences in the response between shRNA-mediated and 
pharmacological inhibition were observed. First, the pharmacological inhibition of Mapk14 
reduced the proliferation rate of tumor cells also as a single treatment. Using SB 202190 as an 
inhibitor, this effect was even comparable with Sorafenib monotherapy. However, a 
combinatorial therapy showed a much higher effect than Sorafenib monotherapy. 
Additionally, the application of the Mapk14 inhibitors showed a higher amount of cell death 
induction than the shRNA-mediated knockdown. The cell death under SB 202190 and BIRB 
796 treatment alone was higher, than under Sorafenib treatment. Interestingly, by 
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combinatorial treatment with Sorafenib a much higher amount of cell death was identified, 
indicating that this is a specific effect that counts for the combinatorial effect of the Mapk14 
inhibitors in combination with Sorafenib. These differences in phenotypes between shRNA-
mediated knockdown and pharmacological inhibition could be caused by the different modes 
of function. Importantly, in case of shRNA-mediated Mapk14 (p38α) knockdown there is a 
specific inhibition of α isoform, therefore stronger effects conferred by the administration of 
chemical inhibitors could be attributed to above mentioned lack of specificity. Additionally, a 
pharmacological inhibition affects the cells in a more direct and immediate way than shRNA 
mediated knockdown which in turn reduces the protein level of its target gradually and in a 
more extended time frame.  
   
Since BIRB 796 was already applied in in vivo studies, this inhibitor was used to investigate 
the combinatorial treatment using a pharmacological inhibition in the mosaic cancer mouse 
model. In this model, the combinatorial therapy induced a survival benefit in comparison to 
Sorafenib or BIRB 796 monotherapy, indicating that this combination could play a relevant 
role in HCC therapy. Interestingly, also in this experiment a low surfival benefit was observed 
upon BIRB 796 monotherapy which was comparable to Sorafenib monotherapy, indicating 
differences between shRNA mediated knockdown and pharmacological inhibition of Mapk14. 
Apart from the above mentioned potential explanation for this phenotype, also another reason 
for these differences could be likely in the presented in vivo model. As shown before, the 
transposon mediated delivery of transgenes and shRNAs is selective for the hepatocytes of the 
liver, inducing therefore knockdown of Mapk14 only in the hepatocytes. However, a 
pharmacological inhibition of Mapk14 might target other cell types of the corresponding 
individual. Therefore, an inhibition of Mapk14 in other cell types might explain the reduced 
tumor development in mice upon BIRB 796 monotherapy, e.g. by influencing angiogenesis or 
the immune response. 
 
Mapk14 was identified as a candidate in a genetically defined shRNA screen with expression 
of oncogenic NrasG12V in a p19Arf deficient background. This constitutively active Nras 
mutant induces activation of the Ras/MAPK pathway. Although this pathway is frequently 
upregulated in human HCC [14;152] the geneticaly complexity of this cancer type enables 
also tumor growth triggered by other or by additional oncogenes as Akt/mTOR, c-myc, 
Wnt/beta-Catenin or Yap1 [27;34;53;107;141]. To determine, whether the tumor suppressive 
effect of Mapk14 inhibition is restricted to tumors with are triggered by activated Ras/MAPK 
                                                                                                                 Discussion and outlook 
 
96 
 
pathway, we took advantage of the flexibility of our transposon-based mouse model and 
triggered tumor growth by the oncogenic combinations NrasG12V/Akt-1, NrasG12V/c-myc and 
Akt-1/c-myc also in an p19Arf deficient background. These tumors were used to isolate 
additional HCC cell lines, which were also treated either with combinatorial therapy or with 
Sorafenib or different Mapk14 inhibitors alone. Interestingly, all of these HCC cell lines with 
different genotypes showed responses to Sorafenib treatment in combination with Mapk14 
inhibition. However, the response was dependent on the used Mapk14 inhibitor, indicating 
that the genetic background can also predict the outcome of combinatorial therapy. 
Nevertheless, genetic information can be also used for tailored approaches to individual 
patients and thus used in selection of patients for whom this combinatorial treatment would be 
the most efficacious. Nevertheless, there might be a need to identify additional candidates, 
which may improve a Sorafenib therapy also in HCCs were the genetic background might 
reduce the efficiency of the combinatorial therapy. This could be succeeded by additional in 
vivo RNAi screens were the genetic background is adjusted to a background with a lower 
treatment response. 
 
To illuminate the potential of this combinatorial therapy in human HCC patients in general, 
the combination of Sorafenib and Mapk14 inhibitors (using SB 202190 and BIRB 796) was 
tested in a cohort of different human HCC cell lines (PLC/PRF/5, Huh7 and Hep3B). 
Importantly a strong effect by this combinatorial therapy was identified in all tested cell lines. 
Interestingly, in these human cells no difference between SB 202190 and BIRB 796 was 
observed in improvement of Sorafenib treatment.  
 
The results from human data strongly emphasize a clinical relevance of a combinatorial 
therapy of Sorafenib and Mapk14 inhibition although this combinatorial treatment may not 
work against every kind of HCC development. However, the so far used Mapk14 inhibitors 
(SB 202190 and BIRB 796) are not applicable for human patients and, as mentioned before, 
also several other available inhitors are limited due to unspecifity or toxic side effects.  
Nevertheless, some Mapk14 inhibitors have the potential to be approved as therapeutic 
targets. As example, ARRY 797 is investigated in phase 3 of clinical trials. At the moment, no 
relevant side effects are described, although toxic effects in other tissues cannot be excluded. 
Additionally, this inhibitor shows a high specificity to Mapk14 (p38α) and could be therefore 
a promising target for a potential therapy in the clinic [164]. However, due to patent 
procedures, it could not be tested in this study. Another promising candidate is PH 797804 
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which is currently in Phase II of clinical trials in subjects with rheumatoid arthritis and 
obstructive pulmonary disease [165]. This inhibitor is shown to have only small side effects, 
and seems to have less liver toxicity than other Mapk14 inhibtors [149]. PH 797804 could be 
tested and showed a good response in combination with Sorafenib towards murine and human 
HCC cell lines. Also the Mapk14 inhibitor Skepinone-L might be a promising candidate. 
Skepinone-L is also highly specific to Mapk14 and showed only marginal side effects in 
different studies [148]. However, so far it is not yet tested in clinical trials. Interestingly, 
Skepinone-L could also be tested in human and murine HCC cell lines and it could be shown 
that it also cooperates with Sorafenib in reducing cell growth. Interestingly, it showed even a 
better performance that PH-797804 in human HCC cells. 
Taken together these data indicate that a translation in to the clinic might be conceivable by 
using these newly developed Mapk14 inhibitors. Nevertheless, finally clinical studies have to 
show, wether such a translation is possible.    
 
Independently of a possible success of this combinatorial therapy in clinical studies, it 
remains a strong need to further improve HCC treatment. Here shown data present a powerful 
platform to identify specific drug-sensitizing targets. Beyond this, the same model can be 
used in a parallel study to identify straight lethal targets in tumors, driven by Ras or other 
oncogenes.  
By further development of mosaic cancer mouse models, a translation to other organs could 
also be imaginable in order to develop treatment options of other types of cancer.           
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8. Appendix 
 
Table 14 Oligonucleotides of the RomaAmplicon library 
 
Hairpin Oligosequence 
Brd3.411 
TGCTGTTGACAGTGAGCGCCACCATGTTTACAAACTGTTATAGTGAAGCCACAGATGTATAACAGTTTG
TAAACATGGTGTTGCCTACTGCCTCGGA 
Cdkn1a.635 
TGCTGTTGACAGTGAGCGCCTCCCAGTCTCCAAACTTAAATAGTGAAGCCACAGATGTATTTAAGTTTG
GAGACTGGGAGATGCCTACTGCCTCGGA 
FGF12.1037 
TGCTGTTGACAGTGAGCGCCAGAGGGCTAATTGTAATGAATAGTGAAGCCACAGATGTATTCATTACAA
TTAGCCCTCTGTTGCCTACTGCCTCGGA 
Hck.420 
TGCTGTTGACAGTGAGCGCTACCATTGTGGTCGCACTGTATAGTGAAGCCACAGATGTATACAGTGCGA
CCACAATGGTATTGCCTACTGCCTCGGA 
LIPH.1203 
TGCTGTTGACAGTGAGCGAAAGAGGGTTTATTACAATCAATAGTGAAGCCACAGATGTATTGATTGTAA
TAAACCCTCTTCTGCCTACTGCCTCGGA 
Mmp7.125 
TGCTGTTGACAGTGAGCGCCAGGCTCAGAATTATCTTAGATAGTGAAGCCACAGATGTATCTAAGATAA
TTCTGAGCCTGTTGCCTACTGCCTCGGA 
Mmp8.1870 
TGCTGTTGACAGTGAGCGCAATGAAGATTATAAACACATATAGTGAAGCCACAGATGTATATGTGTTTA
TAATCTTCATTTTGCCTACTGCCTCGGA 
Neu1.455 
TGCTGTTGACAGTGAGCGAAGGGATAGTGTTCCTTATCTATAGTGAAGCCACAGATGTATAGATAAGGA
ACACTATCCCTGTGCCTACTGCCTCGGA 
Oat.1833 
TGCTGTTGACAGTGAGCGCTTGAAGGTTAAGCATATGTAATAGTGAAGCCACAGATGTATTACATATGC
TTAACCTTCAATTGCCTACTGCCTCGGA 
Oat.216 
TGCTGTTGACAGTGAGCGACACGTCTGTTGCCACAAAGAATAGTGAAGCCACAGATGTATTCTTTGTGG
CAACAGACGTGGTGCCTACTGCCTCGGA 
ORF9.461 
TGCTGTTGACAGTGAGCGCTAGCGACAAAGTACTTTGATATAGTGAAGCCACAGATGTATATCAAAGTA
CTTTGTCGCTATTGCCTACTGCCTCGGA 
PHKB.338 
TGCTGTTGACAGTGAGCGCACCGGTCTCTTTCCTACTAAATAGTGAAGCCACAGATGTATTTAGTAGGA
AAGAGACCGGTATGCCTACTGCCTCGGA 
Pim1.685 
TGCTGTTGACAGTGAGCGCCACAGTCTACACGGACTTTGATAGTGAAGCCACAGATGTATCAAAGTCCG
TGTAGACTGTGTTGCCTACTGCCTCGGA 
Pld1.4536 
TGCTGTTGACAGTGAGCGCCAGAGTGACAGTTATATCCAATAGTGAAGCCACAGATGTATTGGATATAA
CTGTCACTCTGTTGCCTACTGCCTCGGA 
RCE1.1375 
TGCTGTTGACAGTGAGCGCTTGGGATATTAAAGAGATTTATAGTGAAGCCACAGATGTATAAATCTCTT
TAATATCCCAATTGCCTACTGCCTCGGA 
RCE1.1376 
TGCTGTTGACAGTGAGCGCTGGGATATTAAAGAGATTTAATAGTGAAGCCACAGATGTATTAAATCTCT
TTAATATCCCAATGCCTACTGCCTCGGA 
RNASE4.755 
TGCTGTTGACAGTGAGCGCCAGATAGTATCTCAACGATTATAGTGAAGCCACAGATGTATAATCGTTGA
GATACTATCTGATGCCTACTGCCTCGGA 
RNASE4.916 
TGCTGTTGACAGTGAGCGACCAGTGGAAGATCTCAGACAATAGTGAAGCCACAGATGTATTGTCTGAGA
TCTTCCACTGGGTGCCTACTGCCTCGGA 
Rxra.5180 
TGCTGTTGACAGTGAGCGCCAGATACGTGATGTCATCTAATAGTGAAGCCACAGATGTATTAGATGACA
TCACGTATCTGATGCCTACTGCCTCGGA 
SDHA.2420 
TGCTGTTGACAGTGAGCGAAAGGAAAGTTTGGATATGGTATAGTGAAGCCACAGATGTATACCATATCC
AAACTTTCCTTCTGCCTACTGCCTCGGA 
Tnfsf10.3440 
TGCTGTTGACAGTGAGCGCATGCTGTGACTTATAAATTAATAGTGAAGCCACAGATGTATTAATTTATA
AGTCACAGCATTTGCCTACTGCCTCGGA 
UBE2V2.2678 
TGCTGTTGACAGTGAGCGAAAAGATGTTCTAAATATTTAATAGTGAAGCCACAGATGTATTAAATATTT
AGAACATCTTTGTGCCTACTGCCTCGGA 
UBE2V2.3257 
TGCTGTTGACAGTGAGCGAACCCTTGATGACTATATGTTATAGTGAAGCCACAGATGTATAACATATAG
TCATCAAGGGTCTGCCTACTGCCTCGGA 
UCKL1.225 
TGCTGTTGACAGTGAGCGACACAAGCAAACGTACCATCTATAGTGAAGCCACAGATGTATAGATGGTAC
GTTTGCTTGTGCTGCCTACTGCCTCGGA 
BRMS1.1002 
TGCTGTTGACAGTGAGCGCCTGCACAACTGTGGCCCTGAATAGTGAAGCCACAGATGTATTCAGGGCCA
CAGTTGTGCAGATGCCTACTGCCTCGGA 
CLIC1.573 
TGCTGTTGACAGTGAGCGACCAGCCCTCAATGACAACCTATAGTGAAGCCACAGATGTATAGGTTGTCA
TTGAGGGCTGGGTGCCTACTGCCTCGGA 
CYP27B1.1252 
TGCTGTTGACAGTGAGCGCTCCGTGTAGGAAACTATGTAATAGTGAAGCCACAGATGTATTACATAGTT
TCCTACACGGATTGCCTACTGCCTCGGA 
Ehhadh.1876 
TGCTGTTGACAGTGAGCGAAGCGTTGCTTATATTCCCTTATAGTGAAGCCACAGATGTATAAGGGAATA
TAAGCAACGCTCTGCCTACTGCCTCGGA 
Hck.1981 
TGCTGTTGACAGTGAGCGCTAGCTGTGATTTAAGTGGAAATAGTGAAGCCACAGATGTATTTCCACTTA
AATCACAGCTATTGCCTACTGCCTCGGA 
Id1.334 
TGCTGTTGACAGTGAGCGAAGCATGTAATCGACTACATCATAGTGAAGCCACAGATGTATGATGTAGTC
GATTACATGCTGTGCCTACTGCCTCGGA 
Itpr3.5512 
TGCTGTTGACAGTGAGCGACCGGCAGATCCTGCCACCAAATAGTGAAGCCACAGATGTATTTGGTGGCA
GGATCTGCCGGCTGCCTACTGCCTCGGA 
Mapk14.2590 
TGCTGTTGACAGTGAGCGACTCCTTTACTATCTTTCTCAATAGTGAAGCCACAGATGTATTGAGAAAGAT
AGTAAAGGAGCTGCCTACTGCCTCGGA 
Met.6277 
TGCTGTTGACAGTGAGCGCATGAAGAGTAGTGCAAATTTATAGTGAAGCCACAGATGTATAAATTTGCA
CTACTCTTCATATGCCTACTGCCTCGGA 
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MMP12.1107 
TGCTGTTGACAGTGAGCGCAAGATGAGAAGTACTGGTTAATAGTGAAGCCACAGATGTATTAACCAGTA
CTTCTCATCTTTTGCCTACTGCCTCGGA 
Neu1.1710 
TGCTGTTGACAGTGAGCGCATCGAAATATTTGTAACTTAATAGTGAAGCCACAGATGTATTAAGTTACA
AATATTTCGATTTGCCTACTGCCTCGGA 
ORF9.772 
TGCTGTTGACAGTGAGCGAATCGAAGGATGCATACCCAAATAGTGAAGCCACAGATGTATTTGGGTATG
CATCCTTCGATCTGCCTACTGCCTCGGA 
Parp2.946 
TGCTGTTGACAGTGAGCGCGACATTGAAATTGCCCTTAAATAGTGAAGCCACAGATGTATTTAAGGGCA
ATTTCAATGTCTTGCCTACTGCCTCGGA 
PHKB.3907 
TGCTGTTGACAGTGAGCGCAAGAAGCTTCATTGTTAATAATAGTGAAGCCACAGATGTATTATTAACAA
TGAAGCTTCTTATGCCTACTGCCTCGGA 
Pim2.674 
TGCTGTTGACAGTGAGCGCTCGGGATATCAAGGATGAGAATAGTGAAGCCACAGATGTATTCTCATCCT
TGATATCCCGATTGCCTACTGCCTCGGA 
Rem1.227 
TGCTGTTGACAGTGAGCGACTCACAGAGGATGACTCTTAATAGTGAAGCCACAGATGTATTAAGAGTCA
TCCTCTGTGAGGTGCCTACTGCCTCGGA 
Rpl15.483 
TGCTGTTGACAGTGAGCGCGGCTATGTCATTTACAGGATTTAGTGAAGCCACAGATGTAAATCCTGTAA
ATGACATAGCCTTGCCTACTGCCTCGGA 
Rpo1-1.158 
TGCTGTTGACAGTGAGCGCCACCACGGACTTTCCCGGTAATAGTGAAGCCACAGATGTATTACCGGGAA
AGTCCGTGGTGTTGCCTACTGCCTCGGA 
Stk32c.2014 
TGCTGTTGACAGTGAGCGACTGATATGTTATTGAGGGTAATAGTGAAGCCACAGATGTATTACCCTCAA
TAACATATCAGGTGCCTACTGCCTCGGA 
Stk32c.791 
TGCTGTTGACAGTGAGCGAAACAAGGACATGCACACCTTATAGTGAAGCCACAGATGTATAAGGTGTGC
ATGTCCTTGTTCTGCCTACTGCCTCGGA 
Tnfsf10.3258 
TGCTGTTGACAGTGAGCGCCTGCTGTTAATTCTATAGTAATAGTGAAGCCACAGATGTATTACTATAGA
ATTAACAGCAGATGCCTACTGCCTCGGA 
Trfp.642 
TGCTGTTGACAGTGAGCGAAGCAGATACCATGATACAGTATAGTGAAGCCACAGATGTATACTGTATCA
TGGTATCTGCTGTGCCTACTGCCTCGGA 
Trp53.1224 
TGCTGTTGACAGTGAGCGCGTGTAATACATCTGTGGCTTCTAGTGAAGCCACAGATGTAGAAGCCACAG
ATGTATTACACATGCCTACTGCCTCGGA 
ATOX1.420 
TGCTGTTGACAGTGAGCGCAAAGTCAAGCTGAGTTTGTTATAGTGAAGCCACAGATGTATAACAAACTC
AGCTTGACTTTATGCCTACTGCCTCGGA 
Brd3.298 
TGCTGTTGACAGTGAGCGAAACCTGCCTGATTATCATAAATAGTGAAGCCACAGATGTATTTATGATAA
TCAGGCAGGTTCTGCCTACTGCCTCGGA 
Cdk4.402 
TGCTGTTGACAGTGAGCGAACCCTAGTGTTTGAGCATATATAGTGAAGCCACAGATGTATATATGCTCA
AACACTAGGGTGTGCCTACTGCCTCGGA 
Cdk4.950 
TGCTGTTGACAGTGAGCGCACTGGAAATGCTGACCTTTAATAGTGAAGCCACAGATGTATTAAAGGTCA
GCATTTCCAGTATGCCTACTGCCTCGGA 
CYP27B1.190 
TGCTGTTGACAGTGAGCGACTGGCTGAACTCTTCTGCAAATAGTGAAGCCACAGATGTATTTGCAGAAG
AGTTCAGCCAGGTGCCTACTGCCTCGGA 
Dusp15.514 
TGCTGTTGACAGTGAGCGCATCTTTGTACGTGCTACTTAATAGTGAAGCCACAGATGTATTAAGTAGCA
CGTACAAAGATTTGCCTACTGCCTCGGA 
FGF12.2885 
TGCTGTTGACAGTGAGCGCTACGGTGAGATGTTTACTCAATAGTGAAGCCACAGATGTATTGAGTAAAC
ATCTCACCGTAATGCCTACTGCCTCGGA 
Fkbp5.2813 
TGCTGTTGACAGTGAGCGCCAGTCTCATGTCAGGCATTAATAGTGAAGCCACAGATGTATTAATGCCTG
ACATGAGACTGTTGCCTACTGCCTCGGA 
Hck.1204 
TGCTGTTGACAGTGAGCGACTGGACTTTCTCAAGAGTGAATAGTGAAGCCACAGATGTATTCACTCTTG
AGAAAGTCCAGCTGCCTACTGCCTCGGA 
Hsp90ab1.735 
TGCTGTTGACAGTGAGCGCCACCCTCTATTTGGAGAAGGATAGTGAAGCCACAGATGTATCCTTCTCCA
AATAGAGGGTGATGCCTACTGCCTCGGA 
Mmp3.953 
TGCTGTTGACAGTGAGCGACAGCTCTACTTTGTTCTTTGATAGTGAAGCCACAGATGTATCAAAGAACA
AAGTAGAGCTGCTGCCTACTGCCTCGGA 
Oat.1792 
TGCTGTTGACAGTGAGCGCCAGAACAGTTAAATCATTATATAGTGAAGCCACAGATGTATATAATGATT
TAACTGTTCTGTTGCCTACTGCCTCGGA 
Parp2.1677 
TGCTGTTGACAGTGAGCGCATGGTGAATGTTGATCAGACATAGTGAAGCCACAGATGTATGTCTGATCA
ACATTCACCATATGCCTACTGCCTCGGA 
Parp2.574 
TGCTGTTGACAGTGAGCGAAGCACGCAGGATGAAAGTAAATAGTGAAGCCACAGATGTATTTACTTTCA
TCCTGCGTGCTGTGCCTACTGCCTCGGA 
Pim2.1911 
TGCTGTTGACAGTGAGCGACAGTGGTTGAAATGTAAATAATAGTGAAGCCACAGATGTATTATTTACAT
TTCAACCACTGGTGCCTACTGCCTCGGA 
Pld1.3807 
TGCTGTTGACAGTGAGCGCCAGGAAGGCATTAAATCCTAATAGTGAAGCCACAGATGTATTAGGATTTA
ATGCCTTCCTGTTGCCTACTGCCTCGGA 
Rhod.380 
TGCTGTTGACAGTGAGCGCCAGCTTTGACAACGTCTCCAATAGTGAAGCCACAGATGTATTGGAGACGT
TGTCAAAGCTGTTGCCTACTGCCTCGGA 
Rpo1-1.982 
TGCTGTTGACAGTGAGCGACCCGGGTTCGGGACCATTATATAGTGAAGCCACAGATGTATATAATGGTC
CCGAACCCGGGCTGCCTACTGCCTCGGA 
SDHA.2231 
TGCTGTTGACAGTGAGCGCCTGGCATAATTCTTAAGTGAATAGTGAAGCCACAGATGTATTCACTTAAG
AATTATGCCAGTTGCCTACTGCCTCGGA 
SLC35A2.1390 
TGCTGTTGACAGTGAGCGATCCCATAATTCTAGAGGGATATAGTGAAGCCACAGATGTATATCCCTCTA
GAATTATGGGAGTGCCTACTGCCTCGGA 
SLC35A2.2366 
TGCTGTTGACAGTGAGCGAAACAAATGTCAGGATACCCAATAGTGAAGCCACAGATGTATTGGGTATCC
TGACATTTGTTCTGCCTACTGCCTCGGA 
Srpk1.1217 
TGCTGTTGACAGTGAGCGAAAGCAGGAACCTAGTTTCCTATAGTGAAGCCACAGATGTATAGGAAACTA
GGTTCCTGCTTCTGCCTACTGCCTCGGA 
Trfp.2013 
TGCTGTTGACAGTGAGCGAAAGAGAAGCATAAACAATCTATAGTGAAGCCACAGATGTATAGATTGTTT
ATGCTTCTCTTCTGCCTACTGCCTCGGA 
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UCKL1.1330 
TGCTGTTGACAGTGAGCGAAAGGATATCAGTGATGACCATTAGTGAAGCCACAGATGTAATGGTCATCA
CTGATATCCTTGTGCCTACTGCCTCGGA 
Acy3.1464 
TGCTGTTGACAGTGAGCGACAGACAACTGATCTCATTATATAGTGAAGCCACAGATGTATATAATGAGA
TCAGTTGTCTGGTGCCTACTGCCTCGGA 
Ctbp2.2774 
TGCTGTTGACAGTGAGCGCTAGATTTGTATCAGCTAGTTATAGTGAAGCCACAGATGTATAACTAGCTG
ATACAAATCTAATGCCTACTGCCTCGGA 
Dusp15.493 
TGCTGTTGACAGTGAGCGCCAGTCTATCTTTCACCTCAAATAGTGAAGCCACAGATGTATTTGAGGTGA
AAGATAGACTGTTGCCTACTGCCTCGGA 
LIPH.1204 
TGCTGTTGACAGTGAGCGCAGAGGGTTTATTACAATCAAATAGTGAAGCCACAGATGTATTTGATTGTA
ATAAACCCTCTTTGCCTACTGCCTCGGA 
Luciferase.1309 
TGCTGTTGACAGTGAGCGCCCGCCTGAAGTCTCTGATTAATAGTGAAGCCACAGATGTATTAATCAGAG
ACTTCAGGCGGTTGCCTACTGCCTCGGA 
Mapk13.445 
TGCTGTTGACAGTGAGCGATACCAGATGCTCAAAGGTCTATAGTGAAGCCACAGATGTATAGACCTTTG
AGCATCTGGTACTGCCTACTGCCTCGGA 
Mapk7.753 
TGCTGTTGACAGTGAGCGAACCGTGATCTTAAACCCTCTATAGTGAAGCCACAGATGTATAGAGGGTTT
AAGATCACGGTGTGCCTACTGCCTCGGA 
Mfap4.676 
TGCTGTTGACAGTGAGCGACTGCCATTTCGCCAATCTCAATAGTGAAGCCACAGATGTATTGAGATTGG
CGAAATGGCAGCTGCCTACTGCCTCGGA 
MMP12.2109 
TGCTGTTGACAGTGAGCGCAACTGTGGTCTTCTAAATAAATAGTGAAGCCACAGATGTATTTATTTAGA
AGACCACAGTTATGCCTACTGCCTCGGA 
Mmp7.170 
TGCTGTTGACAGTGAGCGCACAAAGAAGGTCAATAGTCTATAGTGAAGCCACAGATGTATAGACTATTG
ACCTTCTTTGTTTGCCTACTGCCTCGGA 
Mmp7.352 
TGCTGTTGACAGTGAGCGCCACCTACAGAATTGTATCCTATAGTGAAGCCACAGATGTATAGGATACAA
TTCTGTAGGTGATGCCTACTGCCTCGGA 
Mmp8.2236 
TGCTGTTGACAGTGAGCGACAGAGGTATGGGCACATGATATAGTGAAGCCACAGATGTATATCATGTGC
CCATACCTCTGCTGCCTACTGCCTCGGA 
NDUFS8.354 
TGCTGTTGACAGTGAGCGAAACGTACAAGTATGTGAATAATAGTGAAGCCACAGATGTATTATTCACAT
ACTTGTACGTTGTGCCTACTGCCTCGGA 
NUDT3.2107 
TGCTGTTGACAGTGAGCGATAGCCAAGATGTGAATTGAAATAGTGAAGCCACAGATGTATTTCAATTCA
CATCTTGGCTACTGCCTACTGCCTCGGA 
PCNA.538 
TGCTGTTGACAGTGAGCGCGGAGTACAGCTGTGTAATAAATAGTGAAGCCACAGATGTATTTATTACAC
AGCTGTACTCCTTGCCTACTGCCTCGGA 
PMPCA.2124 
TGCTGTTGACAGTGAGCGAAAGCCTAAAGGTATTTCACAATAGTGAAGCCACAGATGTATTGTGAAATA
CCTTTAGGCTTGTGCCTACTGCCTCGGA 
Renilla.713 
TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCACAGATGTATAGATAAGCA
TTATAATTCCTATGCCTACTGCCTCGGA 
Rpa3.278 
TGCTGTTGACAGTGAGCGCAAGGAAGATACTAATCGCTTTTAGTGAAGCCACAGATGTAAAAGCGATTA
GTATCTTCCTTATGCCTACTGCCTCGGA 
Rpa3.431 
TGCTGTTGACAGTGAGCGCAAGGAAGACTCCTGCAGTTTATAGTGAAGCCACAGATGTATAAACTGCAG
GAGTCTTCCTTATGCCTACTGCCTCGGA 
Rpa3.457 
TGCTGTTGACAGTGAGCGCGCGACTCCTATAATTTCTAATTAGTGAAGCCACAGATGTAATTAGAAATT
ATAGGAGTCGCTTGCCTACTGCCTCGGA 
Senp2.2928 
TGCTGTTGACAGTGAGCGACATATGAAAGTTTGTATTTAATAGTGAAGCCACAGATGTATTAAATACAA
ACTTTCATATGCTGCCTACTGCCTCGGA 
Srpk1.504 
TGCTGTTGACAGTGAGCGCCAGGCGTTAATGGAACACATATAGTGAAGCCACAGATGTATATGTGTTCC
ATTAACGCCTGATGCCTACTGCCTCGGA 
UBE2V2.2103 
TGCTGTTGACAGTGAGCGAAAGGATAGGTTTCTTGACATATAGTGAAGCCACAGATGTATATGTCAAGA
AACCTATCCTTGTGCCTACTGCCTCGGA 
UBE2V2.2582 
TGCTGTTGACAGTGAGCGAAAGGCTGGAATTATAGCCTTATAGTGAAGCCACAGATGTATAAGGCTATA
ATTCCAGCCTTGTGCCTACTGCCTCGGA 
Bcl2l1.1099 
TGCTGTTGACAGTGAGCGCCTCAGTTCTCTTGGCCTCAAATAGTGAAGCCACAGATGTATTTGAGGCCA
AGAGAACTGAGATGCCTACTGCCTCGGA 
Ccnd1.1856 
TGCTGTTGACAGTGAGCGCAGGGATGAAATAGTGACATAATAGTGAAGCCACAGATGTATTATGTCACT
ATTTCATCCCTATGCCTACTGCCTCGGA 
Cdkn1a.639 
TGCTGTTGACAGTGAGCGACAGTCTCCAAACTTAAAGTTATAGTGAAGCCACAGATGTATAACTTTAAG
TTTGGAGACTGGTGCCTACTGCCTCGGA 
Grhpr.628 
TGCTGTTGACAGTGAGCGCCAGGCAGAGTTTGTGCCTATTTAGTGAAGCCACAGATGTAAATAGGCACA
AACTCTGCCTGATGCCTACTGCCTCGGA 
Hck.1554 
TGCTGTTGACAGTGAGCGCCCCAGGTATGTCAAACCCAGATAGTGAAGCCACAGATGTATCTGGGTTTG
ACATACCTGGGTTGCCTACTGCCTCGGA 
Inpp5e.1484 
TGCTGTTGACAGTGAGCGACAGGTACTTCCCAGACCGAAATAGTGAAGCCACAGATGTATTTCGGTCTG
GGAAGTACCTGGTGCCTACTGCCTCGGA 
Itpr3.6963 
TGCTGTTGACAGTGAGCGACACCTTCATCCGAGGCTATAATAGTGAAGCCACAGATGTATTATAGCCTC
GGATGAAGGTGCTGCCTACTGCCTCGGA 
LIPH.291 
TGCTGTTGACAGTGAGCGCCTCCGTGAGACTGATGCTCTATAGTGAAGCCACAGATGTATAGAGCATCA
GTCTCACGGAGATGCCTACTGCCTCGGA 
Mapk14.1095 
TGCTGTTGACAGTGAGCGAAAGATGAACTTCGCAAATGTATAGTGAAGCCACAGATGTATACATTTGCG
AAGTTCATCTTCTGCCTACTGCCTCGGA 
Mfap4.759 
TGCTGTTGACAGTGAGCGCAAGGCTTCTATTACTCCCTCATAGTGAAGCCACAGATGTATGAGGGAGTA
ATAGAAGCCTTTTGCCTACTGCCTCGGA 
MMP12.3571 
TGCTGTTGACAGTGAGCGACTGAGACAGAATAACAAATAATAGTGAAGCCACAGATGTATTATTTGTTA
TTCTGTCTCAGGTGCCTACTGCCTCGGA 
NDUFS8.810 
TGCTGTTGACAGTGAGCGCCAAGGAGAAGCTACTCAACAATAGTGAAGCCACAGATGTATTGTTGAGTA
GCTTCTCCTTGTTGCCTACTGCCTCGGA 
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NUDT3.1284 
TGCTGTTGACAGTGAGCGAAACGAGGAGCTCAACTGTTCATAGTGAAGCCACAGATGTATGAACAGTTG
AGCTCCTCGTTCTGCCTACTGCCTCGGA 
NUDT3.1789 
TGCTGTTGACAGTGAGCGACACGACGTCCTGAGAATACATTAGTGAAGCCACAGATGTAATGTATTCTC
AGGACGTCGTGGTGCCTACTGCCTCGGA 
PHKB.2084 
TGCTGTTGACAGTGAGCGAAAAGTTCATGTTGATCGTTTATAGTGAAGCCACAGATGTATAAACGATCA
ACATGAACTTTGTGCCTACTGCCTCGGA 
Rhod.218 
TGCTGTTGACAGTGAGCGACACAGTGTTTGAGCGCTATAATAGTGAAGCCACAGATGTATTATAGCGCT
CAAACACTGTGGTGCCTACTGCCTCGGA 
Rxra.2109 
TGCTGTTGACAGTGAGCGACTGGGTCATAGCTAACCTATATAGTGAAGCCACAGATGTATATAGGTTAG
CTATGACCCAGGTGCCTACTGCCTCGGA 
Rxra.4414 
TGCTGTTGACAGTGAGCGACAGGGAGTAAAGATAGAGGAATAGTGAAGCCACAGATGTATTCCTCTATC
TTTACTCCCTGCTGCCTACTGCCTCGGA 
Slc29a2.1849 
TGCTGTTGACAGTGAGCGCTCGACTGTCTATGGAAGAGTATAGTGAAGCCACAGATGTATACTCTTCCA
TAGACAGTCGAATGCCTACTGCCTCGGA 
Slc29a2.2001 
TGCTGTTGACAGTGAGCGACTGCTCCTGCATCCAATTAAATAGTGAAGCCACAGATGTATTTAATTGGA
TGCAGGAGCAGGTGCCTACTGCCTCGGA 
Sparc.1898 
TGCTGTTGACAGTGAGCGACAGAACATCACTCAACTGCAATAGTGAAGCCACAGATGTATTGCAGTTGA
GTGATGTTCTGGTGCCTACTGCCTCGGA 
Stk32c.2134 
TGCTGTTGACAGTGAGCGAACCTCTGAGAATTACAGTCTATAGTGAAGCCACAGATGTATAGACTGTAA
TTCTCAGAGGTGTGCCTACTGCCTCGGA 
Tnfsf10.693 
TGCTGTTGACAGTGAGCGCAAGGACAAGGTGAGAACCAAATAGTGAAGCCACAGATGTATTTGGTTCTC
ACCTTGTCCTTTTGCCTACTGCCTCGGA 
Trfp.1593 
TGCTGTTGACAGTGAGCGACTCGGGAAAGCTGTTAATCTATAGTGAAGCCACAGATGTATAGATTAACA
GCTTTCCCGAGCTGCCTACTGCCTCGGA 
Acy3.782 
TGCTGTTGACAGTGAGCGCCTGCCTCATCTCTGAATCCAATAGTGAAGCCACAGATGTATTGGATTCAG
AGATGAGGCAGATGCCTACTGCCTCGGA 
BAK1.1809 
TGCTGTTGACAGTGAGCGACCGGAACCTATGATTACTTGATAGTGAAGCCACAGATGTATCAAGTAATC
ATAGGTTCCGGGTGCCTACTGCCTCGGA 
BAK1.720 
TGCTGTTGACAGTGAGCGCTTGGCTGATATCATACTGCATTAGTGAAGCCACAGATGTAATGCAGTATG
ATATCAGCCAAATGCCTACTGCCTCGGA 
Bcl2l1.974 
TGCTGTTGACAGTGAGCGACAGGAGAACCACTACATGCAATAGTGAAGCCACAGATGTATTGCATGTAG
TGGTTCTCCTGGTGCCTACTGCCTCGGA 
Ccnd1.1847 
TGCTGTTGACAGTGAGCGCCACAGCGGTAGGGATGAAATATAGTGAAGCCACAGATGTATATTTCATCC
CTACCGCTGTGTTGCCTACTGCCTCGGA 
Cdk4.401 
TGCTGTTGACAGTGAGCGCCACCCTAGTGTTTGAGCATATTAGTGAAGCCACAGATGTAATATGCTCAA
ACACTAGGGTGATGCCTACTGCCTCGGA 
Ctbp2.1895 
TGCTGTTGACAGTGAGCGCATGCCTGAAGCTAATCCGATATAGTGAAGCCACAGATGTATATCGGATTA
GCTTCAGGCATTTGCCTACTGCCTCGGA 
CYP27B1.1244 
TGCTGTTGACAGTGAGCGCCAGAGACATCCGTGTAGGAAATAGTGAAGCCACAGATGTATTTCCTACAC
GGATGTCTCTGTTGCCTACTGCCTCGGA 
Ehhadh.528 
TGCTGTTGACAGTGAGCGCCTGGATGTAGTTGTAAAGTCATAGTGAAGCCACAGATGTATGACTTTACA
ACTACATCCAGATGCCTACTGCCTCGGA 
GPT2.3560 
TGCTGTTGACAGTGAGCGACTGGGAAGCTCTGAACAATAATAGTGAAGCCACAGATGTATTATTGTTCA
GAGCTTCCCAGCTGCCTACTGCCTCGGA 
Grhpr.361 
TGCTGTTGACAGTGAGCGACTGACAGATGCCACTGCAGAATAGTGAAGCCACAGATGTATTCTGCAGTG
GCATCTGTCAGGTGCCTACTGCCTCGGA 
Itfg1.1897 
TGCTGTTGACAGTGAGCGCCACTTGATTAGTGAAACATTATAGTGAAGCCACAGATGTATAATGTTTCA
CTAATCAAGTGATGCCTACTGCCTCGGA 
Itfg1.1947 
TGCTGTTGACAGTGAGCGCTGGATCTGAGATATTTATAAATAGTGAAGCCACAGATGTATTTATAAATA
TCTCAGATCCATTGCCTACTGCCTCGGA 
Itpr3.424 
TGCTGTTGACAGTGAGCGCCTGCATATGAAGAGCAACAAATAGTGAAGCCACAGATGTATTTGTTGCTC
TTCATATGCAGATGCCTACTGCCTCGGA 
Mapk13.417 
TGCTGTTGACAGTGAGCGCCAGCGAGGATAAGGTCCAGTATAGTGAAGCCACAGATGTATACTGGACCT
TATCCTCGCTGATGCCTACTGCCTCGGA 
Mfap4.760 
TGCTGTTGACAGTGAGCGCAGGCTTCTATTACTCCCTCAATAGTGAAGCCACAGATGTATTGAGGGAGT
AATAGAAGCCTTTGCCTACTGCCTCGGA 
Mmp8.708 
TGCTGTTGACAGTGAGCGCAACGTGGACTCAAGATTCCAATAGTGAAGCCACAGATGTATTGGAATCTT
GAGTCCACGTTTTGCCTACTGCCTCGGA 
Ndufv1.916 
TGCTGTTGACAGTGAGCGCCAGGTACCAAATTGTTTAACATAGTGAAGCCACAGATGTATGTTAAACAA
TTTGGTACCTGATGCCTACTGCCTCGGA 
Neu1.441 
TGCTGTTGACAGTGAGCGAAACGATGTAGACACAGGGATATAGTGAAGCCACAGATGTATATCCCTGTG
TCTACATCGTTCTGCCTACTGCCTCGGA 
Pim1.882 
TGCTGTTGACAGTGAGCGCCAGAGTGTCAGCACCTTATTATAGTGAAGCCACAGATGTATAATAAGGTG
CTGACACTCTGATGCCTACTGCCTCGGA 
Pim2.1464 
TGCTGTTGACAGTGAGCGACACAAACCACGTAGACACTTATAGTGAAGCCACAGATGTATAAGTGTCTA
CGTGGTTTGTGGTGCCTACTGCCTCGGA 
SDHA.2825 
TGCTGTTGACAGTGAGCGACAGCAATTGTAAGCCAAATAATAGTGAAGCCACAGATGTATTATTTGGCT
TACAATTGCTGGTGCCTACTGCCTCGGA 
Tmprss2.1223 
TGCTGTTGACAGTGAGCGCCCCATCCAAATTACGACTCTATAGTGAAGCCACAGATGTATAGAGTCGTA
ATTTGGATGGGATGCCTACTGCCTCGGA 
Tmprss2.1667 
TGCTGTTGACAGTGAGCGCCAGATTGGATCTACCAGCAAATAGTGAAGCCACAGATGTATTTGCTGGTA
GATCCAATCTGTTGCCTACTGCCTCGGA 
Acy3.902 
TGCTGTTGACAGTGAGCGCCAGCGTGGAATCTATATCCAATAGTGAAGCCACAGATGTATTGGATATAG
ATTCCACGCTGATGCCTACTGCCTCGGA 
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BAK1.1345 
TGCTGTTGACAGTGAGCGATACATTGGCTCCCAAGACCAATAGTGAAGCCACAGATGTATTGGTCTTGG
GAGCCAATGTAGTGCCTACTGCCTCGGA 
Cdk4.377 
TGCTGTTGACAGTGAGCGACCGAACTGATCGGGACATCAATAGTGAAGCCACAGATGTATTGATGTCCC
GATCAGTTCGGGTGCCTACTGCCTCGGA 
CLIC1.614 
TGCTGTTGACAGTGAGCGACCTGAAGGTTCTAGACAATTATAGTGAAGCCACAGATGTATAATTGTCTA
GAACCTTCAGGGTGCCTACTGCCTCGGA 
Ehhadh.582 
TGCTGTTGACAGTGAGCGAACGGTTATAGGTAAACCCATATAGTGAAGCCACAGATGTATATGGGTTTA
CCTATAACCGTCTGCCTACTGCCTCGGA 
FGF12.1241 
TGCTGTTGACAGTGAGCGACAGGGTATTCTTTCAATCATATAGTGAAGCCACAGATGTATATGATTGAA
AGAATACCCTGGTGCCTACTGCCTCGGA 
Fkbp5.1219 
TGCTGTTGACAGTGAGCGCCTGGACAGTGCCAATGAGAAATAGTGAAGCCACAGATGTATTTCTCATTG
GCACTGTCCAGTTGCCTACTGCCTCGGA 
GPT2.911 
TGCTGTTGACAGTGAGCGCCAGGCCAGGTACAAAGCAGAATAGTGAAGCCACAGATGTATTCTGCTTTG
TACCTGGCCTGTTGCCTACTGCCTCGGA 
Hsp90ab1.1308 
TGCTGTTGACAGTGAGCGCCCGCAAGAACATCGTCAAGAATAGTGAAGCCACAGATGTATTCTTGACGA
TGTTCTTGCGGATGCCTACTGCCTCGGA 
Id1.299 
TGCTGTTGACAGTGAGCGACCAGAACCGCAAAGTGAGCAATAGTGAAGCCACAGATGTATTGCTCACTT
TGCGGTTCTGGGTGCCTACTGCCTCGGA 
Itfg1.698 
TGCTGTTGACAGTGAGCGCCACGACATTGACTGCCTCTAATAGTGAAGCCACAGATGTATTAGAGGCAG
TCAATGTCGTGATGCCTACTGCCTCGGA 
Mapk7.2760 
TGCTGTTGACAGTGAGCGCCAGACCCACCTTTCAGCCTTATAGTGAAGCCACAGATGTATAAGGCTGAA
AGGTGGGTCTGATGCCTACTGCCTCGGA 
Met.3642 
TGCTGTTGACAGTGAGCGACTGGACAATGACGGAAAGAAATAGTGAAGCCACAGATGTATTTCTTTCCG
TCATTGTCCAGCTGCCTACTGCCTCGGA 
Mettl1.259 
TGCTGTTGACAGTGAGCGACAAGTGGAGTTTGCAGACATATAGTGAAGCCACAGATGTATATGTCTGCA
AACTCCACTTGGTGCCTACTGCCTCGGA 
MMP12.1110 
TGCTGTTGACAGTGAGCGAATGAGAAGTACTGGTTAATAATAGTGAAGCCACAGATGTATTATTAACCA
GTACTTCTCATCTGCCTACTGCCTCGGA 
Mmp3.1478 
TGCTGTTGACAGTGAGCGCGACCCACATATTGAAGAGCAATAGTGAAGCCACAGATGTATTGCTCTTCA
ATATGTGGGTCATGCCTACTGCCTCGGA 
Mmp7.256 
TGCTGTTGACAGTGAGCGCCATCATGGAAATAATGCAGAATAGTGAAGCCACAGATGTATTCTGCATTA
TTTCCATGATGTTGCCTACTGCCTCGGA 
Neu1.452 
TGCTGTTGACAGTGAGCGCCACAGGGATAGTGTTCCTTATTAGTGAAGCCACAGATGTAATAAGGAACA
CTATCCCTGTGTTGCCTACTGCCTCGGA 
ORF9.566 
TGCTGTTGACAGTGAGCGAATGATGGAAGTTCCAAACTGATAGTGAAGCCACAGATGTATCAGTTTGGA
ACTTCCATCATCTGCCTACTGCCTCGGA 
Pld1.2050 
TGCTGTTGACAGTGAGCGCCACGAAGATTATGAAGCCAAATAGTGAAGCCACAGATGTATTTGGCTTCA
TAATCTTCGTGATGCCTACTGCCTCGGA 
PMPCA.1841 
TGCTGTTGACAGTGAGCGAAAGGCTGGGAAAGATTAGAAATAGTGAAGCCACAGATGTATTTCTAATCT
TTCCCAGCCTTCTGCCTACTGCCTCGGA 
Rem1.1284 
TGCTGTTGACAGTGAGCGCAAGGATGAATAGGCAGACTATTAGTGAAGCCACAGATGTAATAGTCTGCC
TATTCATCCTTTTGCCTACTGCCTCGGA 
Rpo1-1.947 
TGCTGTTGACAGTGAGCGCCCGGCATGAGAAACTCAAGAATAGTGAAGCCACAGATGTATTCTTGAGTT
TCTCATGCCGGATGCCTACTGCCTCGGA 
Sparc.1733 
TGCTGTTGACAGTGAGCGAATGGCAAGTCTTAGTAGCCTATAGTGAAGCCACAGATGTATAGGCTACTA
AGACTTGCCATGTGCCTACTGCCTCGGA 
Acy3.69 
TGCTGTTGACAGTGAGCGCAGGCATTGGCTTTACCATCTATAGTGAAGCCACAGATGTATAGATGGTAA
AGCCAATGCCTATGCCTACTGCCTCGGA 
Bcl2l1.101 
TGCTGTTGACAGTGAGCGAATCCTGGAAGAGAATCGCTAATAGTGAAGCCACAGATGTATTAGCGATTC
TCTTCCAGGATCTGCCTACTGCCTCGGA 
BRMS1.485 
TGCTGTTGACAGTGAGCGCCAGGAATAAGTATGAGTGTGATAGTGAAGCCACAGATGTATCACACTCAT
ACTTATTCCTGATGCCTACTGCCTCGGA 
Ccs.1009 
TGCTGTTGACAGTGAGCGACAGATAAGTGCTGTAGCCTGATAGTGAAGCCACAGATGTATCAGGCTACA
GCACTTATCTGCTGCCTACTGCCTCGGA 
Ccs.914 
TGCTGTTGACAGTGAGCGCACAGAGCCTCATGTCAGGTTATAGTGAAGCCACAGATGTATAACCTGACA
TGAGGCTCTGTTTGCCTACTGCCTCGGA 
FGF12.1933 
TGCTGTTGACAGTGAGCGCAAGCAGAAGGTAACTAGTTAATAGTGAAGCCACAGATGTATTAACTAGTT
ACCTTCTGCTTTTGCCTACTGCCTCGGA 
Grhpr.1009 
TGCTGTTGACAGTGAGCGACCCAGCGAACTCAAGCTGTAATAGTGAAGCCACAGATGTATTACAGCTTG
AGTTCGCTGGGCTGCCTACTGCCTCGGA 
Grhpr.771 
TGCTGTTGACAGTGAGCGCCAGCAGAGGAGATGTGGTAAATAGTGAAGCCACAGATGTATTTACCACAT
CTCCTCTGCTGATGCCTACTGCCTCGGA 
Mapk13.261 
TGCTGTTGACAGTGAGCGCCCGCGAGCTTCTGCTCTTGAATAGTGAAGCCACAGATGTATTCAAGAGCA
GAAGCTCGCGGTTGCCTACTGCCTCGGA 
Mapk14.2964 
TGCTGTTGACAGTGAGCGCCAGGTCTTGTGTTTAGGTCAATAGTGAAGCCACAGATGTATTGACCTAAA
CACAAGACCTGTTGCCTACTGCCTCGGA 
Mettl1.182 
TGCTGTTGACAGTGAGCGACAGAGTTCTTTGCTCCGCTTATAGTGAAGCCACAGATGTATAAGCGGAGC
AAAGAACTCTGGTGCCTACTGCCTCGGA 
Ndufv1.221 
TGCTGTTGACAGTGAGCGCCCGGATCTTTACCAACCTGTATAGTGAAGCCACAGATGTATACAGGTTGG
TAAAGATCCGGTTGCCTACTGCCTCGGA 
Parp2.1429 
TGCTGTTGACAGTGAGCGAGAGGCCAATCCTAAAGCACAATAGTGAAGCCACAGATGTATTGTGCTTTA
GGATTGGCCTCCTGCCTACTGCCTCGGA 
Pip5k2c.3201 
TGCTGTTGACAGTGAGCGACAGTGTTGCCATCTTTACTTATAGTGAAGCCACAGATGTATAAGTAAAGA
TGGCAACACTGCTGCCTACTGCCTCGGA 
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Rhod.732 
TGCTGTTGACAGTGAGCGCCCGGTTTACTCCGCTGCAGAATAGTGAAGCCACAGATGTATTCTGCAGCG
GAGTAAACCGGATGCCTACTGCCTCGGA 
RNASE4.499 
TGCTGTTGACAGTGAGCGCCCCAGTGCACTTTGACAGATATAGTGAAGCCACAGATGTATATCTGTCAA
AGTGCACTGGGATGCCTACTGCCTCGGA 
RNASE4.610 
TGCTGTTGACAGTGAGCGACTCGTGCCTTATACTCACATATAGTGAAGCCACAGATGTATATGTGAGTA
TAAGGCACGAGCTGCCTACTGCCTCGGA 
Rpa3.431 
TGCTGTTGACAGTGAGCGCAAGGAAGACTCCTGCAGTTTATAGTGAAGCCACAGATGTATAAACTGCAG
GAGTCTTCCTTATGCCTACTGCCTCGGA 
Rpa3.457 
TGCTGTTGACAGTGAGCGCGCGACTCCTATAATTTCTAATTAGTGAAGCCACAGATGTAATTAGAAATT
ATAGGAGTCGCTTGCCTACTGCCTCGGA 
Rpo1-1.311 
TGCTGTTGACAGTGAGCGCCCGGAGAATCCTGTTAGCTGATAGTGAAGCCACAGATGTATCAGCTAACA
GGATTCTCCGGATGCCTACTGCCTCGGA 
Rxra.2278 
TGCTGTTGACAGTGAGCGACAGGGTTAGCCAACTATAGTATAGTGAAGCCACAGATGTATACTATAGTT
GGCTAACCCTGGTGCCTACTGCCTCGGA 
Senp2.1668 
TGCTGTTGACAGTGAGCGCCAGGATGAAAGCAAGACCAAATAGTGAAGCCACAGATGTATTTGGTCTTG
CTTTCATCCTGTTGCCTACTGCCTCGGA 
Stk32c.724 
TGCTGTTGACAGTGAGCGACTGGACTACCTGCGTAGCCAATAGTGAAGCCACAGATGTATTGGCTACGC
AGGTAGTCCAGGTGCCTACTGCCTCGGA 
UCKL1.1081 
TGCTGTTGACAGTGAGCGACGGCTGCTTATTGAACATGCATAGTGAAGCCACAGATGTATGCATGTTCA
ATAAGCAGCCGCTGCCTACTGCCTCGGA 
Bcl2l1.2091 
TGCTGTTGACAGTGAGCGCCCTTGTGAAGATGATATACTATAGTGAAGCCACAGATGTATAGTATATCA
TCTTCACAAGGATGCCTACTGCCTCGGA 
BRMS1.888 
TGCTGTTGACAGTGAGCGACAGGATTAACATTTCTCTGCATAGTGAAGCCACAGATGTATGCAGAGAAA
TGTTAATCCTGCTGCCTACTGCCTCGGA 
Ccnd1.3415 
TGCTGTTGACAGTGAGCGCTACAGCATTGTGCTAATGTAATAGTGAAGCCACAGATGTATTACATTAGC
ACAATGCTGTAATGCCTACTGCCTCGGA 
Ccs.625 
TGCTGTTGACAGTGAGCGATACCTTCCGGATAGAGGATAATAGTGAAGCCACAGATGTATTATCCTCTA
TCCGGAAGGTAGTGCCTACTGCCTCGGA 
GPT2.3284 
TGCTGTTGACAGTGAGCGCTTAGCTGTTCTAAGAGATTAATAGTGAAGCCACAGATGTATTAATCTCTTA
GAACAGCTAAATGCCTACTGCCTCGGA 
Gstp1.491 
TGCTGTTGACAGTGAGCGCCCAGATCTCCTTTGCCGATTATAGTGAAGCCACAGATGTATAATCGGCAA
AGGAGATCTGGTTGCCTACTGCCTCGGA 
Inpp5e.2892 
TGCTGTTGACAGTGAGCGCCAGGCAACCTCTGGTATCCTATAGTGAAGCCACAGATGTATAGGATACCA
GAGGTTGCCTGATGCCTACTGCCTCGGA 
Itfg1.503 
TGCTGTTGACAGTGAGCGCACCACTGATTATGGACTTCAATAGTGAAGCCACAGATGTATTGAAGTCCA
TAATCAGTGGTTTGCCTACTGCCTCGGA 
Itpr3.2907 
TGCTGTTGACAGTGAGCGCCAGAAGCAAATTTGAGGACAATAGTGAAGCCACAGATGTATTGTCCTCAA
ATTTGCTTCTGTTGCCTACTGCCTCGGA 
Mapk14.2364 
TGCTGTTGACAGTGAGCGACTCCAGCTACTTTGTGTTGAATAGTGAAGCCACAGATGTATTCAACACAA
AGTAGCTGGAGGTGCCTACTGCCTCGGA 
Met.6602 
TGCTGTTGACAGTGAGCGCCTGATGAATCATACAGTTGAATAGTGAAGCCACAGATGTATTCAACTGTA
TGATTCATCAGATGCCTACTGCCTCGGA 
Mfap4.1356 
TGCTGTTGACAGTGAGCGCCGGCTACTGCTCAACTCTGAATAGTGAAGCCACAGATGTATTCAGAGTTG
AGCAGTAGCCGTTGCCTACTGCCTCGGA 
Mmp3.249 
TGCTGTTGACAGTGAGCGAGACAGTAGTCTTATTGTCAAATAGTGAAGCCACAGATGTATTTGACAATA
AGACTACTGTCCTGCCTACTGCCTCGGA 
NDUFS8.807 
TGCTGTTGACAGTGAGCGCCAACAAGGAGAAGCTACTCAATAGTGAAGCCACAGATGTATTGAGTAGCT
TCTCCTTGTTGTTGCCTACTGCCTCGGA 
Ndufv1.914 
TGCTGTTGACAGTGAGCGCTTCAGGTACCAAATTGTTTAATAGTGAAGCCACAGATGTATTAAACAATT
TGGTACCTGAATTGCCTACTGCCTCGGA 
Npr3.2769 
TGCTGTTGACAGTGAGCGCCACAGTGGTGATACGTTTAAATAGTGAAGCCACAGATGTATTTAAACGTA
TCACCACTGTGTTGCCTACTGCCTCGGA 
PHKB.131 
TGCTGTTGACAGTGAGCGAAACGCTTATGATAAGAATCAATAGTGAAGCCACAGATGTATTGATTCTTA
TCATAAGCGTTGTGCCTACTGCCTCGGA 
Pim1.602 
TGCTGTTGACAGTGAGCGAATCAAGGACGAGAACATCTTATAGTGAAGCCACAGATGTATAAGATGTTC
TCGTCCTTGATGTGCCTACTGCCTCGGA 
Pim2.1471 
TGCTGTTGACAGTGAGCGACACGTAGACACTTAGTTCAAATAGTGAAGCCACAGATGTATTTGAACTAA
GTGTCTACGTGGTGCCTACTGCCTCGGA 
Senp2.590 
TGCTGTTGACAGTGAGCGCTACGCTGAAATCGGAAGGCTATAGTGAAGCCACAGATGTATAGCCTTCCG
ATTTCAGCGTAATGCCTACTGCCTCGGA 
Sparc.1196 
TGCTGTTGACAGTGAGCGAAACAAGGATCTGGTGATCTAATAGTGAAGCCACAGATGTATTAGATCACC
AGATCCTTGTTGTGCCTACTGCCTCGGA 
Srpk1.349 
TGCTGTTGACAGTGAGCGAAAAGAAGTTTGTAGCAATGAATAGTGAAGCCACAGATGTATTCATTGCTA
CAAACTTCTTTCTGCCTACTGCCTCGGA 
Srpk1.350 
TGCTGTTGACAGTGAGCGCAAGAAGTTTGTAGCAATGAAATAGTGAAGCCACAGATGTATTTCATTGCT
ACAAACTTCTTTTGCCTACTGCCTCGGA 
UCKL1.1661 
TGCTGTTGACAGTGAGCGATCCGAGCTACTCTTATTTCTATAGTGAAGCCACAGATGTATAGAAATAAG
AGTAGCTCGGACTGCCTACTGCCTCGGA 
Brd3.1245 
TGCTGTTGACAGTGAGCGCCTCGAATTGTTATAAGTACAATAGTGAAGCCACAGATGTATTGTACTTAT
AACAATTCGAGATGCCTACTGCCTCGGA 
Cdkn1a.643 
TGCTGTTGACAGTGAGCGCCTCCAAACTTAAAGTTATTTATAGTGAAGCCACAGATGTATAAATAACTTT
AAGTTTGGAGATGCCTACTGCCTCGGA 
CLIC1.1126 
TGCTGTTGACAGTGAGCGATAGGACAACGCATTTCAGTAATAGTGAAGCCACAGATGTATTACTGAAAT
GCGTTGTCCTACTGCCTACTGCCTCGGA 
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CLIC1.1130 
TGCTGTTGACAGTGAGCGAACAACGCATTTCAGTAATAAATAGTGAAGCCACAGATGTATTTATTACTG
AAATGCGTTGTCTGCCTACTGCCTCGGA 
Dusp15.491 
TGCTGTTGACAGTGAGCGACACAGTCTATCTTTCACCTCATAGTGAAGCCACAGATGTATGAGGTGAAA
GATAGACTGTGGTGCCTACTGCCTCGGA 
Fkbp5.3272 
TGCTGTTGACAGTGAGCGCCTCAGACGATTTACACGGAAATAGTGAAGCCACAGATGTATTTCCGTGTA
AATCGTCTGAGATGCCTACTGCCTCGGA 
Fkbp5.628 
TGCTGTTGACAGTGAGCGCATCCGTAGAATCAAACGGAAATAGTGAAGCCACAGATGTATTTCCGTTTG
ATTCTACGGATATGCCTACTGCCTCGGA 
GPT2.3193 
TGCTGTTGACAGTGAGCGCCAGATTATAAATAACCCTCCATAGTGAAGCCACAGATGTATGGAGGGTTA
TTTATAATCTGATGCCTACTGCCTCGGA 
HP_141864_Mfap4 
TGCTGTTGACAGTGAGCGCCCTCCTGACACTGAAGCAGAATAGTGAAGCCACAGATGTATTCTGCTTCA
GTGTCAGGAGGTTGCCTACTGCCTCGGA 
HP_235196_Brms1 
TGCTGTTGACAGTGAGCGCCGGACCCTGACCCTGCATTTATAGTGAAGCCACAGATGTATAAATGCAGG
GTCAGGGTCCGTTGCCTACTGCCTCGGA 
HP_239339_Trfp 
TGCTGTTGACAGTGAGCGCGCTGTTAATCTACAAAGTGTATAGTGAAGCCACAGATGTATACACTTTGT
AGATTAACAGCTTGCCTACTGCCTCGGA 
HP_268893_Gstp1 
TGCTGTTGACAGTGAGCGAGCCCAGATGGATATGGTGAATTAGTGAAGCCACAGATGTAATTCACCATA
TCCATCTGGGCGTGCCTACTGCCTCGGA 
HP_273644_Pmpca 
TGCTGTTGACAGTGAGCGCCCTAGTAGAATGTGCCAGAAATAGTGAAGCCACAGATGTATTTCTGGCAC
ATTCTACTAGGTTGCCTACTGCCTCGGA 
HP_273729_Gstp1 
TGCTGTTGACAGTGAGCGCCCTCACCCTTTACCAATCTAATAGTGAAGCCACAGATGTATTAGATTGGTA
AAGGGTGAGGTTGCCTACTGCCTCGGA 
HP_281235_Srpk1 
TGCTGTTGACAGTGAGCGCGGCATAAAGAGGATCTGCATATAGTGAAGCCACAGATGTATATGCAGATC
CTCTTTATGCCTTGCCTACTGCCTCGGA 
HP_295174_Senp2 
TGCTGTTGACAGTGAGCGCCGCTGAAATCGGAAGGCTATATAGTGAAGCCACAGATGTATATAGCCTTC
CGATTTCAGCGTTGCCTACTGCCTCGGA 
HP_304374_Id1 
TGCTGTTGACAGTGAGCGCCGTCCTGCTCTACGACATGAATAGTGAAGCCACAGATGTATTCATGTCGT
AGAGCAGGACGTTGCCTACTGCCTCGGA 
Inpp5e.1796 
TGCTGTTGACAGTGAGCGAACGCATCGTGTCTCAGATCAATAGTGAAGCCACAGATGTATTGATCTGAG
ACACGATGCGTGTGCCTACTGCCTCGGA 
Met.4214 
TGCTGTTGACAGTGAGCGCCACATTTGATATCACTATCTATAGTGAAGCCACAGATGTATAGATAGTGA
TATCAAATGTGTTGCCTACTGCCTCGGA 
NPR3.871 
TGCTGTTGACAGTGAGCGATACGCTTTCTTCAACATTGAATAGTGAAGCCACAGATGTATTCAATGTTGA
AGAAAGCGTAGTGCCTACTGCCTCGGA 
Pip5k2c.3266 
TGCTGTTGACAGTGAGCGCTACTCCCGATATCACAATAAATAGTGAAGCCACAGATGTATTTATTGTGA
TATCGGGAGTAATGCCTACTGCCTCGGA 
Pld1.3383 
TGCTGTTGACAGTGAGCGATACGTTCTTGTCGATAGCATATAGTGAAGCCACAGATGTATATGCTATCG
ACAAGAACGTAGTGCCTACTGCCTCGGA 
Sparc.1758 
TGCTGTTGACAGTGAGCGAAAGGAAAGACAGAATAATCCATAGTGAAGCCACAGATGTATGGATTATT
CTGTCTTTCCTTGTGCCTACTGCCTCGGA 
Tmprss2.846 
TGCTGTTGACAGTGAGCGAAACGAGCTTTATGAAGCTGAATAGTGAAGCCACAGATGTATTCAGCTTCA
TAAAGCTCGTTGTGCCTACTGCCTCGGA 
ATOX1.64 
TGCTGTTGACAGTGAGCGCCTCCGTGGACATGACCTGTGATAGTGAAGCCACAGATGTATCACAGGTCA
TGTCCACGGAGATGCCTACTGCCTCGGA 
Ehhadh.2855 
TGCTGTTGACAGTGAGCGCCACATTGAGTTCAATGGTTCATAGTGAAGCCACAGATGTATGAACCATTG
AACTCAATGTGTTGCCTACTGCCTCGGA 
Gstp1.14 
TGCTGTTGACAGTGAGCGACTCTGTCTACGCAGCACTGAATAGTGAAGCCACAGATGTATTCAGTGCTG
CGTAGACAGAGGTGCCTACTGCCTCGGA 
Gstp1.377 
TGCTGTTGACAGTGAGCGCCACCAACTATGAGAATGGTAATAGTGAAGCCACAGATGTATTACCATTCT
CATAGTTGGTGTTGCCTACTGCCTCGGA 
HP_234766_Slc29a
2 
TGCTGTTGACAGTGAGCGCCGACTGTCTATGGAAGAGTAATAGTGAAGCCACAGATGTATTACTCTTCC
ATAGACAGTCGATGCCTACTGCCTCGGA 
HP_265487_Dusp1
5 
TGCTGTTGACAGTGAGCGACCGGAATAAGATCACACATATTAGTGAAGCCACAGATGTAATATGTGTGA
TCTTATTCCGGCTGCCTACTGCCTCGGA 
HP_303160_Ctbp2 
TGCTGTTGACAGTGAGCGCGGTCCTGCAGAGCTTGTTCTATAGTGAAGCCACAGATGTATAGAACAAGC
TCTGCAGGACCTTGCCTACTGCCTCGGA 
HP_320788_Cyp27
b1 
TGCTGTTGACAGTGAGCGACCTTGCCTAATTTACAGCGTTTAGTGAAGCCACAGATGTAAACGCTGTAA
ATTAGGCAAGGGTGCCTACTGCCTCGGA 
HP_328142_Ccs 
TGCTGTTGACAGTGAGCGAGGTTTATTAATGCTGGGTATTTAGTGAAGCCACAGATGTAAATACCCAGC
ATTAATAAACCCTGCCTACTGCCTCGGA 
Luciferase.1309 
TGCTGTTGACAGTGAGCGCCCGCCTGAAGTCTCTGATTAATAGTGAAGCCACAGATGTATTAATCAGAG
ACTTCAGGCGGTTGCCTACTGCCTCGGA 
NUDT3.1654 
TGCTGTTGACAGTGAGCGAGAGATTCTTTCTGTAATGCTATAGTGAAGCCACAGATGTATAGCATTACA
GAAAGAATCTCCTGCCTACTGCCTCGGA 
Oat.136 
TGCTGTTGACAGTGAGCGACACACGATGCTTTCTAAACTATAGTGAAGCCACAGATGTATAGTTTAGAA
AGCATCGTGTGGTGCCTACTGCCTCGGA 
Pip5k2c.796 
TGCTGTTGACAGTGAGCGAAAAGTGTATATTGGTGAAGAATAGTGAAGCCACAGATGTATTCTTCACCA
ATATACACTTTCTGCCTACTGCCTCGGA 
RCE1.1385 
TGCTGTTGACAGTGAGCGCAAAGAGATTTAACTTGGGTAATAGTGAAGCCACAGATGTATTACCCAAGT
TAAATCTCTTTATGCCTACTGCCTCGGA 
Renilla.713 
TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCACAGATGTATAGATAAGCA
TTATAATTCCTATGCCTACTGCCTCGGA 
Rpa3.278 
TGCTGTTGACAGTGAGCGCAAGGAAGATACTAATCGCTTTTAGTGAAGCCACAGATGTAAAAGCGATTA
GTATCTTCCTTATGCCTACTGCCTCGGA 
                                                                                                                                        Appendix 
119 
 
Rpa3.431 
TGCTGTTGACAGTGAGCGCAAGGAAGACTCCTGCAGTTTATAGTGAAGCCACAGATGTATAAACTGCAG
GAGTCTTCCTTATGCCTACTGCCTCGGA 
Rpa3.457 
TGCTGTTGACAGTGAGCGCGCGACTCCTATAATTTCTAATTAGTGAAGCCACAGATGTAATTAGAAATT
ATAGGAGTCGCTTGCCTACTGCCTCGGA 
Senp2.604 
TGCTGTTGACAGTGAGCGAAAGGCTATAATAGAAGGCCAATAGTGAAGCCACAGATGTATTGGCCTTCT
ATTATAGCCTTCTGCCTACTGCCTCGGA 
 
 
Table 15 Resuls from in vivo and in vitro screen in NrasG12V; p19Arf-/- genetic background 
in vivo     in vitro   
short hairpin depletion (fold-change) 
 
short hairpin depletion (fold-change) 
ATOX1.420 511,462 
 
BAK1.1809 199,770 
PHKB.3907 330,690 
 
Mettl1.182 86,587 
Ehhadh.2855 157,339 
 
NPR3.871 65,000 
Id1.334 143,573 
 
Neu1.452 42,236 
UBE2V2.2103 121,975 
 
SLC35A2.2366 36,687 
Itfg1.1897 117,601 
 
Rhod.732 20,385 
Cdk4.377 106,746 
 
MMP12.3571 17,964 
Rhod.380 63,976 
 
Inpp5e.1484 16,087 
Srpk1.1217 34,276 
 
235196_Brms1 10,972 
Neu1.441 31,598 
 
Pip5k2c.3201 10,683 
Ccnd1.1856 29,170 
 
CYP27B1.1252 9,883 
Sparc.1733 27,802 
 
RCE1.1385 9,001 
Ctbp2.1895 27,443 
 
GPT2.911 8,815 
FGF12.1241 22,494 
 
UBE2V2.3257 8,071 
RNASE4.916 22,306 
 
SDHA.2420 7,338 
SLC35A2.1390 21,752 
 
Tmprss2.1667 6,797 
NPR3.871 20,916 
 
Grhpr.771 6,350 
CYP27B1.1244 17,105 
 
Mapk14.2964 6,044 
Oat.1792 14,246 
 
Hck.1981 5,964 
273644_Pmpca 13,881 
 
UBE2V2.2103 5,964 
NUDT3.1284 13,502 
 
Srpk1.1217 5,860 
Ehhadh.1876 13,265 
 
Cdkn1a.635 5,765 
Itfg1.698 11,130 
 
GPT2.3560 5,654 
Senp2.590 10,465 
 
Pim2.1911 5,238 
Mmp7.125 10,336 
 
273644_Pmpca 5,227 
Slc29a2.2001 10,335 
 
Inpp5e.2892 5,121 
Fkbp5.3272 10,172 
 
Mapk13.261 4,685 
Itpr3.6963 10,074 
 
Hck.420 4,632 
Parp2.574 9,997 
 
Ctbp2.1895 4,343 
Pip5k2c.3201 9,919 
 
UCKL1.1661 3,937 
Fkbp5.628 9,884 
 
Sparc.1733 3,858 
Ehhadh.582 9,456 
 
Mapk14.2590 3,626 
ORF9.566 9,366 
 
CLIC1.614 3,572 
Senp2.2928 8,797 
 
Tmprss2.1223 3,461 
Inpp5e.2892 8,780 
 
Inpp5e.1796 3,222 
PHKB.2084 8,746 
 
Mmp7.125 3,203 
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Pld1.4536 8,020 
 
Id1.334 3,060 
PMPCA.2124 7,730 
 
ORF9.461 3,059 
FGF12.1037 7,273 
 
Pld1.4536 3,003 
Ndufv1.221 7,271 
 
Mmp3.249 2,971 
Mapk14.2964 7,129 
 
141864_Mfap4 2,934 
Brd3.1245 7,066 
 
PHKB.3907 2,898 
ATOX1.64 7,062 
 
Senp2.604 2,846 
Pim1.685 6,616 
 
Ccnd1.3415 2,618 
Brd3.298 6,475 
 
Acy3.1464 2,540 
Hsp90ab1.735 6,473 
 
NDUFS8.810 2,444 
BAK1.720 6,434 
 
Mmp7.352 2,422 
Itfg1.1947 6,434 
 
Mettl1.259 2,415 
Met.4214 6,434 
 
Oat.216 2,335 
Mmp8.1870 6,434 
 
Itfg1.698 2,304 
RCE1.1385 6,434 
 
Ndufv1.916 2,233 
RNASE4.610 6,434 
 
320788_Cyp27b1 2,131 
Rpo1-1.947 6,434 
 
Rem1.1284 2,063 
SLC35A2.2366 6,434 
 
Rxra.5180 2,034 
ORF9.772 6,405 
 
SDHA.2231 2,031 
Fkbp5.1219 6,167 
 
Renilla.713 2,011 
Bcl2l1.2091 5,971 
 
Itpr3.2907 1,933 
Senp2.1668 5,683 
 
UBE2V2.2678 1,907 
Rpo1-1.158 5,606 
 
Grhpr.628 1,864 
Stk32c.791 5,346 
 
Dusp15.514 1,846 
UBE2V2.3257 4,898 
 
304374_Id1 1,836 
Gstp1.377 4,822 
 
Fkbp5.628 1,809 
273729_Gstp1 4,815 
 
Mapk14.2364 1,779 
UBE2V2.2678 4,758 
 
UCKL1.1330 1,742 
235196_Brms1 4,721 
 
Met.6602 1,711 
Pip5k2c.796 4,621 
 
MMP12.2109 1,707 
Parp2.1677 4,319 
 
Hsp90ab1.735 1,700 
Ctbp2.2774 4,273 
 
PMPCA.2124 1,640 
SDHA.2825 4,191 
 
LIPH.1203 1,628 
Rem1.227 4,171 
 
LIPH.1204 1,628 
Hck.1204 4,164 
 
Mmp3.953 1,626 
Tnfsf10.3258 4,135 
 
CYP27B1.190 1,623 
Mfap4.1356 4,094 
 
RNASE4.499 1,618 
LIPH.291 4,072 
 
Id1.299 1,535 
NDUFS8.807 3,912 
 
Brd3.411 1,522 
Oat.1833 3,896 
 
Pim2.674 1,502 
Rxra.4414 3,894 
 
Tnfsf10.3440 1,501 
Cdkn1a.643 3,665 
 
Pip5k2c.796 1,451 
Ndufv1.916 3,616 
 
Hsp90ab1.1308 1,439 
281235_Srpk1 3,597 
 
Ccs.914 1,435 
UCKL1.1081 3,596 
 
Sparc.1758 1,434 
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Tmprss2.1223 3,502 
 
MMP12.1110 1,433 
Tmprss2.846 3,410 
 
Npr3.2769 1,344 
Ccnd1.1847 3,194 
 
Itpr3.424 1,333 
Itpr3.5512 3,182 
 
ORF9.566 1,327 
CLIC1.573 3,127 
 
Mfap4.760 1,311 
Gstp1.14 3,033 
 
Mfap4.759 1,311 
295174_Senp2 2,988 
 
Parp2.1429 1,301 
Hsp90ab1.1308 2,945 
 
239339_Trfp 1,296 
BAK1.1345 2,933 
 
Mfap4.1356 1,232 
234766_Slc29a2 2,717 
 
Slc29a2.2001 1,013 
Slc29a2.1849 2,717 
 
Tmprss2.846 -0,836 
Mfap4.759 2,673 
 
Brd3.298 -0,841 
Mfap4.760 2,673 
 
268893_Gstp1 -0,841 
Bcl2l1.1099 2,577 
 
Stk32c.2014 -0,854 
Rpo1-1.311 2,529 
 
Tnfsf10.3258 -0,860 
Met.6277 2,520 
 
Gstp1.14 -0,924 
Rhod.218 2,509 
 
Cdk4.402 -0,929 
Cdk4.950 2,462 
 
Cdk4.401 -0,929 
NDUFS8.810 2,453 
 
295174_Senp2 -0,931 
Dusp15.514 2,435 
 
Trfp.642 -0,937 
UCKL1.1330 2,429 
 
BRMS1.888 -0,947 
Cdkn1a.635 2,362 
 
NUDT3.1789 -0,950 
CLIC1.614 2,309 
 
Dusp15.491 -0,953 
Acy3.782 2,215 
 
Rpo1-1.158 -0,976 
Itfg1.503 2,084 
 
BAK1.720 -0,979 
CYP27B1.190 2,080 
 
Itfg1.1947 -0,979 
Mapk7.753 2,041 
 
Mapk13.417 -0,979 
Parp2.1429 1,978 
 
RNASE4.610 -0,979 
MMP12.2109 1,967 
 
Rpo1-1.947 -0,979 
UCKL1.225 1,960 
 
Mapk13.445 -0,980 
Grhpr.628 1,897 
 
Bcl2l1.101 -1,005 
Mapk14.2364 1,849 
 
Gstp1.491 -1,015 
Itpr3.424 1,806 
 
265487_Dusp15 -1,027 
304374_Id1 1,802 
 
Stk32c.2134 -1,039 
Ehhadh.528 1,787 
 
234766_Slc29a2 -1,042 
Rem1.1284 1,775 
 
Slc29a2.1849 -1,042 
Rpl15.483 1,746 
 
Ehhadh.582 -1,063 
SDHA.2231 1,735 
 
328142_Ccs -1,070 
Mmp3.953 1,715 
 
Fkbp5.3272 -1,076 
Ndufv1.914 1,689 
 
Pip5k2c.3266 -1,093 
Tnfsf10.3440 1,662 
 
Met.3642 -1,097 
BRMS1.1002 1,586 
 
Ccs.625 -1,113 
RNASE4.755 1,515 
 
303160_Ctbp2 -1,117 
Mfap4.676 1,493 
 
Rem1.227 -1,123 
CLIC1.1130 1,484 
 
FGF12.1037 -1,168 
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Grhpr.1009 1,483 
 
Oat.1833 -1,174 
GPT2.3284 1,464 
 
Neu1.455 -1,176 
GPT2.3560 1,457 
 
Oat.136 -1,189 
PCNA.538 1,446 
 
Rhod.218 -1,242 
Luciferase.1309 1,437 
 
NUDT3.1654 -1,254 
NUDT3.1789 1,404 
 
Mfap4.676 -1,271 
RCE1.1375 1,402 
 
Mmp8.1870 -1,275 
RCE1.1376 1,402 
 
Senp2.1668 -1,302 
Pim2.674 1,354 
 
Rpa3.431 -1,302 
Inpp5e.1796 1,353 
 
Pld1.3807 -1,314 
Neu1.455 1,324 
 
Itpr3.6963 -1,326 
Rxra.5180 1,315 
 
Trfp.2013 -1,326 
Grhpr.771 1,297 
 
Rpa3.278 -1,362 
BRMS1.485 1,282 
 
Rhod.380 -1,365 
Dusp15.491 1,261 
 
PHKB.131 -1,378 
Mettl1.182 1,260 
 
Acy3.902 -1,392 
ORF9.461 1,233 
 
RNASE4.755 -1,416 
Rpa3.431 1,221 
 
Pim2.1464 -1,417 
Dusp15.493 1,128 
 
Acy3.69 -1,447 
Pim1.882 1,101 
 
Ccs.1009 -1,502 
Trfp.642 1,095 
 
Itfg1.503 -1,510 
Pim2.1471 1,073 
 
NUDT3.2107 -1,520 
Acy3.69 1,072 
 
UCKL1.1081 -1,531 
Rpo1-1.982 1,047 
 
Mapk7.2760 -1,540 
Grhpr.361 1,046 
 
SLC35A2.1390 -1,543 
Brd3.411 1,042 
 
281235_Srpk1 -1,577 
FGF12.1933 1,001 
 
Srpk1.504 -1,597 
Mapk13.261 -1,005 
 
UBE2V2.2582 -1,635 
Ccs.914 -1,010 
 
Mmp3.1478 -1,654 
Parp2.946 -1,019 
 
Met.4214 -1,661 
MMP12.1110 -1,024 
 
FGF12.2885 -1,668 
Rhod.732 -1,038 
 
RCE1.1376 -1,722 
Gstp1.491 -1,049 
 
RCE1.1375 -1,722 
GPT2.911 -1,050 
 
Dusp15.493 -1,723 
Sparc.1196 -1,087 
 
PMPCA.1841 -1,736 
320788_Cyp27b1 -1,143 
 
Pim2.1471 -1,791 
Renilla.713 -1,150 
 
Pld1.2050 -1,800 
Pim2.1911 -1,170 
 
Parp2.1677 -1,834 
Mmp7.170 -1,189 
 
NDUFS8.354 -1,859 
MMP12.3571 -1,240 
 
Neu1.441 -1,872 
303160_Ctbp2 -1,283 
 
Itpr3.5512 -1,901 
NUDT3.1654 -1,336 
 
Hck.1554 -1,902 
NDUFS8.354 -1,352 
 
PCNA.538 -1,932 
PHKB.131 -1,386 
 
Fkbp5.2813 -1,946 
PHKB.338 -1,401 
 
Bcl2l1.1099 -2,044 
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NUDT3.2107 -1,405 
 
Gstp1.377 -2,057 
SDHA.2420 -1,437 
 
GPT2.3193 -2,094 
Senp2.604 -1,454 
 
GPT2.3284 -2,118 
BRMS1.888 -1,480 
 
BRMS1.485 -2,124 
Hck.1981 -1,543 
 
PHKB.2084 -2,143 
Trfp.2013 -1,561 
 
Senp2.590 -2,283 
Acy3.1464 -1,712 
 
BAK1.1345 -2,341 
Bcl2l1.974 -1,723 
 
ATOX1.64 -2,379 
Pld1.3383 -1,765 
 
Ctbp2.2774 -2,392 
Rpa3.278 -1,788 
 
CLIC1.1130 -2,402 
Npr3.2769 -1,868 
 
Luciferase.1309 -2,466 
Sparc.1898 -1,872 
 
ATOX1.420 -2,506 
UBE2V2.2582 -1,920 
 
Hck.1204 -2,548 
328142_Ccs -1,942 
 
CLIC1.573 -2,562 
Pip5k2c.3266 -2,083 
 
MMP12.1107 -2,589 
Cdkn1a.639 -2,115 
 
Pld1.3383 -2,617 
239339_Trfp -2,203 
 
Rxra.4414 -2,675 
Mmp7.352 -2,210 
 
Ndufv1.914 -2,786 
Ccs.1009 -2,237 
 
ORF9.772 -3,120 
Trfp.1593 -2,379 
 
Ccnd1.1847 -3,135 
Srpk1.349 -2,531 
 
Senp2.2928 -3,149 
Srpk1.350 -2,531 
 
Grhpr.1009 -3,209 
Mmp3.249 -2,541 
 
273729_Gstp1 -3,214 
Met.6602 -2,645 
 
Fkbp5.1219 -3,360 
Ccs.625 -2,795 
 
Acy3.782 -3,405 
CLIC1.1126 -2,823 
 
Neu1.1710 -3,453 
Mapk13.445 -2,838 
 
Ehhadh.528 -3,505 
Cdk4.402 -2,900 
 
Rpa3.457 -3,603 
Cdk4.401 -2,900 
 
Rxra.2109 -3,655 
Pld1.3807 -2,973 
 
Pim1.882 -3,788 
Tnfsf10.693 -3,005 
 
RNASE4.916 -3,867 
Itpr3.2907 -3,164 
 
Parp2.946 -3,881 
LIPH.1203 -3,255 
 
Rpl15.483 -3,950 
LIPH.1204 -3,255 
 
Cdk4.377 -4,004 
Stk32c.724 -3,284 
 
Tnfsf10.693 -4,062 
UCKL1.1661 -3,546 
 
Rxra.2278 -4,109 
Pim1.602 -3,556 
 
SDHA.2825 -4,141 
MMP12.1107 -3,611 
 
Srpk1.349 -4,340 
GPT2.3193 -3,674 
 
Srpk1.350 -4,340 
Oat.216 -3,808 
 
Cdk4.950 -4,397 
Inpp5e.1484 -3,843 
 
Oat.1792 -4,654 
Id1.299 -3,861 
 
Trfp.1593 -4,701 
Hck.1554 -4,046 
 
Rpo1-1.982 -5,049 
Rpa3.457 -4,126 
 
Cdkn1a.643 -5,175 
Mapk7.2760 -4,162 
 
UCKL1.225 -5,192 
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FGF12.2885 -4,605 
 
Met.6277 -5,316 
265487_Dusp15 -4,729 
 
PHKB.338 -5,388 
Srpk1.504 -5,172 
 
Stk32c.791 -5,467 
141864_Mfap4 -5,547 
 
Mapk7.753 -5,642 
Stk32c.2014 -5,599 
 
Bcl2l1.974 -5,729 
268893_Gstp1 -5,671 
 
Itfg1.1897 -5,825 
Bcl2l1.101 -5,912 
 
Ndufv1.221 -6,117 
Fkbp5.2813 -6,088 
 
NUDT3.1284 -6,360 
Pim2.1464 -6,508 
 
FGF12.1241 -6,457 
Neu1.452 -6,710 
 
Stk32c.724 -6,932 
Rxra.2278 -6,874 
 
Rpo1-1.311 -6,995 
Mmp8.2236 -7,385 
 
CLIC1.1126 -7,069 
Stk32c.2134 -7,611 
 
Mmp7.256 -7,097 
CYP27B1.1252 -9,698 
 
Mmp8.2236 -8,070 
Mmp3.1478 -9,836 
 
Ehhadh.1876 -8,702 
Mmp7.256 -10,405 
 
NDUFS8.807 -8,772 
Ccnd1.3415 -10,711 
 
FGF12.1933 -8,870 
Sparc.1758 -10,861 
 
BRMS1.1002 -9,205 
Pld1.2050 -12,052 
 
Pim1.602 -9,501 
RNASE4.499 -12,578 
 
Mmp7.170 -10,762 
Tmprss2.1667 -13,777 
 
Brd3.1245 -11,871 
Oat.136 -15,116 
 
Sparc.1196 -11,937 
Rxra.2109 -15,450 
 
Cdkn1a.639 -12,339 
Neu1.1710 -20,524 
 
Sparc.1898 -12,347 
Acy3.902 -20,606 
 
Ehhadh.2855 -14,082 
Mapk13.417 -23,589 
 
LIPH.291 -15,123 
Mettl1.259 -37,513 
 
CYP27B1.1244 -20,959 
Met.3642 -44,385 
 
Grhpr.361 -22,233 
Hck.420 -69,178 
 
Pim1.685 -24,115 
Mmp8.708 -76,167 
 
Mapk14.1095 -49,379 
BAK1.1809 -79,266 
 
Ccnd1.1856 -50,624 
Mapk14.1095 -138,285 
 
Parp2.574 -58,230 
PMPCA.1841 -163,065 
 
Bcl2l1.2091 -81,355 
Mapk14.2590 -324,163   Mmp8.708 -101,143 
 
